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1.1  General aspects of the skin and the skin barrier 
The skin is a versatile organ and provides a life-sustaining interface between our body 
and the potentially harmful environment. Among other tasks, the skin protects our 
body from environmental insults, is a regulator of our body temperature and prevents 
water loss to the environment. The latter function of the skin has been called 
“la raison d’être” of the epidermis. (1) The skin can be divided into three layers: 
the epidermis, the dermis and the subcutaneous tissue. The epidermis and dermis are 
host to melanocytes and immune cells, serving as a first line of defense against 
threads from the external environment. The epidermis is the outermost layer of 
the skin and has a complex organization of cells, which contributes to the vital role as 
protector from dehydration. The dermis is the underlying layer, providing strength 
and elasticity to the skin.
1.1.1  Skin structure and function
The epidermis
The epidermis is the outermost part of the skin and consists of stratified squamous 
epithelium, formed by keratinocytes (figure 1). The keratinocytes undergo programmed 
differentiation, designed to continuously renew the skin and maintain or restore 
tissue homeostasis. This is eminently important in skin wounding. The innermost 
layer of the epidermis consists of a single row of columnar cells, the basal cells. These 
basal cells divide to form keratinocytes in the spinous layer, connected via intercellular 
bridges. These keratinocytes synthesize proteins, which eventually become a major 
component of the outer layer. The cells continue to ﬂatten in the granular layer and 
finally die as they reach the surface to form the stratum corneum, which plays an 
Figure 1  Structure of the epidermis. From: Baroni et al, 2012 (2)
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important role in the barrier function. (1) The epidermis is also host to melanocytes 
and immune cells. 
The dermis
The boundary between the epidermis and dermis consists of an aggregation of 
attachment molecules, collectively known as the basement membrane. (3) The vascularized 
dermis provides structural and nutritional support. The layer is composed of a fibrous 
matrix, containing collagen and elastin, providing strength and elasticity. The vascular 
structures in the dermis are accompanied by nerves and mast cells, which provide 
nutrition and cutaneous sensations. In addition, fibroblasts, macrophages and dendritic 
cells reside in the dermis.  
Immunology
Numerous microbial communities colonize the surface of the skin and appendages 
and interact with epithelial and immune cells of the skin. The skin provides an active 
defense against these micro-organisms and environmental substances and prevents 
infection. These immune responses are strictly regulated by crosstalk between keratino - 
cytes and immune cells.
The immunity can be divided into two systems: the innate and the adaptive immunity. 
The innate immune system protects the body before initial adaptive immune response, 
is present from birth and recognizes microbes through receptors specific for molecular 
components of microorganisms. Resident dendritic cells in the suprabasal layers of the 
epidermis form a bridge between the innate and adaptive immune system. They can 
recognize microbial agents and start producing proinﬂammatory cytokines and hereby 
activate resident T lymphocytes. Additionally, the dendritic cells migrate to the lymph 
nodes, where the adaptive immune system becomes activated. In this phase T and B 
lymphocytes proliferate and create mechanisms for neutralizing or eliminating microbes 
mediated by antibodies produced by B lymphocytes and medicated by T lymphocytes. (4)
1.1.2  Stratum corneum 
The structure of the stratum corneum (SC) protects the body from dehydration, 
external toxins and bacterial invasion. It is also protecting the keratinocytes from 
mechanical disruption. A common conceptual model of the SC, the horny layer of the 
skin, is the “bricks and mortar” model. (5-7) In this model the SC is modeled as a brick 
wall, in which the corneocytes are considered to be the bricks and the intercellular 
lipids are considered to be the mortar. The intercellular lipids are released by lamellar 
bodies formed by the keratinocytes in the stratum granulosum and spinosum into the 
intercellular spaces as the keratinocytes transform into corneocytes, the end product 
of the epidermal differentiation. (8) In the stratum granulosum also keratohyalin 
granules are formed, which are full of protein. (9) 
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The corneocytes are cells with a mean thickness of 1 µm and a mean surface area of 
approximately 1000 µm. These features vary according to age, anatomical allocations 
and conditions that inﬂuence the epidermal proliferation. The SC typically consists of 
12-16 layers of corneocytes. (10, 11) Each corneocyte simplistically is an insoluble protein 
complex consisting primarily of highly organized keratin macrofibrillar matrix. (6) The 
keratin is encapsuled by a cornified cell envelope (CE), consisting of specialized lipids 
and structural proteins. (12)
The continuous phase of the skin barrier is the intercellular lipid matrix, which 
constitutes approximately 20% of the SC volume. Ceramides account for 50% by mass 
for the lipid species, fatty acids for 10-20% by mass and cholesterol for 25% by mass. 
(13) The ceramides play an important role in the organization and functioning of the 
barrier. (14) Alterations in the long carbon chain lengths of the SC ceramides and free 
fatty acids are believed to be the primary determinant of the physical properties of the 
SC lipid bilayers. (6) The lamellar bodies of the SC also release proteolytic enzymes, 
involved in desmosome hydrolysis as well as inhibitors of these enzymes to control 
rates of desquamation. (15)
1.2  Sensitive skin
By the time this thesis was written, over 5 million hits are revealed by google.com, 
when it is searched for the term ‘sensitive skin’. A plethora of products treating or 
diminishing complaints of sensitive skin are offered for large amounts of money and 
beauty advices for the sensitive skin by highly recognized cosmetic companies are 
widely promoted. To determine whether you have a sensitive skin, many ﬂowcharts 
with corresponding life style advices are offered. What is a sensitive skin exactly?
1.2.1  Sensitive skin in context
Before 1970, the term sensitive skin was rarely described in scientific literature and a 
physiological cause and recognition as a medical entity was questioned by biomedical 
researchers. Only a few research groups focused on objective approaches to identify 
the key mechanisms underlying sensitive skin. (16-25) In 1946, Bernstein already described 
that cleansing of sensitive skin requires extra care (26). Maibach et al. already investigated 
skin irritation in 1989, in order to elucidate the mechanisms of irritation and to define 
more predictive screening assays (27), elaborating on the study of Bjornberg et al, 1968. 
In that study, in fact, it was shown that some irritants could discriminate between 
subjects with hand eczema and those with normal skin, while other irritants could not. 
In the last two decades this skeptical view on sensitive skin was subject to change. 
An increasing number of publications on sensitive skin appeared in recognized scientific 
journals (figure 2), emphasizing the importance of the condition for research groups 
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of the cosmetic and pharmaceutical industry and for biomedical researchers. Large 
epidemiological studies have been conducted on the prevalence of sensitive skin in 
different countries and among different ethnicities and cultures. Since especially 
across industrialized countries the prevalence of sensitive skin is high and seems to 
have serious impact on the quality of life, the identification of the pathways underlying 
sensitive skin and treatments thereof has become a key topic for research. Many 
studies used different chemical agents in order to identify subjects with sensitive skin 
and to discover underlying pathways. Despite this extensive research, a consensus on 
the definition has not been reached yet and attempts to establish valid diagnostic 
tests to identify the profile of sensitive skin have failed. 
Terms and definitions proposed in literature to describe symptoms commonly designated 
as sensitive skin are abundant: ‘susceptible skin’, ‘hyper sensitive skin’, ‘reactive skin’, 
‘hyper reactive skin’, ‘intolerant skin’, ‘hyper irritable skin’, ‘cosmetic intolerance syndrome’, 
‘status cosmeticus’, ‘delicate skin’ and ‘sensory skin irritation’. Currently, the term 
sensitive skin is most commonly used, however, a uniform definition has not been 
established yet and its pathways have not been deciphered yet. This might be caused 
inter alia by the highly heterogeneous presentation, the lack of objective tests and the 
inconsistent results reported by clinical studies.
More knowledge on the pathophysiological background of and reality behind sensitive 
skin is of great interest for researchers and clinicians working in the area of skin 
irritation and skin-material interactions, who aspire to look beyond the cosmetic 
perspective and include objective measurements of sensitive skin. Evidence on the 
pathways underlying sensitive skin will enable addressing solutions for individual 
differences in skin reactions, which is highly desired both by patients and consumers 
in this new era. 
Figure 2  Publications on sensitive skin in Pubmed
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1.2.2  Clinical manifestation and eliciting factors
There is no consensus on the symptom profile of sensitive skin. People assessing their 
skin as sensitive experience unpleasant sensations of the skin, particularly characterized 
by stinging, burning or itching sensations. (28-30) Remarkably, visible signs of skin 
irritation, as erythema or skin dryness, are absent in many individuals. (29-33) Since 
the symptoms reported by subjects are rather nonspecific, the differentiation from or 
the relationship with dermatological disorders such as irritant contact dermatitis, 
allergic contact dermatitis, rosacea, physical urticaria and dermographism, xerosis, 
(atopic) dermatitis and photodermatoses may be challenging. Deeper understanding 
of sensitive skin will enable placing this condition in context with skin pathology. 
Factors impeding the detection and definition of sensitive skin are the frequent absence 
of clinical signs of skin irritation and subjective character of symptoms (29, 34, 35)  and 
the heterogeneity thereof. (29) 
Sensitive skin perceptions are elicited by exogenous and endogenous factors that 
usually have considerably low impact in individuals and frequently do not cause skin 
irritation. (33, 36-39) In order to define the symptom profile and to address specific 
exogenous and endogenous factors which may elicit skin reactions, non-uniform 
comprehensive questionnaires have been conducted in different populations (33, 37, 38), 
showing various risk factors and triggers. Among these factors, important triggers 
are: cosmetics and soaps (29, 30, 39-41), environmental climate (temperature changes 
(29, 40, 42, 43), heat (29, 30, 39, 42, 43), cold (29, 39, 42, 43) and dampness (40)), sun 
exposure (30, 40, 43), stress or emotions (29, 30, 39), wind (39, 42, 43) and friction from 
clothes (30). Having a dry or greasy skin (40, 44), the history of childhood atopic 
dermatitis (AD) (33, 40, 44), female gender (40) and fair skin types (40) are important 
host factors increasing the risk to have sensitive skin. (40) 
1.2.3  Definitions
Kligman et al, 2006 (45) used a novel nomenclature for sensitive skin, by proposing 
different subtypes of sensitive skin defined by clinical presentation or possible 
underlying etiology as following: (i) ‘subjective irritation’ refers to an irritant response 
without visible clinical signs; (ii) ‘neurosensory irritation’ signifies neurally mediated 
responses such as itching, stinging, burning, tightness; (iii) ‘chemosensory’ relates to 
sensory responses induced by chemicals in contrast to physical, mechanical and 
environmental factors; and (iv) ‘psychophysical irritation’ implies a psychological 
component. Willis et al (33) described several clinical forms depending on the intensity 
of clinical symptoms: (i) ‘very sensitive skin’ dry or fatty, bitterly reacting both to 
exogenous factors, i.e. cosmetic products and environmental factors and endogenous 
features. The clinical symptoms are acute and permanent, and both triggered 
determining psychological reactions; (ii) ‘environmentally sensitive skin’, often clear, 
dry and thin skin, essentially reactive to environmental factors, i.e. heat and rapid 
14
CHAPTER 1
temperature changes, with frequent bouts of ﬂushing; and (iii) ‘cosmetically sensitive 
skin’, essentially reactive to cosmetics. This intolerance is lighter and often limited to 
some identifiable cosmetic products. Farage et al, 2006 proposes a heterogeneous 
phenomenon with multiple etiologic aspects (46). 
1.2.4  Epidemiology
In order to determine the prevalence of sensitive skin and to characterize the symptom 
profile and its eliciting factors, several surveys have been conducted in large cohorts 
across different geographical areas. Studies have mainly been conducted in industrialized 
countries, where commercial enterprises with respect to products for personal care 
are highly widespread and accessible for the majority of inhabitants. 
Since sensitive skin is a subjective condition by its current definition, it is difficult to 
objectively investigate the prevalence. Many studies applied a four-point scale (29, 36, 
38, 40, 42-44, 47, 48) in order to classify the self-reported skin sensitivity, in which the 
classes, though not universally defined, seem to be comparable: (i) Very sensitive skin, 
strong sensitive skin  or ‘I strongly agree with having a sensitive skin’; (ii) sensitive skin, 
moderately sensitive skin, rather sensitive skin or ‘I somewhat agree with having a 
sensitive skin’; (iii) not very sensitive, slightly sensitive, somewhat sensitive skin or 
‘I somewhat disagree with having a sensitive skin’; (iv) not sensitive at all, not sensitive 
or ‘I strongly disagree with having a sensitive skin’. Some studies used a two point scale, 
‘sensitive or not sensitive’, or did not explain the definition of the used scale. (33, 44) 
Surveys have been administered using different modalities as digital questionnaires, 
telephone interviews or direct questions of the researcher to the subject. Results show 
that approximately 50% of people in the industrialized world reports to have some 
degree of sensitive skin (table 1). Some epidemiological studies included solely females 
(29, 30, 41, 43), while other studies included a cohort comprising both genders of which 
most often the majority is female. Among the European population, 60% of females 
report having a sensitive skin (29, 30, 33, 37, 47), and 36% of males report having a 
sensitive skin. (33, 37, 47) Three studies in the USA show that also 59% of females 
assesses their skin as sensitive (36, 43, 48), and two studies show that 45% of males 
assesses their skin as sensitive (36, 48). These numbers are calculated from table 1, 
corrected for the number of subjects included. In Brazil, Russia and Japan, similar 
percentages were found for females. Among Japanese men, 52.8% reports a sensitive 
skin, while lower numbers are found among men in Brazil and Russia (22.3% and 25.4% 
respectively). The overall prevalence of sensitive skin in China is lower compared to 
European countries and the USA. 
The abundant number of people reporting to have a ‘sensitive skin’ might reﬂect the 
fact that this condition is commonly addressed in the media and is known among this 
relatively prosperous population. Cultural factors and the media might have inﬂuence 
on the propensity to report to self-perceived sensitive skin.
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1.2.5  Subject selection in clinical studies
To enable conduction of clinical studies in a sample population with sensitive skin and 
with non-sensitive skin, assumptions on the definition and inclusion criteria have to 
be made. Erroneous selection of subjects may possibly lead to formulating wrong 
conclusions on pathomechanisms. Moreover, since symptoms might be subclinical in 
situations in which the skin is not challenged, differences in physiology may be small 
and difficult to detect, and therefore careful selection of subjects with sensitive skin is 
of high importance. 
A recently performed systematic literature review on objective measurements on 
sensitive skin has identified studies including subjects by means of perception e.g. burning, 
stinging, itching, general skin discomfort etc. (51) This self-reported skin sensitivity 
was determined (i) by sensory skin reactions following application of specific stimuli 
or (ii) by questionnaire. Subsequently, the relation of group characteristics of the 
selected populations and selected study population with objective measurements 
were studied, both at baseline and following specific stimulations. 
Table 1   The prevalence of self-reported sensitive skin in large cohorts identified  
by surveys.
  
Reference Country N % female SS (%) 
of total
SS(%) 
of females
SS(%) 
of males
Farage (2009) (36) U.S.A. 1039 84 68.4 69.0 64.4
Jourdain (2002) (43) U.S.A. 811 100 n.a. 52.0 n.a.
Misery (2011) (48) U.S.A. 994 50.2 44.6 50.9 38.2
Misery (2009) (44, 49) France 1006 n.a. 82 59 44
Morizot (2000) (29) France 319 100 n.a. 90 n.a.
Guinot (2006) (37) France 8522 59.5 49 61 32
Saint-Martory (2008) (30) France 400 100 n.a. 85 n.a.
Willis (2001) (33) U.K. 2058 87.5 49.7 51.4 38.2
Sparavigna (2005) (39) Italy 2101 88.5 n.a. 56.5 n.a.
Lofﬂer (2001) (47) Germany 420 38.6 75.2 63.6 82.5
Misery (2009) (44) Europe 4506 n.a. 38.4 49.4 37.0
Kamide (2013) (42) Japan 1500 51.8 54.5 56.0 52.8
Xu (2013) (40) China 9154 57.1 13 15.9 8.6
Farage (2012) (41) China 408 100 n.a. 23.0 n.a.
Taieb (2014) (50) Brazil 1022 n.a. n.a. 45.7 22.3
Taieb (2014) (50) Russia 1500 n.a. n.a. 50.1 25.4
The percentages are either extracted or calculated from the Result sections of the original articles.
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A high number of studies selected subjects by means of self-perceived sensitive skin 
inventoried by questionnaires, using different definitions for sensitive skin, as 
explained in the epidemiology section. Some research groups solely included the 
question: ‘Do you have a sensitive skin, yes or no’. In one study the skin sensitivity is 
scored on a labeled magnitude scale, permitting both semantic descriptors and a 
continuum of intensity rankings to compare individuals. (52) In contrast, other research 
groups conducted extensive non-uniform questionnaires addressing sensory, objective 
symptoms and additionally encompassing numerous potentially eliciting factors by 
means of inclusion of subjects with sensitive skin and with non-sensitive skin.  
Recently, a new ten item questionnaire has been developed by Misery et al. (53) With 
this questionnaire, researchers made an attempt to establish a standardized patent 
questionnaires, which might allow scoring in a reproducible manner on a ‘sensitive 
scale’ and might be suited to monitor the evolution of the skin condition. (53) However, 
only a selected population with sensitive skin diagnosed in a private clinic was included 
in this study, limiting the application of the developed scale as a diagnostic tool for 
selecting sensitive and non-sensitive subjects for research purposes.  
Many research groups have selected sensitive subjects and non-sensitive subjects as 
a control group by evaluation of sensory discomfort after application of a chemical 
agent on the skin. The lactic acid is one of the most frequently used agents (54-63) and 
the lactic acid stinging test (LAST) was previously even proposed as the best diagnostic 
test available for sensitive skin (64). LAST identifies ‘stingers’ – subjects perceiving 
sensations of stinging after application of lactic acid on the nasolabial fold – who are 
assumed to correlate with sensitive skin subjects. (65) Next to using lactic acid as a 
challenge, studies of sensitive skin reactions and sensations have been performed 
using a wide range of chemical agents. Furthermore, material interactions and 
electrical provocations (66) followed by non-invasive measurements of biophysical 
parameters of the skin have been appraised to people reporting perceptions of 
sensitive skin to quantify sensory irritation and to reveal underlying mechanisms of 
sensitive skin. Many provocations used in experiments resulted in sensory skin 
reactions, but again, these might not be specifically addressing the sensitive skin. 
1.3 Non-invasive biophysical analysis of the skin
Understanding the skin barrier is of major importance for dermatological science, the 
cosmopharmaceutical industry and the personal care sector. In dermatology, a wide 
range of dermatological diseases is caused by impairments in the skin barrier and in 
the personal care sector, maintaining or restoring a functional skin barrier is of interest 
to minimize skin complaints following treatments interacting with the skin. 
17
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Techniques have been developed for in vivo measurements to investigate the skin 
more in detail, evaluate topically applied products and monitor skin diseases. These 
easy-to-use techniques consist of hand-held probes placed in contact with the skin 
allowing to perform rapid, in vivo measurements. This field of non-invasive diagnosis 
is growing. Professor Kligman, U.S.A., had already predicted this development in 
dermatology in 1966, where a blind man will be able to diagnose skin diseases in 
patients. “If size and accessibility were advantages, we should know little about those 
tiny tissues, the adrenal and pituitary, about which we probably know the most”.
1.3.1  Transepidermal water loss 
The internal environment of our body has a higher water concentration compared to 
the surface and the external environment and therefore, the SC receives water by 
diffusion mostly from the underlying tissues and sweat glands with constant 
evaporation to the environment. (67, 68) TEWL corresponds to the ﬂux density of 
water diffusing through the SC and it is expressed in kg m-2 s-1 or, more practically, in 
g cm-2 h-1. (2)  Under the assumption of steady-state conditions, this ﬂux density and 
the water concentration of the SC can be approximated by Fick’s first law of diffusion 
(68, 69) and can be expressed as following:
Fick’s law: F = - D δc/δx (68, 69)
F =  rate of transfer per unit area (the water vapor ﬂux density or TEWL, kg m-2 s-1) 
D =  diffusion coefficient (water in the SC, m2 s-1) 
c =  the concentration of the diffusing substance (the concentration difference 
across the membrane, kg m-3)
x = the space coordinate measured normal to the section (the membrane 
thickness, m)
When the measurements are made below the thermal sweating threshold, the 
measured water vapour ﬂux density can be approximated to the liquid water ﬂux 
density diffusing through the SC, i.e. the true TEWL, since the contribution of the 
passive sweat gland activity is low. It is generally appreciated that in vivo measurements 
of TEWL can be used to non-invasively monitor changes in the barrier function of the 
SC. (68) Differences in the nature of the intercellular lipids and/or the corneocytes 
provide the structural basis for the wide variations in permeability observed on 
different body sites. (70, 71)
Numerous instruments have been developed to measure TEWL, with a major 
application in cosmetic studies to evaluate the effect of moisturizers on the skin 
barrier. TEWL assessment can be performed using different techniques. (68) 
18
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An example is the AquaFlux AF200 (Biox Systems, London, U.K.), which uses the 
patented condenser-chamber method for measuring water vapor ﬂux. The humidity 
difference between skin and condenser of the probe causes water vapor to migrate to 
the condenser by passive diffusion.
The disadvantage of TEWL assessment is the variety of variables able to affect the 
measurements, of both person-linked and environmental origin. Known person-linked 
variables are for example: sex, age and race (72, 73); anatomical sites (72); skin surface 
temperature  (72, 73); and sweating (74). In addition, skin diseases which alter the 
barrier function also affect the measurements, and there is a large inter- and intra-in-
dividual variation (73). Important environmental inﬂuences are the temperature and 
humidity of the measurement room (72, 73). Guidelines have been defined in order to 
standardize measurement procedures and minimize the inﬂuence of these factors. 
1.3.2  Electrical methods to measure skin hydration
Stratum corneum hydration gained considerable interest recent years, because the 
water content of the SC inﬂuences physical characteristics of the skin such as barrier 
function, drug penetration and mechanical properties. Skin hydration depends on two 
major elements: (i) Natural Moisturizing Factor (NMF) consisting of amino acids, lactic 
acid, urea and sugars and (ii) the structure and composition of the lipids in the SC, 
consisting of ceramides, cholesterol and free fatty acids. (1)
The SC hydration is commonly measured using  electrical methods like capacitance 
and conductance, though the relevance of these indirecte methods is under discussion. 
The Corneometer CM825 (Courage + Khazaka electronic FmbH, Cologne, Germany) is 
one of the instruments used for measuring skin hydration based on its electrical 
properties. This device uses a small electric field of low frequency (40-75Hz) to estimate 
the water content of the skin in arbitrary (relative) units. Electrical transport through 
keratinized tissue involves different types of electrical charge carriers of which the 
conduction exchange of protons along the H-bonded network of water molecules 
dominates, and is therefore highly dependent on water content. (75) It is important 
to take into account, however, that electrical methods provide only an indirect 
assessment of the water content in the SC, and moreover, the relationship between 
electrical conductance and water content is not linear and could be affected by several 
variables, similarly, analogously to the case of TEWL assessment. Furthermore, the SC 
hydration measured through electrical methods is inﬂuenced by many factors, as for 
example the skin surface roughness, and needs compliance to guidelines for obtaining 
reliable and standardized measurements. 
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1.3.3  Optical methods
The major limitation of TEWL and electrical techniques with respect to the 
measurement of the skin barrier and hydration is that they are indirect methods, that 
is they do not measure directly the SC molecular composition. During the past decade, 
the direct measurement of skin morphology and composition by means of optical 
methods has been proposed using Optical Coherence Tomography (OCT), Reﬂectance 
Confocal Microscopy (RCM) and Confocal Raman Micro-Spectroscopy (CRS). (76-79)
OCT is an imaging modality that uses light-based interferometry to obtain real-time 
cross-sectional image the skin. The skin can be visualized until the mid-dermis, where 
for example different skin layers and collagen can be distinguished. OCT enables the 
imaging of structures with a spatial resolution 3-15 µm at a depth of up to about 1 mm, 
where Optical Coherence Microscopy (OCM) offers even more superior resolution 
(al a loss of imaging depth, though). While being widely accepted in ophthalmology 
as a diagnostics tool, OCT is less explored in clinical assessment and research of skin 
diseases. (78, 79) 
RCM is superior compared to OCT with respect to spatial resolution (approximately 1 µm), 
achieved by using a high numerical aperture microscope objective and rejection of 
out-focus light using a confocal pinhole. However, it is unable to measure deeper than 
approximately 200 µm in the skin (as in contrast to OCT it does not use lock-in 
detection). 
Both OCT and RCM for in vivo skin imaging typically has a near infrared laser source to 
minimize light losses due to scattering and absorption in the visible range, assuring a 
larger penetration and a detection depth and to minimize a risk of tissue damage due 
absorption of a highly focused laser beam. 
Both in OCT and in RCM the contrast of the images is based on mostly on differences 
in refractive indices of anatomical structures of the skin layers, individual cells, and cell 
organelles. (80)
RCM, individual cells can be imaged in a horizontal plane with resolutions comparable 
to conventional histology.  (80)
Confocal Raman Micro-Spectroscopy uses molecular-specific information contained 
in the Raman spectra of the skin and its structures. Pioneering studies of Caspers started 
in 2000 made it feasible the direct measurement of the SC molecular composition and 
its distribution in vivo, non-invasively and at a high spatial - and temporal resolution, 
by means of CRS commercially-available device. (77)
1.3.4  Skin color
Skin color results from absorption and scattering of light light by different chromophores 
it contains among which those with the most prominent absorption in visible part 
of the spectrum are bilirubin, melanin and hemoglobin. In clinical practice, visual 
assessment of skin color is one of the tools of the dermatologist, in order to use 
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quantitative objective methods to measure skin redness. Next to skin color image 
analysis, two main types of systems to objectively assess skin color have been 
developed: reﬂectance spectrophotometry and colorimetry. 
Reﬂectance spectrophotometry either records information over a full visble spectrum 
of light or focuses on the quantification of reﬂectance at a few selected light 
wavelengths corresponding to the peak absorption of specific biological chromophores, 
such as melanin, hemoglobin and bilirubin due to selective absorption, though their 
spectrum in visible to near-infrared range is highly overlapping. (81) White light is 
nearly perpendicularly directed to the skin surface, and reﬂected and absorbed by the 
skin. The reﬂected spectrum is detected by photodiodes of the device and translated 
to color values. (81) The Mexameter MX 18 (Courage + Khazaka electronic FmbH, 
Cologne, Germany) is an example.
In reﬂectance tristimulus CIE (Commission Internationale de l’Eclairage) colorimetry, 
the colors can be expressed in a 3D space by means of L* (brightness coordinate), a* 
(red-green chromaticity coordinate) and b* (blue-yellow chromaticity coordinate). For 
example, the higher the a* value, the more green light is absorbed, and the less green 
light is reﬂected by skin the skin. This results in a visual assessment of the color ‘red’ by 
the human eye. The a* value is frequently used as a parameter to quantify and monitor 
skin redness in clinical studies. A frequently used device is the Chroma Meter 2600d 
(Konica Minolta, Tokyo, Japan). (81)
1.4  Histology
Where non-invasive analysis is frequently used in cosmetology, immunohistochemi-
cal analysis is considered as the golden standard in dermatology. Skin tissue, obtained 
by skin biopsies, is assessed using antibodies. 
By specific and sensitive labeling of certain cells, antibodies can be used to detect and 
quantify all kinds of cells. Various processes in the skin can be identified and monitored 
in this way. Hereby proliferating keratinocytes can be detected, endothelial cells, 
immune cells as for example T-cells, dendritic cells in general more specifically 
Langerhans cells etc. 
1.5  Aims addressed and outline of this thesis
Sensitive skin is highly prevalent in the western world and has impact on the quality of 
life. Therefore, identifying pathomechanisms causing perceptions of skin discomfort 
designated as sensitive skin could lead to an evidence-based diagnosis and rational 
solutions for subjects with sensitive skin, enabling personalized medicine, highly 
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aspired in this modern time. As a part of this, there could be measures preventing 
undesired effects of cosmetic products and personal care devices. For example, 
consumers could be advised on the personal care device and/or setting most suitable 
to the needs of their skin. 
Therefore we aimed at increasing of fundamental knowledge about sensitive skin and 
skin responses to daily triggers to fuel new developments in the medical, pharma-cos-
meceutical and personal care sector. 
Currently, scientists are still being challenged by a relatively early stage of knowledge 
about this unexplored phenomenon, where we are convinced that only by taking into 
the picture clinical-, biophysical- and histological hallmarks of this condition one could 
be able to unravel the sensitive skin phenomenon. A new step in diagnosis and 
treatment of the condition could only be taken by conducting cross-disciplinary, 
collaborative research, including experts contribution in dermatology, cosmetic 
sciences, psychologists and biophysicists. 
Chapter 2 comprises a systematic literature review about what sensitive skin is and of 
its objective measurements. In this chapter we aimed to give an overview of 
morphological, physiological and biophysical characteristics of sensitive skin, to 
critically appraise the quality and reliability of diagnostic tests, to identify knowledge 
gaps and unmet needs and to formulate recommendations for future research 
directions. This study enabled us to evaluate the position of available provocations 
and objective methods in the identification of pathways underlying sensitive skin. 
In Chapter 3, a digital survey is described, aimed to define characteristics of subjects 
reporting sensitive skin, the symptom profile and the discriminative factors for 
sensitive skin. It also aimed at answering the question whether sensitive skin can be 
triggered by multiple eliciting factors of different nature, where a positive answer 
would indicate a possibility of having more uniform and comparable selection of 
subjects using quantification of perceptions of the sensitive subjects. Translation of 
these perceptions to biophysical properties and detailed histological data might be 
the best approach to measure this dominantly subjective skin condition. One of the 
criteria, which we thought should be included in the selection tool is skin reaction to 
multiple stimuli, to prevent misinterpreting irritant or allergic contact dermatitis or 
heat intolerance for example as a sensitive skin phenomenon. Therefore, percep-
tion-based selection of subjects through a questionnaire spanning a range of 
provocations, including those of chemical, mechanical and thermal origin and 
including multiple signs and symptoms, might be a more valid and applicable selection 
tool than selection by reaction to one chemical agent only. 
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Chapter 4 describes the clinical exploration and includes studies on sensitive skin. New 
approaches in this research field might encompass highly reproducible in vivo skin 
models in order to enable studying skin reactions in the subject with sensitive skin. 
We aimed to gain insight in underlying pathways by developing a novel approach on 
subject selection and dynamic analysis, including clinical, biophysical and immuno-
histochemical parameters. We also attempted to link unpleasant skin sensations and 
symptoms of the SS condition to physiological processes in the skin and hereby to gain 
knowledge on the pathways underlying SS. By eliciting skin responses, the mechanisms 
underlying sensitive skin might be enhanced and measurable, and moreover when 
elicited in a standardized way, skin reactions in subjects with different conditions will 
be comparable. Processes set off may be studied in a dynamic fashion, by exploring 
parameters at several moments in time following the stimulus. In addition, a better 
understanding of morphology and physiology of reactions might be established by 
exploration of different potential mechanisms applying different perspectives: clinical, 
biophysical and immunohistochemical. These methodologies could be complementary 
and could enable decisively answering questions on the contribution of physiologic 
impairments and a suitable definition can be established. The hypothesis of multiple 
etiologies underlying sensitive skin would not be farfetched as also proposed by 
Maibach and Farage. An impaired skin barrier function is strongly hypothesized in 
literature to be a key player in the pathomechanism of sensitive skin. However, 
consistent evidence is lacking. Immunohistochemistry could function as a reference 
in order to validate or investigate more in detail the stratum corneum. This enables 
further research by non-invasive analysis of the skin barrier for example. 
Chapter 5 focuses more in detail on the stratum corneum in relation with sensitive 
skin, inspired by the outcomes of our previously conducted clinical studies. Advanced 
biophysical techniques, such as Confocal Raman Spectroscopy can accurately and 
specifically quantify these components in a non-invasive way. However, of note, 
differences in biophysical measurements do not ensure differences in skin sensitivity 
since these parameters have high inter-individual variability in the general population. 
Additional parameters measuring the same process could strengthen specific 
pathways and might explain previously described inconsistencies in study outcomes. 
We aimed to show that aberrant properties of the SC are present in sensitive skin, 
compared to non-sensitive skin. We also aimed to place sensitive skin in context of 
atopic conditions. Furthermore, we aimed to show aberrant penetration patterns of a 
topical through the stratum corneum between sensitive and non-sensitive skin 
subjects. The second part of the chapter describes corneocyte adhesion in sensitive 
skin. As we previously showed that the stratum corneum is more easily detached in 
sensitive skin subjects, here we hypothesized that desmoglein might play a role in a 
potential impaired corneocyte adhesion and were checking our assumption. 
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In Chapter 6 main conclusions resulting from this research are drawn and the content 
of the chapters is discussed. Chapter 7 provides a Dutch summary and in Chapter 8, 
the bibliography and Curriculum Vitae of the author are given. 
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Abstract 
Despite sensitive skin being highly prevalent, no consensus on the definition and the 
pathomechanism exists. Here we report the results of a systematic literature review 
of diagnostic methods for sensitive skin at clinical, histological and biophysical levels. 
A systematic search revealed 27 out of 1701 articles which we appraised in detail. 
Impaired skin barrier function and increased vascular reactivity are most often 
associated with sensitive skin. We identified key reasons causing an ambiguity around 
the sensitive skin phenomenon. We propose using standardized selection methods of 
subjects by a multifactorial questionnaire, spanning a range of provocations, including 
those of chemical, mechanical and environmental origin, followed by clinical, histological 
and top-notch biophysical measurements. This could lead to a break-through in the 
understanding of the sensitive skin phenomenon, fueling advances of biomedical and 
dermatological science.
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Introduction
In the previous century, sensitive skin was rarely reported in scientific literature and its 
existence was questioned by biomedical scientists. Various imprecisely defined terms 
have been proposed to characterize the susceptible skin, emphasizing its heterogeneous 
presentation and only few research groups focused on objective approaches to identify 
differences in sensitive skin[1-10].
In the past years, the view on sensitive skin has changed dramatically. Large epidemi-
ological studies on the prevalence of sensitive skin have been conducted, concluding 
that the percentage of self-reported sensitive skin among women is as high as 50% to 
61%[11-15], and among men 30% to 44%[11-14]. Since the prevalence of sensitive skin 
proves to be high across industrialized countries and to have considerable impact on 
the quality of life[16], unraveling clinical, biophysical and histological characteristics of 
sensitive skin has become a significant topic of research for cosmetic and pharmaceutical 
industries and for biomedical researchers.
People classifying themselves as having sensitive skin perceive skin discomfort, particularly 
characterized by stinging, burning or itching sensations [16-18]. Remarkably, visible 
signs of skin irritation are frequently absent[14, 17-20]. To define the symptom profile 
and to address exogenous and endogenous factors which may elicit skin reactions, 
non-uniform questionnaires have been conducted in different populations[12-14]. 
Furthermore, various chemical and electrical provocations followed by non-invasive 
measurements of biophysical parameters of the skin have been widely appraised to 
persons having sensitive skin perceptions to quantify sensory irritation and to reveal 
underlying mechanisms of sensitive skin[9, 19, 21-23]. Various exogenous factors such 
as cosmetic ingredients and environmental conditions have been indicated to trigger 
sensitive skin reactions. Many provocations used in experiments resulted in sensory 
skin reactions[19, 21, 22, 24], however, susceptibility to one provocative agent does not 
predict susceptibility to another[25-28]. 
Despite extensive research a consensus on the definition of sensitive skin has not 
been reached and attempts to develop a valid diagnostic test to objectively identify 
the complete profile of sensitive skin have failed. Factors that impede detection of 
sensitive skin are the heterogeneity of symptoms[17], the subjectivity of sensory 
discomfort[29] and the absence of visible clinical features[17, 21]. Moreover, various 
exogenous factors such as cosmetic ingredients and environmental conditions have 
been indicated to trigger sensitive skin reactions[16]. Updates were published recently, 
but a systematic approach and a critical appraisal of published studies is still lacking 
[19, 22, 30, 31].
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Objectives
The objective of this review is to shape a different perspective on research in the area 
of sensitive skin by relating perceptions, quantitative sensory measurements and 
objective biophysical and morphological aspects of this phenomenon. We aim the 
following objectives: 
1. overview morphologic, physiologic and biophysical characteristics of sensitive skin
2. critically appraise the quality and reliability of diagnostic tests for sensitive skin
3. identify gaps in the knowledge of sensitive skin
4. formulate recommendations for future research directions
This systematic review may be particularly interesting for both innovators working in 
the area of skin irritation research and experimental dermatology, who aspire to look 
beyond the solely cosmetic perspective and embrace objective measurements of 
sensitive skin, and clinicians, who are seeking evidence on the pathomechanical 
background of sensitive skin to address solutions for individual differences in skin 
reactions. 
Materials and methods
To collect data on sensitive skin, an extensive literature search (table S1) was performed 
for articles published from January 2000 to July 2012 in the following electronic 
bibliographic indexes: PubMed, EMBASE, BIOSIS, Kosmet, PASCAL, LIFESCI, HCAplus, 
Inspec and Compendex. Since the path towards understanding of sensitive skin was 
paved by several research groups previously and served as a basis to trigger new 
generation of experimental studies after 2000. Search strategy one contained all 
possible synonyms for sensitive skin: “sensitive”, “sensitivity”, “hypersensitive”, “hyper-
reactive”, “irritation”, “irritated”, ”susceptibility”, “sensibility”, “intolerance” and “cutaneous 
sensitivity”.  The second search strategy contained specific and general terms on 
diagnostics and physiology. Third, symptoms and sensations were included, being the 
phenomenon of sensitive skin based on perceptions. The three searches were crossed 
and restricted to publications on humans, English language and articles which were 
published after the first of January 2000. 
Study selection criteria
3267 citations were identified by the search strategy. Duplicate citations were removed. 
Relevant articles were selected by a four-stage process (figure 1). A first selection on 
1701 articles (RR) was made using a checklist containing four items: descriptions of 
definition, epidemiology, demography (e.g. age, gender, ethnicity, skin type) and 
diagnostics on sensitive skin and skin irritation. The presence of at least one of these 
items was mandatory for an article to be included in the next steps of the analysis. 
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Second, abstracts of selected titles were assessed independently by two reviewers 
(RR and PvE) using a more detailed checklist to select articles considered to be relevant. 
Main reason for exclusion was when testing irritation potential of substances was 
addressed or when perceptions of individuals were lacking. Consensus was reached by 
discussion on inclusion. 93 abstracts were eligible for detailed full-text assessment.
Article screening
After critical assessment of full-texts in the third stage, 24 articles were included. The main 
reason for exclusion was absence of descriptions or evaluation of perceptions of 
sensitive skin e.g. burning feeling, stinging feeling, discomfort etc. Finally, to ensure 
that all relevant studies were included, reference lists of literature reviews and 
included full text articles were additionally scanned, resulting in inclusion of 3 articles.
Figure 1  Article selection process
Total articles identified:
Pubmed/Embase: n=1153
Bioengineering database n=2114
Titles to screen:
n=1701
Excluded titles:
n=1331
 
Abstracts to screen:
n=370
Excluded abstracts:
n=277
 
Articles to screen:
n=93
Excluded duplicates
n=1566
Excluded articles:
n=69
 
Selected references for
abstract screening: n=121
Included references; n=3
 
Articles included:
n=24
Articles included:
n=27
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Quality assessment
The STROBE method, STrengthening the Reporting of OBservational studies in 
Epidemiology, was used in the assessment of quality of studies as this tool comprises 
level of evidence determination according to study design of observational studies[32]. 
Each study received a score of 0 to 22 by two independent reviewers (DF, RR), relating 
to three grades of recommendation, based on the fulfillment of quality criteria. 
When scores differed by more than 1.5, consensus was reached by discussion. Quality 
assessment and data extraction tables are added in table S2. 
Results
Article quality
Five articles were classified in category C (score <60%) and the remaining 22 articles 
were classified in category B (score 60-80%). The mean score of articles was 63.4±5.6%. 
Shortcomings mainly refer to poor or absent (i) explanation of the choice of study 
design and population size, (ii) addressing bias and limitations of the study and (iii) 
indication of the number of participants included at each stage.
Definition of sensitive skin
Our review confirmed that there is no consensus on the definition of a symptom 
profile of sensitive skin. The condition has been characterized by solely neurosensory 
discomfort in eight studies, while nine studies suggest that these perceptions may be 
accompanied by visible skin irritation, such as erythema and dryness. 
Study sample characteristics
All studies included are observational studies in adults. The majority (n=16) included 
both sexes, nearly all with a higher proportion of women (n=13). Out of twenty studies 
that appointed the mean age of subjects, fourteen studies addressed a mean age 
between 25 and 40 years. Eight studies appointed ethnicity of subjects: five studies 
included Caucasian subjects, three studies Asian subjects and one study compared 
these two skin types. Studies comparing a predetermined population with sensitive 
skin with a control group included small groups (4 to 36 subjects). Most frequently 
investigated body sites were the nasolabial fold (n=12), the volar forearm (n=10), the 
cheek (n=5), other facial areas (n=6) and the hands (n=4). 
Sensory hyperreactivity
Population selection methods: Different methods are applied to enable assessment of 
sensitive skin behavior, including provocations with chemical substances and selection 
by self-reported perceptions obtained by questionnaire. Studies addressing individual 
differences in skin reactions elicited sensations by different agents: lactic acid (LA), 
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sodium lauryl sulphate (SLS) and various other topical agents such as capsaicin, 
menthol, benzoic acid, transcinnamic acid, octane, cumene, methylnicotinate and acetyl- b-
methylcholine chloride (vasodilators), ethanol, allergens, occlusion, cocamidopropyl 
betaine and benzalkonium chloride (surfactants) and balsam of Peru. One study 
selected subjects by determining the current perception threshold (CPT) in the 
neck[33]. Twelve studies selected subjects based on self-assessment by questionnaire. 
The lactic acid stinging test (LAST), first developed to appraise the stinging capacity of 
topically applied substances [34], is proposed as the best predictor available for 
sensitive skin. and it is widely used to select volunteers for clinical studies[3]. We also 
confirm that LAST identifies ‘stingers’ – subjects perceiving stinging sensations when 
LA is applied on the nasolabial fold – assuming to correspond to sensitive skin and was 
most frequently used to categorize subjects on skin sensitivity (n=9). A detailed 
evaluation of the articles included in this review reveals that in sensitive skin the time 
to the onset of stinging and time to peak are shorter, higher peak amplitudes are 
observed [35] and mean overall stinging scores are higher in response to LA[36, 37]. 
However, the test lacks objectivity, sensitivity and specificity for sensitive skin. In fact, 
59.9%[15] and 64%[35] of subjects with self-reported sensitive skin reports a positive 
reaction to the LAST. A study by Cho et al, found that 80% of sensitive subjects report 
stinging following LAST, however, also 66.7% of non-sensitive subjects experience this 
reaction [38]. Moreover, several studies have shown that sensitivity to one substance 
seems not to predict sensitivity to another[28, 35, 39], questioning the validity of LAST 
as reliable diagnostic test for sensitive skin.
Only two studies using LAST as an indicator of sensitive skin found significant differences 
in biophysical measurements in stingers, namely a higher TEWL on the nasolabial fold 
(p=0.03), and on the right (p=0.05) and left cheek (p=0.03)[40, 41]. Important to note 
here is that Distante et al, 2002 included subjects that also met the criteria of 
self-reported sensitive skin and having specific skin reactions besides a positive LAST. 
Differences in skin reactions could barely be enhanced by physical irritants such as 
SLS[42]. In the past, enhancement of differences in skin reactions between stingers 
and non-stingers also failed[25, 27]. Schliemann et al, 2011 observed that only after 
5 days stingers showed significantly higher skin irritation following repetitive cumene 
and octane application. However, differences in biophysical measurements do not 
ensure differences in skin sensitivity since these parameters have high inter-individual 
variability in the general population. 
As stated earlier, besides LAST, twelve studies selected sensitive skin subjects and 
non-sensitive skin subjects using either extended non-uniform questionnaires 
including sensory perceptions, visible symptoms and environmental and endogenous 
factors or asking whether an individual has sensitive skin or not. In particular, one 
study used a labeled magnitude scale permitting both semantic descriptors and a 
continuum of intensity rankings to compare individuals[43].
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When sensitive and non-sensitive subjects were selected by questionnaire, few 
studies found significant differences in biophysical parameters between sensitive 
subjects and non-sensitive subjects. An inverse correlation was shown between 
detection thresholds of capsaicin and sensitive skin indexed by questionnaire[44], 
suggesting that these methods could be more specific than the LAST in detecting 
sensitive skin. It is known that whenever skin is challenged by capsaicin, noxious heat 
or low pH, transient receptor potential vanilloid 1 (TRPV1) is activated[45, 46] resulting 
in nociceptor mediated burning pain. An overexpression of this ion channel could play 
a key role in the pathophysiology of sensitive skin, as its inhibition results in reduced 
burning sensation following capsaicin application[47]. Differences in pain perceptions 
were also observed in subjects with sensitive skin by fMRI. Subjects with sensitive 
skin indexed by questionnaire show activity in bilateral peri-insular regions, when 
stimulated with LA on the right nasolabial fold, whereas only the left primary sensori- 
motor area is active in subjects with non-sensitive skin[36]. 
Impaired barrier function
Transepidermal waterloss: Eleven studies focused on transepidermal waterloss (TEWL) as 
a parameter of skin barrier function (table 1). Most studies observed higher TEWL in 
unchallenged skin of subjects with sensitive skin compared to subjects with non- 
sensitive skin[20, 41, 48, 49] and in stingers compared to non-stingers[39-41, 50, 51], while 
only two studies identified significantly higher TEWL in sensitive skin[40, 41]. Moreover, 
higher TEWL at baseline seems to correlate with stronger TEWL increase following 
provocation[40]: plastic occlusion resulted in significantly longer evaporation half life 
time in subjects with sensitive skin[49] and a trend to increased recovery time of TEWL 
following SLS stimulation was also observed[20]. A stronger increase of TEWL was also 
found following SLS provocation both in sensitive atopic skin versus non-sensitive 
atopic skin [52] and in a population of Japanese women versus German women[53]. 
The latter finding is particularly interesting as, in general, Asian women often report 
sensitive skin. 
Stratum corneum hydration (measured through capacitance, CAP): 11 studies presented 
data on hydration of the stratum corneum in sensitive skin (table 1). A significantly 
lower CAP at facial areas in subjects with sensitive skin[37] and in stingers[40] and a 
non-significantly lower CAP at facial areas in subjects with sensitive skin were 
found[41]. Challenging the skin with octane or cumene however, resulted in a 
significantly lower CAP in stingers compared to non-stingers[51]. A lower CAP at 
baseline predicted earlier onset of stinging and a weak correlation (Spearman’s test: 
r=0.307, p=0.03) with a higher clinical stinging score was identified[39]. On the other 
hand, other studies found no difference in CAP between stingers and non-stingers[40, 
50, 51] nor between subjects with sensitive skin and subjects with non-sensitive 
skin[20, 48], either challenged or unchallenged[20, 48, 51]. The lower CAP is consistent 
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with findings of a clinically dryer skin[15] and a lower facial ceramid content of the 
stratum corneum found in subjects with sensitive skin (p=0.037)[38].This implies that 
an impaired skin barrier and a dryer skin underlie sensitive skin. 
Sebum and pH: Previously, a study reported a significantly lower sebum in subjects 
with sensitive skin[9]. In studies evaluated in this review, clinically less oily (p<0.01) 
skin was detected in subjects with sensitive skin[37], however, objective surface 
sebum measurements show no differences between subjects with sensitive skin and 
subjects with non-sensitive skin[37, 54] and between stingers and non-stingers[40]. It 
is remarkable that Asian people who more often report sensitive skin[53, 55] have a 
clinically more oily skin compared to Caucasians (31.9% vs. 24%). Aramaki et al., 2002 
detected differences in sebum secretion levels between Japanese and Caucasian 
women following SLS provocation. This indicates that Japanese skin could be more 
susceptible to chemical irritation, possibly due to alterations in sebum secretion levels. 
Literature is inconclusive with regard to the role of sebum secretion in sensitive skin 
perceptions. 
Recent studies show no significant differences in skin surface pH for subjects with 
sensitive skin[37, 54] and stingers[40], while previous studies reported significantly 
higher baseline pH in subjects with sensitive skin[9] and significantly stronger increase 
of pH at t=25 minutes post stimulus among stingers compared to non-stingers[4]. 
Skincare products of pH 8 affect the impact of SLS as evidenced by significant increase 
of TEWL[56]. It seems reasonable to conclude that there is an impaired barrier function, 
allowing faster penetration of LA and therefore faster increase of surface pH after 
LA[4], enhancing sensitivity to chemical agents[56]. 
Skin structure and viscoelasticity: Skin of stingers with self-reported sensitive skin 
appears to be rougher since FFT evaluation of tapes after tape-stripping the stratum 
corneum in 243 stingers reveals lower contents of cells. This implies a more irregular 
and rougher[57], possibly less hydrated skin. However, objectively measured skin 
elasticity and distensability show no correlation to hypersensitivity[54].
Based on these results, we suggest that an impaired skin barrier function plays a role 
in the pathomechanism of sensitive skin and needs to be investigated in depth. 
Inflammatory or vascular response
Individuals with sensitive skin frequently report reddening of their skin[15, 35, 37, 38, 
43, 44, 49, 57, 58]. Therefore, the assessment of erythema in skin irritation has been 
widely investigated, either by visual assessment[28, 37, 41, 59, 60], or by quantitative 
methods as reﬂectance tristimulus colorimetry (a* value)[20, 50-52] or reﬂectance 
spectrophotometry (erythema index, EI)[38, 53, 59] or Laser Doppler Flowmetry 
(cutaneous blood ﬂow, CBF)[20, 41, 48, 50, 51, 53, 61]. Increased vascular reactivity has 
been emphasized in literature as a key player in sensitive skin pathophysiology. In this 
review, lower objective values for redness were found at baseline: lower a* values in 
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subjects with sensitive skin[20, 50, 53] and lower EI and CBF in stingers[38, 41, 50, 51] 
and subjects with sensitive skin[20, 38, 48] were observed (table 2). With respect to 
enhanced vascular reactivity following provocations, inconclusive evidence was found 
(table 2). Application of LA, SLS, capsaicin or cumene failed to enhance differences in 
erythema responses[20, 50, 51, 53], while application of octane, acetyl-b-methylcholine 
chloride, allergen patch testing (European standard and cosmetics) and methyl 
nicotinate (MN) resulted in a stronger erythema response in stingers and in sensitive 
skin[37, 51]. Similar results on MN were found in 1991[1]. One study remarkably 
observed a blanching reaction following MN in solely subjects with sensitive skin[37]. 
Japanese women demonstrate stronger vascular reactions compared to Caucasian 
women[53]. A proposed explanation for vascular reactivity in sensitive skin is a higher 
concentration of chemical agents absorbed in the skin, possibly implying an impaired 
barrier function which could elicit vascular responses[62]. At a histological level, no 
differences with respect to endothelium markers are observed[33]. With respect to 
genetic characteristics, non-atopic subjects with a G-to-A-transition (TNF-α polymorphism 
-308) have significantly higher stinging response following LAST compared to non- 
atopic subjects with the wild type (p=0.03), suggesting that TNF-α and an increase in 
NGF plays a role in the perception of skin irritation[60].
Allergic predisposition
Epidemiological studies support the association between sensitive skin and atopic 
diathesis due to a significantly higher individual manifestation of atopy in the sensitive 
skin group[14]. This indicates that impaired skin barrier function and increased mast 
cell degranulation could be involved in the pathophysiology. One of the included 
studies showed that atopic predisposition enhances erythema responses (p=0.03)
[52]. Although dermographism is comparable between subjects with sensitive skin 
and subjects with non-sensitive skin[37], histologically, increased numbers of CD117+ 
mast-cells (p<0.08) and larger cross-sectional area of lymphatic vessels identified by 
LYVE-1 and podoplanin (p<0.001) were seen in individuals with a low CPT[33]. Such 
differences in physiology are possibly responsible for the modulation of the perception 
threshold of nociceptive stimuli, via the release of mast-cell mediators. Total IgE in the 
blood does not differ[33]. 
Discussion 
Sensitive skin being highly prevalent in the western world, understanding of the 
physiological reality of sensitive skin is of high importance. This systematic literature 
review concludes that potential causal pathways hypothesized to lead to a response 
pattern commonly designated as sensitive skin are the following: sensory hyperreac-
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tivity, impaired barrier function, inﬂammatory or vascular responsiveness and atopic 
predisposition. 
This review also confirms that identification of sensitive skin is complex. A single 
overall definition for sensitive skin is not supported by evidence and no objective 
diagnostic test is found to be sensitive and reproducible. Strong evidence on pathways 
underlying sensitive skin is lacking. Only few provocative methods, as SLS, vasodilators 
and capsaicin possibly trigger the mechanism of sensitive skin, since these agents 
enhanced differences between subjects with sensitive and non-sensitive skin. The 
strongest evidence refers to an impaired skin barrier function. This impaired barrier 
may trigger both vascular hyperreactivity and sensory perceptions, suggesting 
different mechanisms by different discomfort presentation. 
Potentially, the variety of tests, selection methods and measurement methods has led 
to the large diversity of theories on the mechanism of sensitive skin. First, highly 
heterogeneous methods to measure biophysical characteristics are applied following 
different provocations at different body sites in different moments in time in order to 
select subjects with sensitive skin. Even within the LAST method various concentrations 
and inclusion criteria are used, different from the original LAST (Frosch and Kligman, 
1977). Second, some studies did not set the required environmental conditions for 
biophysical measurements on TEWL and CAP, as recommended in the published 
guidelines[40]. And, despite the assumption that various host factors such as allergic 
predisposition promote sensitive skin[21], many included studies did not take these 
potential confounders into consideration in selection processes resulting in different 
populations or did not report these confounders. Moreover, useful research data of 
cosmetic industry is frequently kept confidential or published studies have 
methodological shortcomings and enrolled small subject groups, complicating the 
reliability and completeness of data on sensitive skin. 
In order to unravel the pathomechanism and potential triggering pathways of this 
mechanism, first of all the symptom- and perception profile associated with sensitive 
skin should be identified. Perception-based selection of subjects enables to investigate 
if structural and physiological differences of sensitive skin compared to ‘normal’ skin. 
This selection could be more specific than the LAST. 
Second, an important question is whether sensitive skin is a ‘container term’ 
comprising multiple pathways that elicit sensitivity. More specifically and with 
relevance for clinical practice: is there a set of triggers that are able to predict certain 
proclivity to have sensitive skin? Since sensitive skin seems not a one-dimensional 
condition, a more specific identification method for sensitive skin compared to 
provocations with LA or capsaicin may be a questionnaire or a scoring scale for 
neurosensory perceptions. A questionnaire enables to include a broader spectrum of 
triggers and common symptoms of sensitive skin and is applicable for clinical practice 
in order to predict one’s propensity to experience sensitive skin. 
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We propose that selection methods with higher specificity such as subjective scoring 
scales could be adequate diagnostic tools to detect subjects with sensitive skin for 
research purposes and when combined with consistent biophysical measurements, 
could possibly highlight significant differences in subjects with sensitive skin with 
respect to non-sensitive subjects and lead to consistent results. We propose using 
multifactorial questionnaires, spanning a range of provocations, including those of 
chemical, mechanical and environmental origin, followed by clinical, histological and 
top-notch biophysical measurements. This could lead to a break-through in the 
understanding of the sensitive skin phenomenon, fueling advances of biomedical and 
dermatological science. Next steps could be to zoom in on potential involved 
mechanisms with advanced techniques. For example an extended analysis of the skin 
barrier structure and composition could provide new insights in pathways involved in 
development of the sensitive skin phenomenon.  
Born out of clinical practice, it might be that sensitive skin plays a role in inter-individual 
variability in reactivity potential among dermatological patients, as experienced in 
skin diseases as psoriasis or acne [6] [63]. This knowledge relates sensitive skin to 
knowledge on pathology in skin diseases and could be basis for addressing solutions 
to differences in individual skin reactions in clinical practice. The ultimate goal of 
identification of underlying mechanisms is to develop rational interventions for each 
individual with sensitive skin, implementing personalized medicine. For the future, we 
recommend using approaches focused on identifying pathomechanisms causing 
perceptions of skin discomfort designated as sensitive skin to propose an evidence- 
based diagnosis and intervention for patients with sensitive skin.
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OBJECTIVE MEASUREMENTS OF SENSITIVE SKIN
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Supplement 2   Data extraction tables.
Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
SRSS combined with LAST
Berardesca et al., 2009, RCT, STROBE C
face Moisturizing lotion/
Milk, twice daily,  
4 weeks
- bacterial count 
-  elasticity/ 
distensability
- TEWL
- CAP
- roughness
- pH
- color 
- clinical score
n=20
Stinger + SRSS
Non-lesional 
atopic skin
P
n=20
Stinger + SRSS 
Non-lesional 
atopic skin
Placebo
0 30-59 n.a. - interfering Rx
- pregnant/ lactating
- allergic to cosmetics
- washout cosmetic use 2wk 
Gr. I: decrease skin roughness, TEWL, dryness, irritation and 
desquamation. 
Increase capacitance and erythema.
Gr. II: Increase erythema, decrease dryness
Distante et al., 2002, CC, STROBE C 
Facial areas n.a. - TEWL 
- CAP
- CBF
n=10 
Stinger, SRSS 
and reaction 
to external 
factors
n=10
Non-stinger, 
NSS and no 
reaction to 
external 
factors
NSS
0 19-45
36±2
Caucasian
II-IV
- contact dermatitis
- washout cosmetics 12h
Highest values: chin and paranasal sites all measurements
I: higher TEWL. Cheekbone (p<0.05)
I: lower CAP (n.s.) 
I: higher skin ﬂux. Forehead (p<0.05)
Questionnaire or self-reported sensitive skin
Cho et al., 2012, CC, STROBE B
- cheek 
- forearm
- thigh
- leg
- back
- palm
LA 10% -stinging 
-TEWL 
-EI
-ceramid contents
n=20 
SS 
n=30
NSS
I: 30
II: 60
I: 29.5
II: 30.5
n.a. - Rx of diseases related to SS -no diff. gr. I and II in TEWL and EI 
-no correlation TEWL and LAST
-ceramid content  I < II. Face:  p=0.037
-stinging I: 80%, II: 66.7%, difference increases over time (n.s.)
Diogo and Papoila, 2010, CC, STROBE B
Questionnaire: SRSS following use of household products
Hands - SLS 50µl, 5%, 24h 
- Distilled water
-TEWL 
-a*values 
-CAP
-CBF
n=12
SRSS
n=12
NSS
0 38.9±13 Caucasian -  systemic or dermatological 
disorders 
- Rx
Baseline: a*-value gr. I < II (p=0.033). TEWL, CAP, blood ﬂow (n.s.)
30 minutes post stimulus: gr. I and II increased a*value (n.s.), 
TEWL (n.s.), CAP (n.s.) and blood perfusion (n.s.) 
Recovery time a*-value and TEWL gr. I > II (n.s.)
Jourdain et al., 2005, CrS, STROBE B
Questionnaire: 20 items
nasolabial fold -  Capsaicin in 
5 different 
concentrations  
- water
Nature  
and intensity of 
sensation
n=150 n.a. 0 35 n.a. - allergy to capsaicin/chili pepper
- disorder in test area
- topical or systemic Rx
Detection thresholds: large variation. 27% no threshold 
detectable (30% in stingers)
23.3% detected lowest concentration (3.16x10-5%). 
89% reported 1 sensation (majority stinging or burning) 
Correlation capsaicin threshold and questionnaire items 
on SS: Kendall’s τb values and p-values (general inverse 
correlation).
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
SRSS combined with LAST
Berardesca et al., 2009, RCT, STROBE C
face Moisturizing lotion/
Milk, twice daily,  
4 weeks
- bacterial count 
-  elasticity/ 
distensability
- TEWL
- CAP
- roughness
- pH
- color 
- clinical score
n=20
Stinger + SRSS
Non-lesional 
atopic skin
P
n=20
Stinger + SRSS 
Non-lesional 
atopic skin
Placebo
0 30-59 n.a. - interfering Rx
- pregnant/ lactating
- allergic to cosmetics
- washout cosmetic use 2wk 
Gr. I: decrease skin roughness, TEWL, dryness, irritation and 
desquamation. 
Increase capacitance and erythema.
Gr. II: Increase erythema, decrease dryness
Distante et al., 2002, CC, STROBE C 
Facial areas n.a. - TEWL 
- CAP
- CBF
n=10 
Stinger, SRSS 
and reaction 
to external 
factors
n=10
Non-stinger, 
NSS and no 
reaction to 
external 
factors
NSS
0 19-45
36±2
Caucasian
II-IV
- contact dermatitis
- washout cosmetics 12h
Highest values: chin and paranasal sites all measurements
I: higher TEWL. Cheekbone (p<0.05)
I: lower CAP (n.s.) 
I: higher skin ﬂux. Forehead (p<0.05)
Questionnaire or self-reported sensitive skin
Cho et al., 2012, CC, STROBE B
- cheek 
- forearm
- thigh
- leg
- back
- palm
LA 10% -stinging 
-TEWL 
-EI
-ceramid contents
n=20 
SS 
n=30
NSS
I: 30
II: 60
I: 29.5
II: 30.5
n.a. - Rx of diseases related to SS -no diff. gr. I and II in TEWL and EI 
-no correlation TEWL and LAST
-ceramid content  I < II. Face:  p=0.037
-stinging I: 80%, II: 66.7%, difference increases over time (n.s.)
Diogo and Papoila, 2010, CC, STROBE B
Questionnaire: SRSS following use of household products
Hands - SLS 50µl, 5%, 24h 
- Distilled water
-TEWL 
-a*values 
-CAP
-CBF
n=12
SRSS
n=12
NSS
0 38.9±13 Caucasian -  systemic or dermatological 
disorders 
- Rx
Baseline: a*-value gr. I < II (p=0.033). TEWL, CAP, blood ﬂow (n.s.)
30 minutes post stimulus: gr. I and II increased a*value (n.s.), 
TEWL (n.s.), CAP (n.s.) and blood perfusion (n.s.) 
Recovery time a*-value and TEWL gr. I > II (n.s.)
Jourdain et al., 2005, CrS, STROBE B
Questionnaire: 20 items
nasolabial fold -  Capsaicin in 
5 different 
concentrations  
- water
Nature  
and intensity of 
sensation
n=150 n.a. 0 35 n.a. - allergy to capsaicin/chili pepper
- disorder in test area
- topical or systemic Rx
Detection thresholds: large variation. 27% no threshold 
detectable (30% in stingers)
23.3% detected lowest concentration (3.16x10-5%). 
89% reported 1 sensation (majority stinging or burning) 
Correlation capsaicin threshold and questionnaire items 
on SS: Kendall’s τb values and p-values (general inverse 
correlation).
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Lofﬂer et al., 2001, CrS, STROBE B
Questionnaire: 11 items
Volar
forearm
SLS 48h,  
0.5% patch
- TEWL 
- CBF 
- CAP
Questionnaire
n=420
SLS patch test: 
n=152/420
n.a. 39 49 n.a. n.a. 50% strong to severe SS.
Predominant features and body areas: reddening, burning, 
tension; all body parts, not hands. 
Correlation with: nickel allergy, female sex. No correlation: age, 
season, Fitzpatrick skin type.
(Un)challenged skin and after SLS: TEWL, CBF and CAP: no 
differences between degrees of SRSS. 
Pinto et al., 2011,  CC, STROBE B
Questionnaire: Self-perceived sensitive skin, not specified.
dorsal hand plastic occlusion 
patch testing
- TEWL n=15 
SS
n=18 NSS 0 I: 54±10
II: 34±10
n.a. n.a. Baseline: µ TEWL gr I > II (p=0.059)
Challenged skin:  evaporation t½ and DWM gr. I > II: (p=0.005) 
and p=0.0001)
Robinson and Perkins, 2001, CrS, STROBE B
Questionnaire: Skin reactivity: higher scores on recall VAS (mean >25)
P1: cheek 
P2: forearm
P1: LA on disc, 3 min
P2: capsaicin in  
80% ethanol on 
filter, 3 min
P1: stinging (VAS) 
P2: stinging (VAS)
n= 46
P1:n=10, P2: 
n=18
water Both
n.a.
18-65 n.a. - skin conditions and diseases,
- anti-inﬂammatory Rx. 
P1: Correlation with stinging recall VAS. responses no relation 
to recall VAS.
P2: Low capsaicin threshold (<1000 µM) relation with VAS >25. 
High threshold to capsaicin(>1000 µM) 5/8 had VAS <25.
Roussaki-Schulze et al., 2005, CC, STROBE B
Questionnaire: Subjective disturbances to environmental or cosmetic factors, without clinical manifestations.
P1: nasolabial 
fold and 
forearm
P2: back
P3: face
P4: n.a.
P5: forearm
P6: forearm
P7: blood
P8: n.a.
P1: LAST 
P2: 48h patch 36 
allergens
P5: 50% NaOH alkali 
resistance test.
P6: MN 0.5%, MN 
1.4%, Actetyl-b-
methylcholine 
chloride
P1: stinging 
P2: reaction 
P3: Sebum + hydration 
levels
P4: pH
P5: redness or edema
P6: erythema 
P7: total IgE 
P8:dermographism
n= 32 
SS 
n=30 NSS I: 40.6
II:43.3
I: 32.6 
II: 30.4
n.a. n.a. Sign. differences gr. I  and II. 
P1: higher stinging (p<0.001), P2: higher allergic reactions 
to European(p<0.01) and cosmetics(p<0.05), higher toxic 
reactions to cosmetics (p<0.01), P3: dryer skin(p<0.05) and 
lower fatness (p<0.01) P5: higher risk to develop alkali 
resistance. (p<0.05) (OR:3.82 [1.33-10.9]), P6 stronger erythema 
(p<0.01), acetyl-b-methylcholine chloride: erythema and 
blanching reactions occurred.
Bowman et al., 2000,  CC, STROBE C
Questionnaire: 20 items
nasolabial fold P1: LA 10% cotton 
pad
P2: Balsam of Peru 
10% cotton pad 
P3: Chloroform/ 
Methanol 10:90
- burning
- stinging
n=405 SS n=612
NSS
0 18-65 n.a. n.a. Onset sensation gr I > II (sign. P1, P2) 
Peak sensation.  gr I > II (sign. P1, P2, P3) 
T  to onset sensation gr I < II (sign. P1, P2, P3)
T  to peak sensation gr I < II (sign. P1, P2) 
I: non-responders: P1: 22%, P2: 36%, P3: 7%
No correlation SRSS and response to chemicals.
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Lofﬂer et al., 2001, CrS, STROBE B
Questionnaire: 11 items
Volar
forearm
SLS 48h,  
0.5% patch
- TEWL 
- CBF 
- CAP
Questionnaire
n=420
SLS patch test: 
n=152/420
n.a. 39 49 n.a. n.a. 50% strong to severe SS.
Predominant features and body areas: reddening, burning, 
tension; all body parts, not hands. 
Correlation with: nickel allergy, female sex. No correlation: age, 
season, Fitzpatrick skin type.
(Un)challenged skin and after SLS: TEWL, CBF and CAP: no 
differences between degrees of SRSS. 
Pinto et al., 2011,  CC, STROBE B
Questionnaire: Self-perceived sensitive skin, not specified.
dorsal hand plastic occlusion 
patch testing
- TEWL n=15 
SS
n=18 NSS 0 I: 54±10
II: 34±10
n.a. n.a. Baseline: µ TEWL gr I > II (p=0.059)
Challenged skin:  evaporation t½ and DWM gr. I > II: (p=0.005) 
and p=0.0001)
Robinson and Perkins, 2001, CrS, STROBE B
Questionnaire: Skin reactivity: higher scores on recall VAS (mean >25)
P1: cheek 
P2: forearm
P1: LA on disc, 3 min
P2: capsaicin in  
80% ethanol on 
filter, 3 min
P1: stinging (VAS) 
P2: stinging (VAS)
n= 46
P1:n=10, P2: 
n=18
water Both
n.a.
18-65 n.a. - skin conditions and diseases,
- anti-inﬂammatory Rx. 
P1: Correlation with stinging recall VAS. responses no relation 
to recall VAS.
P2: Low capsaicin threshold (<1000 µM) relation with VAS >25. 
High threshold to capsaicin(>1000 µM) 5/8 had VAS <25.
Roussaki-Schulze et al., 2005, CC, STROBE B
Questionnaire: Subjective disturbances to environmental or cosmetic factors, without clinical manifestations.
P1: nasolabial 
fold and 
forearm
P2: back
P3: face
P4: n.a.
P5: forearm
P6: forearm
P7: blood
P8: n.a.
P1: LAST 
P2: 48h patch 36 
allergens
P5: 50% NaOH alkali 
resistance test.
P6: MN 0.5%, MN 
1.4%, Actetyl-b-
methylcholine 
chloride
P1: stinging 
P2: reaction 
P3: Sebum + hydration 
levels
P4: pH
P5: redness or edema
P6: erythema 
P7: total IgE 
P8:dermographism
n= 32 
SS 
n=30 NSS I: 40.6
II:43.3
I: 32.6 
II: 30.4
n.a. n.a. Sign. differences gr. I  and II. 
P1: higher stinging (p<0.001), P2: higher allergic reactions 
to European(p<0.01) and cosmetics(p<0.05), higher toxic 
reactions to cosmetics (p<0.01), P3: dryer skin(p<0.05) and 
lower fatness (p<0.01) P5: higher risk to develop alkali 
resistance. (p<0.05) (OR:3.82 [1.33-10.9]), P6 stronger erythema 
(p<0.01), acetyl-b-methylcholine chloride: erythema and 
blanching reactions occurred.
Bowman et al., 2000,  CC, STROBE C
Questionnaire: 20 items
nasolabial fold P1: LA 10% cotton 
pad
P2: Balsam of Peru 
10% cotton pad 
P3: Chloroform/ 
Methanol 10:90
- burning
- stinging
n=405 SS n=612
NSS
0 18-65 n.a. n.a. Onset sensation gr I > II (sign. P1, P2) 
Peak sensation.  gr I > II (sign. P1, P2, P3) 
T  to onset sensation gr I < II (sign. P1, P2, P3)
T  to peak sensation gr I < II (sign. P1, P2) 
I: non-responders: P1: 22%, P2: 36%, P3: 7%
No correlation SRSS and response to chemicals.
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Querleux et al., 2008, CC, STROBE C
Questionnaire: 13 items
nasolabial fold P: LA (R)
C: saline (L)
- discomfort
-  fMRI brain 
activity
n=9
SS
n=9
NSS
0 33±9 n.a. -  anti-inﬂammatory, topical or 
systemic Rx, 
-  facial dermatological, 
neurological or vascular 
conditions
Gr. I  responses to products at all time points.
fMRI: n=15 (7-8): Attention right side, no increased fMRI 
activity is seen (both groups). 
Discomfort gr I both sides, gr. II, left primary sensorimotor 
area. Increase bilateral dorsal fronto-parietal II < I. 
Solely in gr. I: activity bilateral peri-insular regions.
Vijver van de et al., 2003, CrS, STROBE C
Questionnaire: questions on characteristics, behavior, use of cosmetics and hypersensitivity
- forehead
- volar forearm
n.a. Forehead: sebum 
volar forearm:
- pH
- CAP
-  viscoelastic 
properties
n=302 n.a. 49.3 18-75 n.a. n.a. 15% reported skin irritation or hyper-sensitivity to skin care 
products ( 23%, 8%)
SRSS vs non SRSS: no differences pH, CAP, viscoelastic 
properties
LAST positive
de Campos Dieamant et al., 2008, RCT, STROBE B 
face P1: RCAC facial 
serum applied  
twice a day 
C: placebo
immunoassays 
keratinocytes 
(β-endorfphin, 
encephalin, CGRP, 
substance P,IL-1α, 
TNF-α, IL-10)
-  sensation 
stinging
-  dryness 
sensation 
- TEWL
n=60
stinger
P1
n=60 
stinger
placebo
n.a. 40-55 I-III n.a. I: sign. Better skin comfort, reduced skin dryness sensation and 
lower TEWL. 
3 experiments with RCAC in vitro showed:
- Upregulation: β-endorfphin and encephalin
- Decrease of substance P and CGRP production
- Restored induced cytokine levels
Kim et al., 2008, CC, STROBE B
-forearm
-face
P1: capsaicin
0.075%,  80µL
- CAP
- TEWL
- skin color
- CBF 
- CPT
n=4 
stinger and 
reaction to 
irritants
n=4 
non-stinger
100 I: 23.8 ±1.5
II:23.3
±1.9 
n.a -  systemic or dermatological 
disorders
Baseline measurements: no diff.
I: lower CAP, higher TEWL, higher a*, CBF comparable (n.s.)
P1 face: I wide CPT variation, CPT decreased.
Lee et al., 2009, CC, STROBE B
nasolabial fold
cheek
9 types of 
applications with 
sensory irritation 
inhibitors
- CPT 5Hz
- CPT 250 Hz
- CPT 2000Hz
n=11
stinger
n=9
non-stinger
40 25.8±1.4 n.a. - acne, eczema, psoriasis. 
- anti-inﬂammatory Rx
Baseline: CPT values gr. I < gr. II: 
Only after Strontium Chloride sign. changes: 
Sensory score decreased (gr. I: p <0.01, gr. II: p=0.257) and CPT 
(5&250 Hz) increased (both groups p<0.05).
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Querleux et al., 2008, CC, STROBE C
Questionnaire: 13 items
nasolabial fold P: LA (R)
C: saline (L)
- discomfort
-  fMRI brain 
activity
n=9
SS
n=9
NSS
0 33±9 n.a. -  anti-inﬂammatory, topical or 
systemic Rx, 
-  facial dermatological, 
neurological or vascular 
conditions
Gr. I  responses to products at all time points.
fMRI: n=15 (7-8): Attention right side, no increased fMRI 
activity is seen (both groups). 
Discomfort gr I both sides, gr. II, left primary sensorimotor 
area. Increase bilateral dorsal fronto-parietal II < I. 
Solely in gr. I: activity bilateral peri-insular regions.
Vijver van de et al., 2003, CrS, STROBE C
Questionnaire: questions on characteristics, behavior, use of cosmetics and hypersensitivity
- forehead
- volar forearm
n.a. Forehead: sebum 
volar forearm:
- pH
- CAP
-  viscoelastic 
properties
n=302 n.a. 49.3 18-75 n.a. n.a. 15% reported skin irritation or hyper-sensitivity to skin care 
products ( 23%, 8%)
SRSS vs non SRSS: no differences pH, CAP, viscoelastic 
properties
LAST positive
de Campos Dieamant et al., 2008, RCT, STROBE B 
face P1: RCAC facial 
serum applied  
twice a day 
C: placebo
immunoassays 
keratinocytes 
(β-endorfphin, 
encephalin, CGRP, 
substance P,IL-1α, 
TNF-α, IL-10)
-  sensation 
stinging
-  dryness 
sensation 
- TEWL
n=60
stinger
P1
n=60 
stinger
placebo
n.a. 40-55 I-III n.a. I: sign. Better skin comfort, reduced skin dryness sensation and 
lower TEWL. 
3 experiments with RCAC in vitro showed:
- Upregulation: β-endorfphin and encephalin
- Decrease of substance P and CGRP production
- Restored induced cytokine levels
Kim et al., 2008, CC, STROBE B
-forearm
-face
P1: capsaicin
0.075%,  80µL
- CAP
- TEWL
- skin color
- CBF 
- CPT
n=4 
stinger and 
reaction to 
irritants
n=4 
non-stinger
100 I: 23.8 ±1.5
II:23.3
±1.9 
n.a -  systemic or dermatological 
disorders
Baseline measurements: no diff.
I: lower CAP, higher TEWL, higher a*, CBF comparable (n.s.)
P1 face: I wide CPT variation, CPT decreased.
Lee et al., 2009, CC, STROBE B
nasolabial fold
cheek
9 types of 
applications with 
sensory irritation 
inhibitors
- CPT 5Hz
- CPT 250 Hz
- CPT 2000Hz
n=11
stinger
n=9
non-stinger
40 25.8±1.4 n.a. - acne, eczema, psoriasis. 
- anti-inﬂammatory Rx
Baseline: CPT values gr. I < gr. II: 
Only after Strontium Chloride sign. changes: 
Sensory score decreased (gr. I: p <0.01, gr. II: p=0.257) and CPT 
(5&250 Hz) increased (both groups p<0.05).
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Marriott et al., 2005, CrS, STROBE B
nasolabial fold
volar forearm 
upper outer 
arm
Nasolabial fold 
P1: LA, capsaicin, 
ethanol, menthol
P2: volar forearm 
SDS, CAPB and BKC 
covered patch tests. 
P2: 1m Benzoic acid 
in petrolatum, 125 
mm trans-cinnamic 
acid
P3: upper arm 
Covered patch test 
23h with materials 
of P2.
- sensory perception 
- visual erythema 
- visual dryness
n=58 stinger 
or reaction to 
SDS
C: water 33 39.0 Caucasian - eczema
- dermatitis
- psoriasis 
Sensory perception tests:
91% sensitive to ≥ 1 material. 7% sensitive to all materials.
Reacting (n): 
LA: 45% (22% stinging) Capsaicin: 82% (52% burning)  
Ethanol: 12%
Menthol: 38% (16% cooling)
P2: 67% strong erythema to benzoic acid
19% strong erythema to trans-cinnamic acid
P3: 21% erythema development to all surfactants.
1 person did react to all provocations.
Schliemann et al., 2011, CC, STROBE B
forearm P1: 8 min. single: 
neat n-octane or 
cumene (lipophilic 
irritant) on filter 
discs.
P2: repeated 2dd 
10min for 4 days: 
neat n-octane or 
cumene on filter 
discs.
C: untreated
P1: LDF 
P2: 
- CBF
- chromametry 
- TEWL 
- CAP 
- visual irritation
n=15
stinger
n=15
non-
stinger
I: 33.3
II: 33.3
n.a. n.a. n.a. Baseline; TEWL, CAP and a* values: gr. I > gr. II (n.s.) 
P1: erythema increase gr. I and gr. II. (p<0.001). No sign. diff. gr. I 
vs gr. II: n-octane (p=0.976), cumene(p=0.631) 
P2: all evaluations and irritants SC hydration and visual 
irritation gr. I > II. (significant)
P2: octane repeated: stronger decrease a* value in gr I  p<0.001, 
higher increase CAP (p=0.002 on day 5)
cumene repeated: stronger decrease a* value in gr I  p<0.021, 
higher increase CAP (n.s.)
Sparavigna et al., 2006, CrS, STROBE B
volar forearm n.a. Fast Fourier Transform 
on tapes after SC 
tape-stripping by 
cyanoacrylate. 
n=243 stinger n.a. n.a. 39±12 n.a. - wounds or scars face
- pregnancy/lactation
-  systemic or dermatological 
disorders
- surgery <1yr 
- cosmetics or Rx
Correlated with ISI (irregularity skin index): (rs=0.46, p<0.001)
An et al., 2007, CC, STROBE B
nasolabial fold n.a. - TEWL
- pH 
- CAP
- sebum
n= 44
stinger
n=209
non-
stingers
0 29.2±5.5 Asian -  pre-existing skin disease or  
anti-inﬂammatory Rx.
I: higher TEWL (p=0.03)
pH, CAP, sebum (n.s.) 
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Marriott et al., 2005, CrS, STROBE B
nasolabial fold
volar forearm 
upper outer 
arm
Nasolabial fold 
P1: LA, capsaicin, 
ethanol, menthol
P2: volar forearm 
SDS, CAPB and BKC 
covered patch tests. 
P2: 1m Benzoic acid 
in petrolatum, 125 
mm trans-cinnamic 
acid
P3: upper arm 
Covered patch test 
23h with materials 
of P2.
- sensory perception 
- visual erythema 
- visual dryness
n=58 stinger 
or reaction to 
SDS
C: water 33 39.0 Caucasian - eczema
- dermatitis
- psoriasis 
Sensory perception tests:
91% sensitive to ≥ 1 material. 7% sensitive to all materials.
Reacting (n): 
LA: 45% (22% stinging) Capsaicin: 82% (52% burning)  
Ethanol: 12%
Menthol: 38% (16% cooling)
P2: 67% strong erythema to benzoic acid
19% strong erythema to trans-cinnamic acid
P3: 21% erythema development to all surfactants.
1 person did react to all provocations.
Schliemann et al., 2011, CC, STROBE B
forearm P1: 8 min. single: 
neat n-octane or 
cumene (lipophilic 
irritant) on filter 
discs.
P2: repeated 2dd 
10min for 4 days: 
neat n-octane or 
cumene on filter 
discs.
C: untreated
P1: LDF 
P2: 
- CBF
- chromametry 
- TEWL 
- CAP 
- visual irritation
n=15
stinger
n=15
non-
stinger
I: 33.3
II: 33.3
n.a. n.a. n.a. Baseline; TEWL, CAP and a* values: gr. I > gr. II (n.s.) 
P1: erythema increase gr. I and gr. II. (p<0.001). No sign. diff. gr. I 
vs gr. II: n-octane (p=0.976), cumene(p=0.631) 
P2: all evaluations and irritants SC hydration and visual 
irritation gr. I > II. (significant)
P2: octane repeated: stronger decrease a* value in gr I  p<0.001, 
higher increase CAP (p=0.002 on day 5)
cumene repeated: stronger decrease a* value in gr I  p<0.021, 
higher increase CAP (n.s.)
Sparavigna et al., 2006, CrS, STROBE B
volar forearm n.a. Fast Fourier Transform 
on tapes after SC 
tape-stripping by 
cyanoacrylate. 
n=243 stinger n.a. n.a. 39±12 n.a. - wounds or scars face
- pregnancy/lactation
-  systemic or dermatological 
disorders
- surgery <1yr 
- cosmetics or Rx
Correlated with ISI (irregularity skin index): (rs=0.46, p<0.001)
An et al., 2007, CC, STROBE B
nasolabial fold n.a. - TEWL
- pH 
- CAP
- sebum
n= 44
stinger
n=209
non-
stingers
0 29.2±5.5 Asian -  pre-existing skin disease or  
anti-inﬂammatory Rx.
I: higher TEWL (p=0.03)
pH, CAP, sebum (n.s.) 
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Other selection methods
Aramaki et al., 2002, CC, STROBE B
cheek 
forearm
P1: LAST 10% cheek
C: water
P2: SLS patch test 
(12mm) arm 24h: 
0.25% and 0.5% 
C: water
P1: 
- sensations 
- VAS 
P2: 
- TEWL
- CBF 
- CAP
- sebum
- melanin+ Hb content
 - a* values
I: SLS n=22, LA 
n=18
II: SLS 
n=22, 
LA n=20
0 I SLS 25.8 
LA: 26.6
II: SLS 26.9
LA 26.9
I:
Japanese
II:
German
n.a. Baseline and post SLS: all values content Gr. < Gr. II (n.s.) except 
for:
-  Melanin content: significantly higher in group I at baseline 
and after SLS.
- TEWL values baseline and post SLS gr. I < II (p<0.05) 
-  Sebum secretion baseline gr. I < gr. II, but post SLS gr. I > II. 
Sebum increased in gr I, and decreased in gr II post SLS. 
- VAS scores after LA stinging gr. I > gr II. 
De Jongh et al., 2006, CrS, STROBE B
volar forearm P1: Single 24 hr 
exposure to SLS1% 
P2: Repeated 3 wk 
exposure to SLS 
0,1% for 6 hrs/day, 4 
days/wk.
- TEWL 
- EI
-  SC tape stripping + 
ELISA (IL-1α, IL-1RA, IL-2, 
IL-6, IL-8, IL-10  
and TNF-α)
n=20 n.a. 35  24±5
 25± 8
n.a. - visible skin abnormalities, 
- skin disease
- smoking
- corticosteroids
- tanning  <2months
Baseline: no differences
P1: ΔTEWL (p=0.007), Δerythema  (p=0.03)
P2: TEWL and erythema  progressive until end of wk 2. Large 
variation.
Baseline TEWL   ΔTEWL higher. Atopics Δerythema
Cytokine changes after P2 (p<0.05):  IL-1RA , IL-1α , IL-1RA/ 
IL1α  and IL-8
Marriott et al., 2003, CC, STROBE B
nasolabial fold
forehead
chin
malar 
eminence
P1: LA 10% open 
application
P2: LA 10% under 
occlusion 
C: Ultrapure water 
on contralateral site 
sum values ≥2 = 
stinger at 3 time points 
on stinging, burning, 
itching on 4pt scale.
n=45 n.a. n.a. 36 n.a. n.a. LA: n= 19 stinger (5 ), highest stinging nasolabial fold, n=26 
nonstinger (12 ), highest scores forehead. 
LA under occlusion lower responses: 20/45 reported any 
response.
Quatresooz et al., 2009, CC, STROBE C
neck n.a. CPT + skin biopsy 
neck: (LYVE-1,  human 
podoplanin, CD31, UEA-1, 
CD117)
n=36 
I: reactive skin 
(low CPT) 
n=36 
II: no 
reactive 
skin (high 
CPT) 
50 31.5±8.4 Caucasian Non-fair haired or non-fair 
skinned
Detection stinging gr. I after 10-25s (shorter than gr II)
CD117, LYVE-1, podoplanin: higher density  gr. I (p<0.08) 
CD31, UEA-1: no diff.
Sahlin et al., 2007, CrS, STROBE B 
cheek 
nasolabial fold
P: LA 15% in w/o  
and o/w
C: vehicle without 
LA
- stinging (VAS) n=27, healthy n.a. 48 24 ±5 n.a. skin disorders 15% o/w emulsion with 10% mineral oil vs 50%: increased 
stinging (p=0.077). 
o/w compared to w/o: higher max. stinging capacity 
(p=0.002) and AUC on VAS scale (p=0.006).
Sparavigna et al., 2005, CrS, STROBE B
nasolabial fold P1:  LA 10% -  discomfort, burning  
or stinging
n=2101 
questionnaire
n.a. 11.5 42± 14.0 I: 5; II:28; 
III: 54; 
IV: 12;
V/VI: 1 (%)
- wounds or scars face
- pregnancy/ lactation
-  systemic dermatological 
disorders or cosmetic/ 
pharmatological Rx
SRSS: 59.9%/total, 56.5%/  
Stingers: 54.9%/total, 59.9%/SRSS, 48.4%/non-SRSS
SRSS (%) vs.non SRSS (%): erythema 25.0/8.9, derm. disorders 
19.6/10.5, Xerosis: 17.9/8.2,  desquamation: 13.3/5.8
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Other selection methods
Aramaki et al., 2002, CC, STROBE B
cheek 
forearm
P1: LAST 10% cheek
C: water
P2: SLS patch test 
(12mm) arm 24h: 
0.25% and 0.5% 
C: water
P1: 
- sensations 
- VAS 
P2: 
- TEWL
- CBF 
- CAP
- sebum
- melanin+ Hb content
 - a* values
I: SLS n=22, LA 
n=18
II: SLS 
n=22, 
LA n=20
0 I SLS 25.8 
LA: 26.6
II: SLS 26.9
LA 26.9
I:
Japanese
II:
German
n.a. Baseline and post SLS: all values content Gr. < Gr. II (n.s.) except 
for:
-  Melanin content: significantly higher in group I at baseline 
and after SLS.
- TEWL values baseline and post SLS gr. I < II (p<0.05) 
-  Sebum secretion baseline gr. I < gr. II, but post SLS gr. I > II. 
Sebum increased in gr I, and decreased in gr II post SLS. 
- VAS scores after LA stinging gr. I > gr II. 
De Jongh et al., 2006, CrS, STROBE B
volar forearm P1: Single 24 hr 
exposure to SLS1% 
P2: Repeated 3 wk 
exposure to SLS 
0,1% for 6 hrs/day, 4 
days/wk.
- TEWL 
- EI
-  SC tape stripping + 
ELISA (IL-1α, IL-1RA, IL-2, 
IL-6, IL-8, IL-10  
and TNF-α)
n=20 n.a. 35  24±5
 25± 8
n.a. - visible skin abnormalities, 
- skin disease
- smoking
- corticosteroids
- tanning  <2months
Baseline: no differences
P1: ΔTEWL (p=0.007), Δerythema  (p=0.03)
P2: TEWL and erythema  progressive until end of wk 2. Large 
variation.
Baseline TEWL   ΔTEWL higher. Atopics Δerythema
Cytokine changes after P2 (p<0.05):  IL-1RA , IL-1α , IL-1RA/ 
IL1α  and IL-8
Marriott et al., 2003, CC, STROBE B
nasolabial fold
forehead
chin
malar 
eminence
P1: LA 10% open 
application
P2: LA 10% under 
occlusion 
C: Ultrapure water 
on contralateral site 
sum values ≥2 = 
stinger at 3 time points 
on stinging, burning, 
itching on 4pt scale.
n=45 n.a. n.a. 36 n.a. n.a. LA: n= 19 stinger (5 ), highest stinging nasolabial fold, n=26 
nonstinger (12 ), highest scores forehead. 
LA under occlusion lower responses: 20/45 reported any 
response.
Quatresooz et al., 2009, CC, STROBE C
neck n.a. CPT + skin biopsy 
neck: (LYVE-1,  human 
podoplanin, CD31, UEA-1, 
CD117)
n=36 
I: reactive skin 
(low CPT) 
n=36 
II: no 
reactive 
skin (high 
CPT) 
50 31.5±8.4 Caucasian Non-fair haired or non-fair 
skinned
Detection stinging gr. I after 10-25s (shorter than gr II)
CD117, LYVE-1, podoplanin: higher density  gr. I (p<0.08) 
CD31, UEA-1: no diff.
Sahlin et al., 2007, CrS, STROBE B 
cheek 
nasolabial fold
P: LA 15% in w/o  
and o/w
C: vehicle without 
LA
- stinging (VAS) n=27, healthy n.a. 48 24 ±5 n.a. skin disorders 15% o/w emulsion with 10% mineral oil vs 50%: increased 
stinging (p=0.077). 
o/w compared to w/o: higher max. stinging capacity 
(p=0.002) and AUC on VAS scale (p=0.006).
Sparavigna et al., 2005, CrS, STROBE B
nasolabial fold P1:  LA 10% -  discomfort, burning  
or stinging
n=2101 
questionnaire
n.a. 11.5 42± 14.0 I: 5; II:28; 
III: 54; 
IV: 12;
V/VI: 1 (%)
- wounds or scars face
- pregnancy/ lactation
-  systemic dermatological 
disorders or cosmetic/ 
pharmatological Rx
SRSS: 59.9%/total, 56.5%/  
Stingers: 54.9%/total, 59.9%/SRSS, 48.4%/non-SRSS
SRSS (%) vs.non SRSS (%): erythema 25.0/8.9, derm. disorders 
19.6/10.5, Xerosis: 17.9/8.2,  desquamation: 13.3/5.8
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Body site Provocation Measured 
parameters
Group I Group II
Control
Sex
%
Age (yrs)
µ±SD or range
Ethnicity  
or skintype
Exclusion Outcome
Wu et al., 2003, CrS, STROBE B
nasolabial fold P1: LA 3%
P2: LA 5%
- Stinging score
- time to stinging 
- TEWL 
- CAP
n= 50 n.a. 22 41±10 Chinese n.a. Stinging: P1 n=58%, P2 n=68% 
µ stinging P1 < P2 (p<0.05)
Stinger: higher TEWL, lower SC hydration. 
Baseline SC hydration correlated inversely to  clinical score 
after 5min. ( Spearman’s test: r=0.307, p=0.03) and TEWL 
(p>0.05)and correlated to time to stinging (p>0.05) 
Davis et al., 2011, CrS, STROBE B
nasolabial fold 
and hands
LA 10% - stinging LM scale 
- erythema, dryness 
-  a* values  
(digital images) 
- atopy
-  qPCR genotyping 
TNF-α polymorphism 
-308
n= 74 total gr. 
I-III
I: atopic 
dermatitis
II: general 
atopy
III: non-
atopics, 
n=19
5 n.a. 86% 
Caucasian
Inclusion: hospital workers 
with specific frequency of hand 
hygiene procedures in 2 wk
AA= ‘A’ allele at position -308 (n=28), GG= wild type allele 
(n=46)
AA vs GG: stronger stinging to LA nasolabial fold (p=0.1) 
and water (P=0.001) and to LA hands (p=0.03) and water 
(P=0.006)
Face and hand scores for LA: AA:  r=0.64 p<0.001, GG: r=0.48, 
r=0.001.  Stinging: nasolabial fold > hands. Stinging face water 
> LA.
Stinging scores for LA on the face: 
AA with atopy > GG non-atopic (p=0.03) (similar for hands)
AA non-atopic > GG non-atopic(p=0.04) (similar for water)
GG with atopy > GG non-atopic (p=0.08)
In decreasing order of stinging: (p<0.05) 
AA atopy (n=19), AA non-atopy (n=7) , GG atopy (n=32), GG 
non-atopy (n=12)
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Control
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%
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Ethnicity  
or skintype
Exclusion Outcome
Wu et al., 2003, CrS, STROBE B
nasolabial fold P1: LA 3%
P2: LA 5%
- Stinging score
- time to stinging 
- TEWL 
- CAP
n= 50 n.a. 22 41±10 Chinese n.a. Stinging: P1 n=58%, P2 n=68% 
µ stinging P1 < P2 (p<0.05)
Stinger: higher TEWL, lower SC hydration. 
Baseline SC hydration correlated inversely to  clinical score 
after 5min. ( Spearman’s test: r=0.307, p=0.03) and TEWL 
(p>0.05)and correlated to time to stinging (p>0.05) 
Davis et al., 2011, CrS, STROBE B
nasolabial fold 
and hands
LA 10% - stinging LM scale 
- erythema, dryness 
-  a* values  
(digital images) 
- atopy
-  qPCR genotyping 
TNF-α polymorphism 
-308
n= 74 total gr. 
I-III
I: atopic 
dermatitis
II: general 
atopy
III: non-
atopics, 
n=19
5 n.a. 86% 
Caucasian
Inclusion: hospital workers 
with specific frequency of hand 
hygiene procedures in 2 wk
AA= ‘A’ allele at position -308 (n=28), GG= wild type allele 
(n=46)
AA vs GG: stronger stinging to LA nasolabial fold (p=0.1) 
and water (P=0.001) and to LA hands (p=0.03) and water 
(P=0.006)
Face and hand scores for LA: AA:  r=0.64 p<0.001, GG: r=0.48, 
r=0.001.  Stinging: nasolabial fold > hands. Stinging face water 
> LA.
Stinging scores for LA on the face: 
AA with atopy > GG non-atopic (p=0.03) (similar for hands)
AA non-atopic > GG non-atopic(p=0.04) (similar for water)
GG with atopy > GG non-atopic (p=0.08)
In decreasing order of stinging: (p<0.05) 
AA atopy (n=19), AA non-atopy (n=7) , GG atopy (n=32), GG 
non-atopy (n=12)
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Abstract 
Despite sensitive skin being highly prevalent, no consensus on the definition and the 
pathomechanism exists. Here we report the results of a systematic literature review 
of diagnostic methods for sensitive skin at clinical, histological and biophysical levels. 
A systematic search revealed 27 out of 1701 articles which we appraised in detail. 
Impaired skin barrier function and increased vascular reactivity are most often 
associated with sensitive skin. We identified key reasons causing an ambiguity around 
the sensitive skin phenomenon. We propose using standardized selection methods of 
subjects by a multifactorial questionnaire, spanning a range of provocations, including 
those of chemical, mechanical and environmental origin, followed by clinical, histological 
and top-notch biophysical measurements. This could lead to a break-through in the 
understanding of the sensitive skin phenomenon, fueling advances of biomedical and 
dermatological science.
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Introduction 
Almost one out of two people in the industrialized world reports to have a sensitive 
skin (SS). [1-5] This condition is often characterized by sensory perceptions such as 
burning, stinging and itching following rather mild exogenous and endogenous 
factors [6-10], while visible signs of skin irritation, such as dryness or erythema are 
frequently absent. [2, 6, 7] 
Despite extensive research on SS, there is neither consensus on its symptom profile, 
nor on its pathophysiology. Sensory hyperreactivity, impaired barrier function, 
inﬂammatory or vascular responsiveness and atopic predisposition are named as 
potential causal pathways underlying self-reported SS. The abnormally low skin 
tolerance threshold and frequently observed vasodilation in sensitive skin suggest 
that the cutaneous nervous system is highly involved in the pathophysiology of 
sensitive skin. [11, 12]  Several studies have recently performed and showed that 
sensitive skin subjects have lower nerve fibre densities [13]  and increased expressions 
of transient receptor potential vanilloid-1 [14]. Sensitive subjects were more easily 
showing vascular hyper-reactivity and sensations following capsaicin application. [15] 
Yet, the physiological reality and contribution of each of these in of SS lacks thorough 
understanding. 
To detect pathways underlying SS, various provocative agents enhancing differences 
in skin reactions between subjects with SS and those with less sensitive skin have 
been applied in combination with methods objectively measuring these skin reactions. 
However, studies using these challenges and read-outs showed inconsistent outcomes, 
where applied tools failed to serve as a diagnostic test for SS due to apparent lack of 
sensitivity and reproducibility. For example, application of lactic acid as a provocative 
agent, physically impacts subjects and could not elicit skin reactions in all individuals 
claiming to have SS. [9, 16, 17] The frequent absence of objective clinical features [18, 
19] as well as the heterogeneity of the presentation and severity of SS [19] might be 
impeding factors. While non-uniform questionnaires have been conducted in order to 
select SS subjects for [7, 8, 10], their sensitivity was not yet sufficiently discriminative.
Getting insights on mechanisms underlying SS, requires, in the first place, a complete 
picture of the associated symptom profile. This, could only be achieved by adequately 
selecting subjects, preferably perception-based, to enable investigation of the patho-
physiology of SS following minor skin trauma to a set of triggers, rather than to one 
specific agent. 
The objective of this study was to create a model for selecting subjects in studies on 
SS by identifying characteristics of a population reporting SS and the factors discrimi-
natively describing it. To achieve this, we designed a questionnaire spanning provocations 
of different nature, which were previously reported in literature to induce subjective 
sensations and visible skin reactions. This survey was also an attempt to answer the 
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question if multiple pathyways trigger the SS pathomechanism and if a ‘general’ skin 
sensitivity exist. Establishing a single definition could enable comparison of clinical 
studies, strenthening evidence in search for underlying processes. 
Methods
A digital survey using a web-based survey tool (EFM v 8.1, Verint Systems Inc., USA) was 
conducted August 2013 and February 2014. An invitation email was sent via Verint 
Systems to employees of two research organizations in the Netherlands related to this 
study (n=1168) and to subjects registered in a database of a recruiting agency 
(n=1890). After two weeks the recipients received a reminder. When subjects were 
willing to contribute, they could access the questionnaire via a link. Completed 
anonymous questionnaires were received by the investigators via Verint Systems.
First, questions regarding socio-demographics were asked, including age, gender, 
educational level, ethnicity and country of origin. Second, information concerning 
atopic predisposition, skin diseases, skin type, skin dryness, comorbidity and personal 
care habits was inquired. Third, degree of self-assessed SS, impact of seasonal effects, 
use of products for SS and other eliciting factors were questioned. Finally, core 
questions about the effects of endogenous and exogenous factors, including toiletries, 
shaving, emotions, sun exposure, cold, heat, temperature changes and clothes were 
posted. Subjects had to give answers in terms of subjective sensations and visible skin 
features reporting on frequency, severity (Visual Analogue Scale (VAS) 0-10), localization 
and duration of eight symptoms (discomfort, stinging, burning, itching, tightness, 
redness, dryness and bumps) (s1).  
Statistical analysis
Groups were defined based on reported skin sensitivity (SS and NSS), or the presence of 
concomitant skin diseases. The t-test and Fisher exact tests were used to test differences 
between groups in case of categorical and  continuous variables, respectively. 
Exploratory factor analysis was performed to identify the underlying dimensions of 
the used questionnaire, comprising VAS and duration scores of eight symptoms for 
each of the eight eliciting factors as described above, thus having in total 128 variables. 
This analysis identifies the structure of the data, with the aim to identify correlating 
variables to enable clustering of symptoms or eliciting factors. And, this analysis 
identifies variables explaining the variance of the data, and therefore having large 
impact. This could later lead to a reduction of the initial questionnaire, reveiling almost 
as much information as the extended version. A factor analysis with Varimax rotation 
was applied on these 128 variables, named ‘items’ in the analysis, and Eigenvalues > 1.0 
were used to determine the total number of extracted factors. The Kaiser-Meyer-Olkin 
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(KMO) measure served for verification of the sampling adequacy for the analysis. 
Subsequently, Bartlett’s test of sphericity was applied to test whether the correlations 
between the items were sufficiently large for factor analysis. The percentage of 
explained variance of each factor was presented (table 4). The Cronbach’s alpha was 
calculated to study the internal consistency of each factor. In order to study the 
construct validity of the factors, the hypothesis was formulated that the SS subjects 
had higher scores with respect to VAS and duration compared to NSS subjects. The 
t-test was used to see if there are difference between the SS and NSS group of the 
sumscore of corresponding items allocated to each factor: sum of the VAS scores 
(0-10) and duration scores (o: not experienced; 1: seconds; 2: minutes; 4: less than one 
hour; 7: hour(s); 10: day(s)). 
Multivariable logistic regression with selection procedures was performed in order to 
identify variables that independently contribute to the ability to discriminate SS from 
NSS subjects, where pseudoR2 and AUC of the final model indicated the percentage of 
the explained variance and the discriminatory power. Statistical analysis was performed 
using IBM SPSS Statistics 20.0 for Windows (IBM Corp. Armonk, NY). A p-value of lower 
than 0.05 was considered statistically significant.
Results
Population characteristics
Within the study period as reported in Methods, 481 questionnaires were returned, 
achieving a response rate of 15.7%. Characteristics of the population are summarized 
(Table 1). 60.8% of the population had female gender. The median age was 43 (range: 
16-78) years and the majority of subjects were Caucasian (96.3%,) and were originally 
Dutch (86.4%); (the latter is 79.2% in the Netherlands15). Fitzpatrick skin type 
distribution was: skintype I: 5.3%; II: 32.6%; III: 44.7%; IV: 15.5%; V: 1.9%; VI: 0.0%. 
Respondents who assessed their skin as much more or slightly more sensitive compared 
to others were classified as SS (n=176). Respondents who classified their skin as equally 
or less sensitive compared to others were categorized as NSS (n=255). The prevalence 
of SS was found to be 40.8%, where one out of three subjects reported very SS. SS is 
more frequently reported by females (p<0.001). Subjects with SS predominantly report 
to have skin type II, while NSS subjects mostly report skin type III. In particular, 52.3% 
of SS subjects reports skin type I or II, while this is 30.2% in NSS subjects (p<0.001). 
Atopy, skin diseases and conditions 
Atopic diathesis in general as well as specific atopic diseases (asthma, allergic rhino-
conjunctivitis and atopic dermatitis (AD)), were significantly more frequently reported 
in SS subjects compared to NSS subjects. Subjects with SS suffer more frequently from 
70
CHAPTER 3
a concomitant skin disease compared to subjects with NSS (Table 1), 48.3% and 25.9% 
respectively (p<0.001). The prevalence of skin diseases was significantly different for 
contact dermatitis, either allergic or irritant: 15.9% in SS and 4.7% in NSS (p<0.001).
In general, SS subjects more frequently report a skin type other than ‘normal’ compared 
NSS subjects. Dry skin of the face and of the body are more frequently reported by SS 
compared to NSS subjects (p<0.001). 60.0% of SS subjects reports to have a dry 
corporal skin. Subjects with asthma, allergic rhinoconjunctivitis and AD have borderline 
significantly or significantly dryer facial skin compared to healthy subjects including 
both SS and NSS groups (respectively p=0.019, p=0.053 and p=0.031) 
Skin care
No differences between SS and NSS subjects were found with respect to the number 
of showers taken per week. In the female group, there was no difference between SS 
and NSS with respect to the use of products for facial care and cleansing, body care 
and cleansing and make-up. However, SS subjects more frequently used products 
designed for SS compared to NSS subjects, 52.8% and 42.4% respectively, (p=0.012). 
66% of SS subjects had consulted a doctor for SS, whether or not related to a 
concomitant skin disease. 
Body sites
In general, cheeks, neck, hands, periorbital area, genital area, legs and forehead were 
assigned as most sensitive body sites (Table 2). 20.5% reported to perceive no difference 
in sensitivity between body sites. SS subjects assess the cheeks as most sensitive 
and NSS subjects the neck. Remarkably, 34.7% of SS subjects assigned the legs to the 
five most sensitive body sites, while this was 15.4% in NSS subjects. 
Eliciting factors
Regarding impact of a season, both SS and NSS subjects reported that their skin 
sensitivity is highest in winter, 48.3 and 32.9%, respectively. A smaller fraction of 
participants, 25.6 and 31.8% of SS and NSS subjects, respectively, report that their skin 
sensitivity is not season dependent. SS subjects reacted significantly more frequently 
to all stimuli. In both SS and NSS subjects shaving (70.9% and 52.0% respectively) and 
cold (70.1%) elicited reactions most frequently. Toiletries caused skin reactions in 
68.8% of SS and in 20.9% of NSS subjects (Table 3). 
Skin reactions
Toiletries, clothes, shaving and sun exposure elicited the strongest reactions in both SS 
and NSS subjects. Temperature changes affect the skin in lesser extent. The symptoms 
being elicited strongest in the total group with respect to severity and duration were: 
discomfort, stinging, redness, and dryness.
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Table 1   Population characteristics with respect to gender, age, skin type,  
severity of sensitivity, atopic diathesis, skin diseases and conditions grouped 
by self-reported skin sensitivity.
Total
n (%)
SS
n (%)
NSS 
n (%)
p-value 
Total number
Gender
481 (100) 176 (40.8) 255 (59.2) -
<0.001
   Male
   Female
184
285
(39.2) 
(60.8)
41
129
(24.1)
(75.9)
121
129
(48.4)
(51.6)
n.a.
n.a.
   Missing
Age (med, range)
Skin sensitivity
   More SS
   Slightly SS
   Equally SS
   Less SS 
   I do not know
12
43
53
123
159
96
50
(n.a.)
(16-78)
(12.3)
(28.5)
(36.9)
(22.3)
(n.a.)
6
42
53
123
0
0
n.a.
(n.a.)
(18-69)
(30.1)
(69.9)
(0)
(0)
n.a.
5
44
0
0
159
96
n.a.
(n.a.)
(20-74)
(0)
(0)
(62.4)
(37.6)
n.a.
n.a.
0.140
n.a.
n.a.
n.a.
n.a.
n.a.
Skin type (Fitzpatrick) 
   Skin type I
   Skin type II 
   Skin type III
   Skin type IV
   Skin type V
   Skin type VI
   Missing
25 
154 
211 
73 
9
 0
9
(5.9)
(32.6)
(44.7)
(15.5)
(1.9)
(0)
(n.a.)
11
81
62
20
2
0
0
(6.3)
(46.0)
(35.2)
(11.4)
(1.1)
(0)
(n.a.)
11
64
127
41
5
0
7
(4.4)
(25.8)
(51.2)
(16.5)
(2.0)
(0)
(n.a.)
0.190
<0.001
0.003
0.022
0.127
n.a.
n.a.
Facial skin type <0.001
   Normal
   Dry
   Oily
   Combined 
   Missing
189
94
47
148
3
(39.5)
(19.7)
(9.8)
(31.0)
(n.a.)
40
54
14
68
0
(22.7)
(30.7)
(8.0)
(38.6)
(n.a.)
128
30
32
63
0
(50.6)
(11.9)
(12.6)
(24.9)
(n.a.)
n.a.
n.a.
n.a.
n.a.
n.a.
Body skin type <0.001
   Normal
   Dry
   Oily
   Combined 
   Missing
234
177
9
57
4
(49.1)
(37.1)
(1.9)
(11.9)
(n.a.)
46
106
3
21
0
(26.1)
(60.2)
(1.7)
(11.9)
(n.a.)
156
61
4
30
4
(62.2)
(24.3)
(1.6)
(12.0)
(n.a.)
n.a.
n.a.
n.a.
n.a.
n.a.
Atopic predisposition
   Asthma
   Allergic 
rhinoconjunctivitis
   Atopic dermatitis
   ≥ 1 of above
65
158
62
209
(43.5)
(33.3)
(13.0)
(43.5)
42
70
35
100
(24.0)
(40.5)
(20.1)
(56.8)
18
76
25
95
(7.3)
(30.2)
(9.9)
(37.3)
<0.001
0.030
0.005
<0.001
Skin disease 163 (34.0) 84 (48.3) 65 (25.9) <0.001
SS: sensitive skin; Self-reported much more sensitive or more sensitive skin compared to others; NSS: non-
sensitive skin; Self reported equally sensitive or less sensitive compared to others. Sums may not equal the 
total number, because of missing values; Missing values for gender, skin sensitivity, skin type, facial skin type 
and body skin type are addressed. p-value is the p-value of the t-test (numerical variables) or of the Fisher’s 
exact test of the differences between the groups (SS, NSS).
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Factor analysis and multivariable logistic regression
Information collected from 481 subjects served as an input for the factor analysis, 
where 128 items comprised of VAS scores and durations of eight symptoms following 
eight eliciting factors were included. The Kaiser-Meyer-Olkin measure of sampling 
adequacy was 0.833, above the recommended value of 0.6, and Bartlett’s test of 
sphericity was significant (p<0.001). Finally, communalities were all above 0.6, further 
confirming that each item shared common variance with other items.
The factor analysis identified 30 factors with Eigen values of ≥ 1, with the first factor 
explaining 19% of the variance, the second factor 5%, factors three to six 4% and the 
remaining factors 1-3%. The fourteen factor Varimax solution (Supplement 1), which 
explained 60% of the variance (Table 4), was preferred because of ‘leveling off’ of 
Eigen values on the scree plot. These 14 factors predominantly explain the variance of 
the total data set. Items loading on each factor referred to one eliciting factor and 
were highly consistent (table 4) and therefore are assumed to measure the same 
construct. For example, factor 1 contains all symptoms following clothes and are 
therefore more consistent then for example a specific symptom as stinging being 
elicited by different environmental factors. Factors 1 to 14 were named according to 
the main eliciting factor and the characterizing symptoms, as for example ‘sensations’, 
where solely sensations were included, or for example ‘not bumps’ where bumps did 
not fit in the factor. The Pearson correlation coefficients between each pair of factors 
were as expected low, <0.45.  
Table 2   Percentage of subjects that assigned body sites as one of five most  
sensitive body sites and as most sensitive body site grouped by 
self-reported skin sensitivity.
% of subjects  
that assigned site in top 5 
most sensitive sites
% of subjects 
that assigned site as 
most sensitive site
SS (n=175) NSS (n=255) SS (n=175) NSS (n=255)
Body sites are equally sensitive n.a. n.a. 12.0 26.9
Cheeks 45.7 24.7 17.1 8.6
Neck (ventral and dorsal) 39.2 29.8 6.8 9.0
Hands 34.9 27.5 9.1 7.5
Periorbital area 34.9 28.2 14.9 9.4
Legs 34.7 15.4 6.8 3.5
Forehead 30.7 26.3 4.5 4.7
Genital area 27.8 29.4 3.4 7.5
Armpits 21.6 25.1 0.6 3.9
SS: sensitive skin; NSS: non-sensitive skin; n.a.: not applicable.
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We found that three factors of self-reported SS independently contributed to the 
prediction of self-reported sensitivity (Table 5, 6): toiletries (not red), temperature 
changes (not bumps) and emotions (not bumps). Note that skin complaints with 
respect to temperature changes is expected to be perceived differently within and 
between patients. For this reason we also studied the model without the factor 
temperature (not bumps) and found that this model is similar with respect to both the 
explained variance (pseudoR2: 45% and 43%, respectively) and the discriminative 
power (AUC both 78%). Subjects with skin diseases compared to subjects without skin 
diseases show the same factors contributing to the probability to report SS. 
Table 3   Percentage of subjects perceiving skin reactions ‘never’, or ‘sometimes’ or 
‘often’ following stimuli grouped by self-reported skin sensitivity.
SS (n=176) NSS (n=255) p-value
Toiletries
   Never or not applicable 31.2 79.1
   Sometimes or often 68.8 20.9 <0.001
Shaving
   Never or not applicable 29.1 48.0
   Sometimes or often 70.9 52.0 <0.001
Emotions
   Never or not applicable 56.6 79.5
   Sometimes or often 43.4 20.5 <0.001
Sun exposure
   Never or not applicable 45.4 60.4
   Sometimes or often 54.6 39.6 <0.001
Heat
   Never or not applicable 47.7 71.9
   Sometimes or often 52.3 28.1 <0.001
Cold
   Never or not applicable 29.9 54.9
   Sometimes or often 70.1 45.1 <0.001
Temperature changes
   Never or not applicable 69.3 89.3
   Sometimes or often 30.7 10.7 <0.001
Clothes
   Never or not applicable 49.4 76.0
   Sometimes or often 50.6 24.0 <0.001
SS: sensitive skin; NSS: non-sensitive skin; The p-value is the p-value of the Fisher’s exact test for differences 
between groups (SS and NSS).
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Table 4   The factors and their characteristics.
n Eigenvalues % of explained 
variance
Cronbach’s Alpha
Clothes (all) 16 24.6 19.2 0.92
Toiletries (not red) 15 6.9 5.4 0.91
Temperature (not bumps) 14 5.6 4.4 0.91
Emotions (not bumps) 14 5.2 4.1 0.90
Heat (not bumps) 14 5.0 3.9 0.90
Sun (not VAS for tight, dry) 14 4.6 3.6 0.90
Shaving (not tight, dry) 12 3.8 3.0 0.88
Cold (not burn, sting, bumps) 9 3.7 2.9 0.86
Sun and Shaving (tight, dry) 6 3.5 2.8 0.81
Cold (burn, sting, red) 5 3.0 2.4 0.76
Heat and Temperature (bumps) 4 2.4 1.9 0.59
Emotions (bumps) 2 2.0 1.6 0.85
Cold (bumps)  2 1.9 1.4 0.74
n: the number of items per factor; The cumulative explained variance is 60.0%; KMO: Kaiser-Meyer-Olkin 
measure of sampling adequacy is 0.833; Bartlett’s tests of sphericity has a p-value of <0.001;
Table 5   Mean of the sumscore of each factor grouped by self-reported skin 
sensitivity.
SS (n=176)
Mean score
NSS (n=255)
Mean score 
Mean difference
(95%CI) 
Clothes (all) 20.4 7.6 12.8 (8.0-17.5)
Toiletries (not red) 40.2 9.9 30.3 (25.4-35.3)
Temperature (not bumps) 9.3 1.1 8.2 (5.4-11.1)
Emotions (not bumps) 16.9 3.4 13.4 (9.5-17.5)
Heat (not bumps) 16.3 4.9 11.4 (7.8-15.0)
Sun (not VAS for tight, dry) 29.1 15.6 13.5 (8.2-18.9)
Shaving (not tight, dry) 28.1 16.3 11.9 (7.6-16.1)
Cold (not burn, sting, bumps) 20.6 9.2 11.4 (7.9-14.9)
Sun and Shaving (tight, dry) 7.3 2.6 4.7 (2.9-6.5)
Cold (burn, sting, red) 5.5 2.1 3.4 (2.1-4.7)
Heat and Temperature (bumps) 1.4 0.5 0.9 (0.2-1.6)
Emotions (bumps) 2.7 1.2 1.5 (0.5-2.5)
Cold (bumps)  0.4 0.2 0.3 (-0.1-0.6)
The p-values of the difference in mean sumscore between the groups (SS, NSS) is <0.01 for all factors except 
for cold (bumps): p=0.127
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Unraveling the pathomechanism of SS requires conducting studies where adequate, 
i.e., specific and sensitive, methods are to be used for selection of subjects. Using a 
novel multifactorial questionnaire and data analysis using multivariate logistic 
regression analysis, we have mapped general characteristics of a SS population, and 
we have identified discriminative items for SS with respect to eliciting factors. 
We confirmed the high prevalence of SS, which was 41%, in line with previously 
conducted epidemiological research in Europe [8, 20-22],  where a prevalence of 38% 
was detected (either SS or very SS).  [21] Furthermore, the results of our survey 
correspond with earlier findings that SS is more frequently reported by women [6, 8, 
10, 21, 22] and by subjects with fair skin type [22-26]. Regarding potential pathomech-
anisms, our results support the hypothesis that SS could be caused by an impaired skin 
barrier and atopic predisposition, based on the fact that more SS subjects suffer from 
dry skin and atopic conditions, in line with other studies. [9, 17, 25, 26] A dry skin in its 
turn, could enable permeability for pathogens potentially leading to skin reactions 
expressed in terms of sensations, vascular dilation or inﬂammation. As this hypothesis 
is solely based on the results of self-reported perceptions, an in depth research on in 
particular the stratum corneum composition could give more insights on the role of 
an impaired skin barrier in SS.
Regarding understanding the role of skin diseases in SS, previously, acne and contact 
dermatitis were most frequently named by SS cohorts. [8, 21] Therefore, as dermatological 
diseases are often associated with SS perceptions, one could assume that SS is by a 
large part elicited by these conditions [8, 21]. In line with this, our findings show that 
eliciting factors for SS overlap with key predisposing factors in skin diseases, since a 
high percentage of SS subjects report to have AD and contact dermatitis. Concomitant 
skin diseases were previously reported in 20-28% [8, 25] and 43% of SS subjects [20], 
Table 6   The adjusted OR (95% CI) of factors using multivariable logistic regression 
with selection procedure.
Best model Preferred model
Adj. OR (95% CI) Adj. OR (95% CI)
Toiletries (not red) 1.060 (1.048-1.073) 1.060 (1.048-1.073)
Temperature (not bumps) 1.072 (1.030-1.115) - -
Emotions (not bumps) 1.024 (1.006-1.043) 1.024 (1.006-1.043)
Adj: Adjusted for other variables in the model. AUC: the discriminatory power 
The pseudo R2 of the best model is 0.448 and the discriminatory power is 78%. The pseudo R2 of the preferred 
model is 0.426 and the discriminatory power is 78%.
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and only 15.5% in NSS subjects. [20] However, multivariable logistic regression analysis 
in the subgroup with and without reporting a concomitant skin disease, identified the 
same common discriminative factors, suggesting that SS is not defined by concomitant 
skin diseases only. 
More evidence supporting existence of ‘generalized’ skin sensitivity is based on the 
fact that individuals described their skin as ‘sensitive’ reported reactions or perceptions 
to triggers of different origins. This shows that a questionnaire could enable detection 
of SS better than a provocative test, which sensitivity was shown to be low. Such a 
questionnaire should not focus on specific symptoms but should include skin reactions 
following specific eliciting factors, as supported by the analysis presented here. 
In particular, we demonstrated that reactions to toiletries and emotions deserve 
particular attention as they were found to be discriminative for the SS group. 
Furthermore, in the development of objective diagnostic tests for SS visible signs of 
skin irritation should be considered next to sensations, since these contribute to the 
discriminative capacity of the factors. Validation of a variant of this selection method 
is being studied by Richters et al. 2016 in clinical studies and already revealed objective 
differences between SS and NSS subjects, showing the discriminative power of the 
proposed tool.  [27]
An important limitation of this study is, that data are referred to self-assessed 
sensitivity, which is subjective by definition. However, quantification of the reported 
symptoms is essential in the detection of the pathomechanism and mitigation of SS. 
In conclusion, we developed a multifactorial questionnaire that could serve as a 
method to identify and to select subjects with SS for research potentially susceptible 
for skin irritation prior to testing of skin devices affecting skin comfort. In particular, 
we suggest that reactions to toiletries and emotions should be included next to 
specific symptoms. The cheek seems to be an adequate testing site, since this body 
site was discriminative for skin reactions between SS and NSS subjects. We recommend 
exclusion of subjects with concomitant skin diseases from SS studies, since symptoms 
inherent to these diseases overlap with SS and therefore inﬂuence measured physiologic 
skin processes.
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Abstract 
Intro Sensitive skin (SS) is a complex phenomenon, described as sensory skin reactions, 
sometimes accompanied by erythema and dryness, to endogenous and exogenous 
factors that usually have little impact. No consensus exists on its pathomechanism. 
To gain insight in underlying pathways, we developed a novel approach on subject 
selection and dynamic analysis. 
Methods Subjects with SS (n=8) and non-sensitive skin (NSS) (n=8) were selected 
by means of a questionnaire assessing the severity of symptoms following provocations. 
Subjects with skin diseases and atopy were excluded. Sequential tape stripping was 
used as an in vivo model to identify key drivers in the SS pathomechanism. At baseline, 
0.5, 8, 24 and 72 hours after tape stripping, skin was assessed clinically, biophysically 
and immunohistochemically, including immunological, endothelial, epidermal proliferation 
and differentiation markers. 
Results Less tapes were needed to strip the stratum corneum (SC) in SS subjects, while 
the SC thickness was comparable. Clinically, SS subjects showed ﬂaring responses. The 
estimated mean epidermal thickness was significantly higher in SS subjects 24 hours 
after stimulus and more extensive spongiosis was seen. 
Discussion We confirm that an impaired skin barrier, possibly caused by impaired 
corneo desmosome quality, plays a role in the pathomechanism of SS. Vascular responses 
seem to have additional contribution. Our results show that the applied questionnaire 
could be an adequate selection method and responses to tape stripping provide a 
model, permitting investigation of SS. We propose focus on detailed analysis of the 
skin barrier and vascular responses to further understand the pathomechanism of SS.
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Introduction
One out of two women and one out of three men in the Western world reports to 
have sensitive skin (SS). (1-5) Individuals classifying themselves as having SS frequently 
describe perceptions as stinging, burning or itching sensations of the skin (6-8) and 
erythema and dryness may accompany these sensations. (5, 7-10) As a response to 
this, unraveling the pathophysiology of this condition and developing solutions for 
individuals with SS has become an important topic in biomedical and cosmetic 
research fields. Although many clinical evaluations and biophysical techniques have 
been applied in order to shape understanding and to create consensus on the causal 
pathways of SS, no diagnostic test is found to be sufficiently sensitive and reproducible. 
Its prevalence and its burden for dermatologists stress the urgent need for recognition 
of SS, and the necessity to gain more knowledge to come to a consensus on its 
pathomechanism.
Previous studies proposed potential pathways which may lead to a condition commonly 
designated as SS: impaired barrier function, sensory hyperreactivity, inﬂammatory or 
vascular responsiveness and atopic predisposition. Unfortunately, studies show 
inconsistent outcomes, impeding identification of key pathways in the mechanism of 
SS. Many provocations used as a diagnostic method for SS in explorative studies 
resulted in sensory skin reactions (10-13) however, susceptibility to one provocative 
agent does not predict susceptibility to another. (14-17)
In this study, we aimed at identifying key features in morphology and physiology of 
skin reactions and skin recovery in SS subjects. We evaluated skin reactions to 
standardized provocation using an in vivo model for barrier disruption in selected 
subjects. Evaluation was performed dynamically, i.e. at baseline and at several time 
points after acute barrier disruption. Since tape stripping is widely used as a 
reproducible in vivo human model of cutaneous injury and regeneration, this allows 
studying SS in a dynamic fashion. (18) In order to reduce confounding by concomitant 
skin conditions, we propose an experimental design with exclusion of skin diseases. 
We are of the opinion that a multifactorial questionnaire encompassing a range of 
provocations including chemical, mechanical and thermal origins and multiple signs 
and symptoms, could be a more adequate selection tool than topical agents only. 
These undertaken methods, combining self-reported skin sensitivity with biophysical 
and detailed histological evaluation of skin responses, could enable exploration of a 
range of processes and delivering decisive answers to questions on causal pathways 
of SS and explain previously described inconsistencies.  
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Methods
Population and selection criteria
Participants were recruited via student websites. Volunteers filled out a questionnaire 
on self-assessed skin sensitivity and skin perceptions (i.e. discomfort, stinging, redness 
or dryness) following potential endogenous and exogenous triggers (i.e. toiletries, 
shaving, emotions, heat, cold and clothes). Severity of reactions was scored on a Visual 
Analogue Scale (VAS) and duration on an ordinal scale (i.e. no experience, seconds, 
minutes, less than one hour, hour(s), day(s)). The investigator scored the 24 VAS scores 
and 24 durations (recoded to scores of 0, 1, 2, 4, 7, 10) of the questionnaire. The upper 
quartile and lower quartile of the  sumscore of these 48 items (range: 0 - 480) was 
determined in a large cohort study (n=238, manuscript in preparation). A subject in this 
study was defined as a subject with sensitive skin (SS) if the sumscore was above the 
upper quartile value and the patient reported SS. The subject was defined as a subject 
with non-sensitive skin (NSS) if the sumscore was below the lower quartile value and 
the patient reported NSS. 
Subjects were included when meeting the following criteria: had SS or NSS according 
to the procedure described above, had Fitz-Patrick skintype II or III, did not have or have 
had an atopic condition (asthma, allergic rhinoconjunctivitis or atopic dermatitis 
(AD)), was able to give written informed consent and had no skin disease including 
contact dermatitis. Participants were advised not to apply cosmetics from 24 h before 
the first visit. Groups with SS and NSS skin were matched for gender. The experiments 
were approved by the local ethics committee (METC, region Arnhem-Nijmegen) and 
were conducted conform the Declaration of Helsinki principles. 
In vivo model for skin damage
Sequential tape stripping of four skin sites parallel to the upper side of the intergluteal 
cleft was performed using a metal oblong plate with an oval aperture (13x22mm, 2.9 cm2) 
covered by 6890 PVC Tape, Scotch, to standardize extension of the skin and velocity and 
angle of removal. (18, 19) Stripping was stopped when the skin became homogeneously 
refulgent. Macroscopic images were taken as a reference and tapes were counted.
Measurements
Subjects were acclimatized for 20-25 min to room conditions (21 ± 1°C and 50 ± 10% 
relative humidity). Measurements were performed three times each on non-hairy, 
optically healthy skin without cleansing the skin in the following order:
a. Skin redness (a*) was measured using a spectrophotometer: the Chroma Meter 
2600d (Konica Minolta, Tokyo, Japan). Settings were: 8mm changeable aperture, 
UV100% (illumination that contained all UV components of Xe ﬂash light source), 
M/I+E (SCE was used as the read-out setting), 65d illuminant (standard illuminant 
91
IN VIVO HUMAN MODELS
4
daylight) and 0.0 seconds delay time. The interval between each measurement was 
30 seconds and the device had only brief skin contact to prevent vasoconstriction 
and subsequent hyperemia.
b. Transepidermal waterloss (TEWL) was measured using the AquaFlux AF200 (Biox 
Systems, London, U.K.) perpendicular on the skin. We used intervals of two minutes, 
to ensure evaporation of surface water caused by occlusion and condensation.
c. Stratum corneum hydration was measured using the Corneometer CM825 
(Courage+Khazaka electronic GmbH, Cologne, Germany). Intervals of 10 seconds 
were applied. 
Biopsy procedures and sample processing
Prior to the biopsy procedure, skin was cleansed with chloorhexidin 0.5% m/v in 
alcohol 70% v/v. Punch biopsies (3mm) were taken at baseline and 0.5, 8, 24 and 72 
hours after tape stripping under 1% xylocain-adrenalin. (18, 19) The tissue samples 
were fixed in 10% formalin for paraffin embedding, and sectioned at 6 µm thickness. 
Immunohistochemistry
Paraffin fixed specimens were deparaffinized and rehydrated. Anti-human primary 
antibodies used are summarized in table 1. Antigen retrieval was achieved by citrate 
buffer (pH 6.0, 10 min at 100°C) for Ki67, CD1a, CD31, K16 and filaggrin staining. To retrieve 
the epitopes for the tryptase antibodies and CD3 antibodies, TRIS/EDTA (50 mM TRIS + 
2 mM EDTA, pH 9.0, 10 min at 100°C) and EDTA/Tween-20 (10 mM EDTA, + 0.05% 
Tween-20, pH 8.0, 10 min at 100°C) was used respectively. The S100 and elastase 
primary antibodies did not require antibody retrieval steps. Endogenous peroxidase 
activity was blocked by 3% H2O2 in phosphate-buffered saline (PBS) for Ki67, CD31, 
S100, CD3 and tryptase antibodies and preincubated in 1% bovine serum albumin 
(Dako, Glostrup, Denmark) for 15 minutes before application of Ki67, CD31, K16, S100 
and tryptase antibodies, and 30 minutes before CD3 antibodies. Before anti-filaggrin 
application, sections were preincubated with 20% normal horse serum (Vector 
Laboratories Inc., Burlingame, USA). Sections were incubated with primary antibodies 
dissolved in 1% BSA overnight at room temperature; filaggrin and K16 antibodies were 
incubated for 60 minutes. Amplification was obtained by horseradish peroxidase 
(HRP) labeled polymer (Envision anti-rabbit, Dako, Glostrup Denmark) for S100, and by 
Envision anti-mouse (Dako, Glostrup, Denmark) for the other antibodies. 3,3’‐diamino-
benzidine tetrahydrochloride (DAB) solution (Sigma‐Aldrich, St. Louis, MO) was used 
to visualize the antibody. As a counterstaining, Mayer’s hematoxylin (Sigma-Aldrich, 
Saint Louis, USA) was used. Finally, slides were dehydrated and mounted using 
Permount (Thermo Fisher Scientific, Waltham, USA). Filaggrin and K16 antibodies were 
visualized with Alexa 549 (red) 1:200 and Alexa 488 (green) 1:200 (Invitrogen, USA) 
respectively. DAPI 1mg/µl (Vector Laboratories, USA) 1:3000 was used as counterstaining. 
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Semi-quantitative assessment of immunohistochemical markers
Quantification was performed using Axiokop 2 MOT microscope (Zeiss), Axiocam 
MRc5 digital camera and AxioVision software rel. 4.8 (Zeiss). The epidermal thickness 
was calculated by dividing the epidermal area by the average of the basal membrane 
(BM) length and the surface length. Semiquantitative analysis was performed using 
macro colour deconvolution and color threshold in ImageJ (National Institutes of 
Health, version 1.46). Ki67 positive nuclei were expressed as the number per mm BM. 
Filaggrin was expressed as the number of positive pixels per mm surface length. K16, 
S100 and CD1a were expressed as the percentage of the viable epidermis. CD31, CD3, 
elastase and tryptase were expressed as the number or area of cells per mm2 dermis, 
from the BM down to 300 µm. Spongiosis was assessed by two blinded observers 
(0, no spongiosis; 1, slight spongiosis in a limited area; 2, slight spongiosis in a large area; 
3, strong spongiosis in a large area) and consensus was achieved by discussion. 
Statistical analysis
The characteristics are presented as medians (range). Student’s t-test was used to 
analyze differences between skin sensitivity groups (self-assessed sensitive skin, 
self-assessed non-sensitive skin) for continuous variables at baseline. A linear mixed 
model was used to study differences between the sensitive and non-sensitive groups. 
The dependent variable was the specific variable: biophysical measurements (TEWL, 
SC hydration, a* value) and immunohistochemical quantifications (thickness of 
epidermis and SC, spongiosis, CD1a, CD3, CD31, elastase, filaggrin, K16, Ki67, S100, 
tryptase). The independent class variables were ‘skin sensitivity’ and ‘time’ (baseline, 
0.5, 8, 24 and 72 hours after stimulus respectively) and the value of the specific variable 
Table 1  Antibody specifications.
Biochemical 
specificity
Marker for Designation and source of 
primary antibodies
Dilution
Ki67
CD31
tryptase
CD3
S100
CD1a
elastase 
K16 
filaggrin
Epidermal proliferation
Endothelium
Mast cells
T-cells
Dendritic cells 
Langerhans cells
Neutrophil polymorphonuclear 
granulocyte 
Abnormal epidermal 
differentiation 
Filaggrin 
MIB-1, Dako, Glostrup, Denmark 
JC70A, Dako, Glostrup, Denmark 
AA1, Dako, Glostrup, Denmark 
F7.2.38,  Abcam, Cambridge, UK
Z0311, Dako, Glostrup, Denmark
O10, Dako, Glostrup, Denmark
NP57, Dako, Glostrup, Denmark
LL025, Sanbio BV, Uden,  
the Netherlands 
Covance, Richmond, USA
1:100
1:80
1:100,000
1:100
1:5,000
1:200
1:10,000
1:20
1:200
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at baseline. The estimated mean differences between groups with 95% confidence 
intervals (CIs) are presented at each point of measurement. Analyses were performed 
using SAS version 9.2 for Windows (SAS Institute, Cary, NC) and IBM SPSS 20.0 (IBM 
Corp. Armonk, NY). P-values <0.05 were considered statistically significant. 
Results 
Baseline characteristics
The baseline characteristics of the eight SS subjects and eight NSS subjects are 
presented in table 2. SS subjects and NSS subjects had a median age of 22.5 years 
(range: 20-28) and 20.0 years (19-24) respectively. The questionnaire scores of the SS 
and NSS group were 150.6 (68 – 363) and 30.8 (11 – 44) respectively. Four SS subjects 
reported a dry skin of the body and two SS subjects showed a ﬂare and wheal reaction 
following dermography test, while none of the NSS subjects reported these features. 
The number of tapes required to strip the SC off was significantly lower in the SS 
group compared to the NSS group: 24.4 (16.8-33.0) and 36.8 (25.3-57.5) tapes respectively 
(p=0.017).
Table 2  Baseline characteristics of NSS and SS subjects (n=16).
NSS subjects SS subjects
n (%) / median (range) n (%) / median (range)
Gender
    Male
    Female
4 (50.0)
4 (50.0)
4 (50.0)
4 (50.0)
Age (years) 20.0 (19-24) 22.5 (20-28)
Skin type (Fitzpatrick)
    Skin type II
    Skin type III 
2 (25.0)
6 (75.0)
7 (87.5) 
1 (12.5) 
Facial skin dryness
    Normal
    Dry
    Oily
    Combined
3 (37.5)
2 (25.0)
0 (0.0)
3 (37.5)
2 (25.0)
1 (12.5)
1 (12.5)
4 (50.0) 
Body skin dryness
    Normal
    Dry
    Oily
    Combined
8 (100.0)
0 (0.0)
0 (0.0)
0 (0.0)
3 (37.5)
4 (50.0)
1 (12.5)
0 (0.0)
Questionnaire score  30.8 (11-44) 150.6 (68-363)
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Table 3   Observed medians (range) of biophysical measurements and immuno- 
histochemical markers by skin sensitivity (95% CI) and the estimated  
mean differences at each point of measurement using a linear mixed model  
for repeated measurements adjusted for baseline values.
Observed (median, range) Estimated difference between the groups
baseline 0.5 hours 8 hours 24 hours 72 hours 0.5 hours 8 hours 24 hours 72 hours
n med (range) n med (range) n med (range) n med (range) n med (range) mean (95%CI) mean (95%CI) mean (95%CI) mean (95%CI)
Biophysical measurements 
TEWL (gm-2h-1)
   SS
   NSS
8
8
11.1
11.4
(7.2-16.2)
(9.6-20.5)
8
8
100.2
99.3
(76.7-112.5)
(17.6-87.3)
8
8
107.1
101.0
(81.4-114.2)
(74.1-110.9)
8
8
90.3
91.4
(60.8-105.8)
(67.7-107.5)
8
8
38.1
37.7
(27.1-56.4)
(26.1-66.5)
0.08
0.00
(-12.40;12.56)
(reference) 
5.44 
0.00
(-7.34;18.23)
(reference)
-0.93
0.00 
(-13.41;11.56)
(reference)
-3.46 
0.00
(-15.95;9.02)
(reference)
SC hydration (AU)
   SS
   NSS
8
8
23.0
20.2
(12.3-35.8)
(15.2-24.7)
8
8
45.0
62.1
(30.6-77.8)
(27.8-70.2)
8
8
42.4
44.0
(29.9-58.5)
(31.0-65.3)
8
8
32.8
23.7
(18.3-36.3)
(8.3-36.7)
8
8
2.9
4.5
(0.7-13.0)
(1.4-11.8)
-6.93
0.00 
(-17.58;3.73)
(reference)
-4.87
0.00 
(-15.53;5.79)
(reference)
3.34 
0.00
(-7.32;13.99)
(reference)
-3.01 
0.00
(-13.67;7.64)
(reference)
a* values (AU)
   SS
   NSS
8
8
6.0
6.4
(4.7-7.7)
(2.5-7.4)
8
8
10.9
13.2
(7.9-13.0)
(9.8-16.3)
8
8
12.7
13.8
(9.3-14.6)
(11.5-15.2)
8
8
11.4
12.9
(7.6-14.4)
(7.5-15.1)
8
8
9.1
10.8
(6.4-12.2)
(8.3-12.4)
-2.40
0.00 
(-4.35;-0.45)
(reference)
-1.18
0.00 
(-3.13;0.78)
(reference)
-1.12 
0.00
(-3.07;0.84)
(reference)
-1.64
0.00 
(-3.59;0.31)
(reference)
Epidermal proliferation and differentiation markers
Thickness of viable epidermis (µm)
   SS
   NSS
8
8
75.5
77.6
(65.6-95.4)
(70.7-89.8)
8
8
88.7
78.3
(47.7-124.8)
(70.7-90.5)
8
8
91.0
87.2
(74.7-93.8) 
(69.8-105.5)
8
8
120.8
100.4
(93.8-161.0)
(79.7-113.4)
8
7
132.8
131.7
(105.9-154.8)
(98.6-157.1)
9.10
0.00 
(-4.92;23.13)
(reference)
10.21
0.00 
(-3.81;24.24)
(reference)
29.00
0.00 
(14.98;43.03)
(reference)
4.01 
0.00
(-10.47;18.50)
(reference)
Ki67 (nuclei/mm basement membrane)
   SS
   NSS
8
8
27.1
24.6
(7.4-44.7)
(7.4-44.9)
8
8
27.6
32.8
(22.9-41.6)
(14.5-48.2)
8
8
23.6
38.0
(9.6-42.3)
(15.4-54.1)
8
8
13.4
17.4
(7.0-27.0)
(12.0-38.0)
8
7
82.0
121.3
(49.0-136.1)
(81.6-150.4)
-2.58
0.00 
(-18.96;13.81)
(reference)
-11.60
0.00 
(-27.99;4.78)
(reference)
-5.70 
0.00
(-22.09;10.68)
(reference)
-30.57
0.00 
(-47.51;-13.62)
(reference)
Spongiosis (0-3)
   SS
   NSS
8
8
0.0
0.0
(0.0-0.0)
(0.0-1.0)
8
8
0.0
0.0
(0.0-0.0)
(0.0-1.0)
8
8
0.0
0.0
(0.0-1.0)
(0.0-1.0)
8
8
2.0
1.5
(1.0-3.0)
(1.0-3.0)
8
7
1.0
0.0
(1.0-2.0)
(0.0-1.0)
-0.03
0.00 
(-0.54;0.47)
(reference)
0.22
0.00 
(-0.29;0.72)
(reference)
0.72 
0.00
(0.22;1.22)
(reference)
0.94 
0.00
(0.42;1.46)
(reference)
K16 (% of epidermis )
   SS
   NSS
8
8
0.0
0.1
(0.0-1.0)
(0.0-1.2)
8
8
0.4
0.0
(0.0-1.1)
(0.0-0.6)
8
8
0.1
0.1
(0.0-0.8)
(0.0-0.9)
8
8
0.7
1.0
(0.0-7.8)
(0.0-36.1)
8
7
2.2
0.8
(0.0-10.3)
(0.0-20.2)
0.30
0.00
(-5.45;6.05)
(reference)
-0.01
0.00
(-5.76;5.74)
(reference)
-3.55
0.00
(-9.30;2.20)
(reference)
-3.87
0.00
(-9.62;1.88)
(reference)
Filaggrin (% of epidermis)
   SS
   NSS
8
8
5.1
5.6
(2.3-8.5)
(2.5-9.1)
8
8
2.4
1.4
(0.4-3.9)
(0.8-6.9)
8
8
1.4
2.2
(0.2-3.3)
(0.2-4.2)
8
8
1.5
2.1
(0.1-3.3)
(0.1-3.4)
8
7
12.0
11.2
(3.7-16.4)
(6.4-15.4)
-0.17
0.00
(-2.43;2.09)
(reference)
-0.17
0.00
(-2.44;2.09)
(reference)
-0.31
0.00
(-2.57;1.95)
(reference)
0.99
0.00
(-1.35;3.33)
(reference)
Immunologic and vascular markers 
CD3 (cells/mm² dermis)
   SS
   NSS
8
8
82.0
80.4
(49.0-141.9)
(47.5-110.5)
-
-
n.a.
n.a.
-
-
n.a.
n.a.
-
-
n.a.
n.a.
8
7
167.0
146.8
(29.5-480.6)
(113.6-279.5)
n.a. n.a. n.a. 19.18
0.00
(-103.2;141.6)
(reference)
Elastase (cells/mm² dermis)
   SS
   NSS
8
8
0.0
0.0
(0.0-2.3)
(0.0-1.6)
8
8
4.7
0.0
(0.0-11.7)
(0.0-18.2)
8
8
10.7
10.7
(4.0-53.6)
(1.9-86.3)
8
8
15.7
18.3
(4.4-75.3)
(0.0-92.0)
8
7
6.9
2.4
(0.0-33.0)
(0.0-15.4)
2.46
0.00 
(-17.24;22.16)
(reference)
-0.63 
0.00
(-20.33;19.07)
(reference)
-1.10 
0.00
(-20.80;18.60)
(reference)
6.42 
0.00
(-13.89;26.73)
(reference)
Tryptase (cells/mm² dermis)
   SS
   NSS
8
8
45.5
57.4
(39.0-63.5)
(42.5-69.6)
8
8
47.9
55.9
(26.8-59.0)
(46.0-66.4)
8
8
46.4
54.0
(28.6-59.1)
(44.0-127.0)
8
8
46.4
66.0
(28.7-73.3)
(56.2-84.0)
8
7
54.3
75.2
(46.5-65.6)
(43.3-118.2)
-4.40 
0.00
(-20.17;11.41)
(reference)
-13.77 
0.00
(-29.56;2.27)
(reference)
-13.52
0.00 
(-29.31;2.27)
(reference)
-12.03
0.00 
(-28.26;4.20)
(reference)
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Table 3   Observed medians (range) of biophysical measurements and immuno- 
histochemical markers by skin sensitivity (95% CI) and the estimated  
mean differences at each point of measurement using a linear mixed model  
for repeated measurements adjusted for baseline values.
Observed (median, range) Estimated difference between the groups
baseline 0.5 hours 8 hours 24 hours 72 hours 0.5 hours 8 hours 24 hours 72 hours
n med (range) n med (range) n med (range) n med (range) n med (range) mean (95%CI) mean (95%CI) mean (95%CI) mean (95%CI)
Biophysical measurements 
TEWL (gm-2h-1)
   SS
   NSS
8
8
11.1
11.4
(7.2-16.2)
(9.6-20.5)
8
8
100.2
99.3
(76.7-112.5)
(17.6-87.3)
8
8
107.1
101.0
(81.4-114.2)
(74.1-110.9)
8
8
90.3
91.4
(60.8-105.8)
(67.7-107.5)
8
8
38.1
37.7
(27.1-56.4)
(26.1-66.5)
0.08
0.00
(-12.40;12.56)
(reference) 
5.44 
0.00
(-7.34;18.23)
(reference)
-0.93
0.00 
(-13.41;11.56)
(reference)
-3.46 
0.00
(-15.95;9.02)
(reference)
SC hydration (AU)
   SS
   NSS
8
8
23.0
20.2
(12.3-35.8)
(15.2-24.7)
8
8
45.0
62.1
(30.6-77.8)
(27.8-70.2)
8
8
42.4
44.0
(29.9-58.5)
(31.0-65.3)
8
8
32.8
23.7
(18.3-36.3)
(8.3-36.7)
8
8
2.9
4.5
(0.7-13.0)
(1.4-11.8)
-6.93
0.00 
(-17.58;3.73)
(reference)
-4.87
0.00 
(-15.53;5.79)
(reference)
3.34 
0.00
(-7.32;13.99)
(reference)
-3.01 
0.00
(-13.67;7.64)
(reference)
a* values (AU)
   SS
   NSS
8
8
6.0
6.4
(4.7-7.7)
(2.5-7.4)
8
8
10.9
13.2
(7.9-13.0)
(9.8-16.3)
8
8
12.7
13.8
(9.3-14.6)
(11.5-15.2)
8
8
11.4
12.9
(7.6-14.4)
(7.5-15.1)
8
8
9.1
10.8
(6.4-12.2)
(8.3-12.4)
-2.40
0.00 
(-4.35;-0.45)
(reference)
-1.18
0.00 
(-3.13;0.78)
(reference)
-1.12 
0.00
(-3.07;0.84)
(reference)
-1.64
0.00 
(-3.59;0.31)
(reference)
Epidermal proliferation and differentiation markers
Thickness of viable epidermis (µm)
   SS
   NSS
8
8
75.5
77.6
(65.6-95.4)
(70.7-89.8)
8
8
88.7
78.3
(47.7-124.8)
(70.7-90.5)
8
8
91.0
87.2
(74.7-93.8) 
(69.8-105.5)
8
8
120.8
100.4
(93.8-161.0)
(79.7-113.4)
8
7
132.8
131.7
(105.9-154.8)
(98.6-157.1)
9.10
0.00 
(-4.92;23.13)
(reference)
10.21
0.00 
(-3.81;24.24)
(reference)
29.00
0.00 
(14.98;43.03)
(reference)
4.01 
0.00
(-10.47;18.50)
(reference)
Ki67 (nuclei/mm basement membrane)
   SS
   NSS
8
8
27.1
24.6
(7.4-44.7)
(7.4-44.9)
8
8
27.6
32.8
(22.9-41.6)
(14.5-48.2)
8
8
23.6
38.0
(9.6-42.3)
(15.4-54.1)
8
8
13.4
17.4
(7.0-27.0)
(12.0-38.0)
8
7
82.0
121.3
(49.0-136.1)
(81.6-150.4)
-2.58
0.00 
(-18.96;13.81)
(reference)
-11.60
0.00 
(-27.99;4.78)
(reference)
-5.70 
0.00
(-22.09;10.68)
(reference)
-30.57
0.00 
(-47.51;-13.62)
(reference)
Spongiosis (0-3)
   SS
   NSS
8
8
0.0
0.0
(0.0-0.0)
(0.0-1.0)
8
8
0.0
0.0
(0.0-0.0)
(0.0-1.0)
8
8
0.0
0.0
(0.0-1.0)
(0.0-1.0)
8
8
2.0
1.5
(1.0-3.0)
(1.0-3.0)
8
7
1.0
0.0
(1.0-2.0)
(0.0-1.0)
-0.03
0.00 
(-0.54;0.47)
(reference)
0.22
0.00 
(-0.29;0.72)
(reference)
0.72 
0.00
(0.22;1.22)
(reference)
0.94 
0.00
(0.42;1.46)
(reference)
K16 (% of epidermis )
   SS
   NSS
8
8
0.0
0.1
(0.0-1.0)
(0.0-1.2)
8
8
0.4
0.0
(0.0-1.1)
(0.0-0.6)
8
8
0.1
0.1
(0.0-0.8)
(0.0-0.9)
8
8
0.7
1.0
(0.0-7.8)
(0.0-36.1)
8
7
2.2
0.8
(0.0-10.3)
(0.0-20.2)
0.30
0.00
(-5.45;6.05)
(reference)
-0.01
0.00
(-5.76;5.74)
(reference)
-3.55
0.00
(-9.30;2.20)
(reference)
-3.87
0.00
(-9.62;1.88)
(reference)
Filaggrin (% of epidermis)
   SS
   NSS
8
8
5.1
5.6
(2.3-8.5)
(2.5-9.1)
8
8
2.4
1.4
(0.4-3.9)
(0.8-6.9)
8
8
1.4
2.2
(0.2-3.3)
(0.2-4.2)
8
8
1.5
2.1
(0.1-3.3)
(0.1-3.4)
8
7
12.0
11.2
(3.7-16.4)
(6.4-15.4)
-0.17
0.00
(-2.43;2.09)
(reference)
-0.17
0.00
(-2.44;2.09)
(reference)
-0.31
0.00
(-2.57;1.95)
(reference)
0.99
0.00
(-1.35;3.33)
(reference)
Immunologic and vascular markers 
CD3 (cells/mm² dermis)
   SS
   NSS
8
8
82.0
80.4
(49.0-141.9)
(47.5-110.5)
-
-
n.a.
n.a.
-
-
n.a.
n.a.
-
-
n.a.
n.a.
8
7
167.0
146.8
(29.5-480.6)
(113.6-279.5)
n.a. n.a. n.a. 19.18
0.00
(-103.2;141.6)
(reference)
Elastase (cells/mm² dermis)
   SS
   NSS
8
8
0.0
0.0
(0.0-2.3)
(0.0-1.6)
8
8
4.7
0.0
(0.0-11.7)
(0.0-18.2)
8
8
10.7
10.7
(4.0-53.6)
(1.9-86.3)
8
8
15.7
18.3
(4.4-75.3)
(0.0-92.0)
8
7
6.9
2.4
(0.0-33.0)
(0.0-15.4)
2.46
0.00 
(-17.24;22.16)
(reference)
-0.63 
0.00
(-20.33;19.07)
(reference)
-1.10 
0.00
(-20.80;18.60)
(reference)
6.42 
0.00
(-13.89;26.73)
(reference)
Tryptase (cells/mm² dermis)
   SS
   NSS
8
8
45.5
57.4
(39.0-63.5)
(42.5-69.6)
8
8
47.9
55.9
(26.8-59.0)
(46.0-66.4)
8
8
46.4
54.0
(28.6-59.1)
(44.0-127.0)
8
8
46.4
66.0
(28.7-73.3)
(56.2-84.0)
8
7
54.3
75.2
(46.5-65.6)
(43.3-118.2)
-4.40 
0.00
(-20.17;11.41)
(reference)
-13.77 
0.00
(-29.56;2.27)
(reference)
-13.52
0.00 
(-29.31;2.27)
(reference)
-12.03
0.00 
(-28.26;4.20)
(reference)
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Biophysical measurements: 
At baseline, no significant differences are found between the SS and NSS groups with 
respect to: TEWL (SS: 11.1 gm-2h-1, NSS: 11.4 gm-2h-1); SC hydration (SS: 23.0 A.U., NSS: 
20.2 A.U.); and a* value (SS: 6.0 A.U., NSS: 6.4 A.U.) (table 3). 
Epidermal proliferation and differentiation markers
At baseline, SC and viable epidermal thickness measured in histology appeared to be 
comparable between SS and NSS subjects. The median SC thickness (range) was 15.7 
µm (10.0-23.0) in SS subjects and 15.6 µm (10.3-20.5) in NSS subjects and viable 
epidermal thickness was 75.5 µm (65.6-95.54) and 77.6 µm (70.7-89.8) respectively. 
Thickness of the granular layer expressing filaggrin in SS and NSS subjects was 
respectively 5.1 µm (2.3-8.5) and 5.6 µm (2.5-9.1). No significant difference between SS 
and NSS subjects was found in K16 expression or the number of proliferating cells 
(Ki67) per mm basement membrane.
Immunologic and vascular markers 
With respect to mast cell densities, 45.5 (39.0-63.5) and 57.4 (42.5-69.6) cells were 
counted per mm² dermis in the SS and NSS groups respectively (p=0.104). No poly-
morphonuclear neutrophils (PMNs) were observed in both SS and NSS subjects and 
respectively 3.0% (2.3-3.6) and 2.4% (1.7-3.0) of the dermal area was stained for CD31. 
No significant difference was found in the number of S100+ cells, T-cells and CD1a+ 
cells in the epidermis.
Table 3   Continued.
Observed (median, range) Estimated difference between the groups
baseline 0.5 hours 8 hours 24 hours 72 hours 0.5 hours 8 hours 24 hours 72 hours
n med (range) n med (range) n med (range) n med (range) n med (range) mean (95%CI) mean (95%CI) mean (95%CI) mean (95%CI)
Immunologic and vascular markers 
S100 (% of epidermis )
   SS
   NSS
8
8
5.7
5.5
(3.3-8.3)
(3.4-8.2)
8
8
3.4
5.1
(1.0-6.3)
(4.0-5.6)
8
8
3.1
4.4
(1.9-5.1)
(2.9-8.9)
8
8
2.7
3.2
(1.7-4.0)
(2.5-4.5)
8
7
2.7
2.7
(1.7-3.6)
(1.8-4.4)
-1.29
0.00 
(-2.28;-0.31)
(reference)
-1.63
0.00 
(-2.62;-0.65)
(reference)
-0.73
0.00 
(-1.72;0.25)
(reference)
-0.43
0.00 
(-1.44;0.59)
(reference)
CD1a (% of epidermis)
   SS
   NSS
8
8
4.9
4.4
(3.8-8.2)
(3.0-5.8)
8
8
4.9
4.3
(3.8-6.0)
(3.0-5.2)
8
8
4.6
4.7
(2.2-5.5)
(2.9-6.4)
8
8
3.4
2.9
(1.8-5.3)
(2.6-3.7)
8
7
2.3
2.7
(1.5-3.2)
(2.0-3.5)
0.65
0.00 
(-0.22;1.52)
(reference)
-0.31
0.00 
(-1.17;0.54)
(reference)
0.26 
0.00
(-0.59;1.12)
(reference)
-0.60 
0.00
(-0.46;0.32)
(reference)
CD31 (% of dermis)
   SS
   NSS
8
8
3.1
2.4 
(2.3-3.6)
(1.7-3.0)
-
-
n.a.
n.a.
-
-
n.a.
n.a.
-
-
n.a.
n.a.
8
7
3.1
3.4
(2.6-3.6)
(2.2-4.1)
n.a. n.a. n.a. -0.37
0.00 
(-1.06;0.31)
(reference) 
AU: arbitrary units for SC hydration from 0 (no water at all)  to 120 (water), for a* value color range  
from negative (green) to positive (red); CD1a: marker for Langerhans’ cells; CD3: marker for T-cells; CD31: 
marker for endothelium cells; Elastase: marker for polymorphonuclear neutrophils; K16: marker for abnormal 
differentiation of keratinocytes; Ki67: marker for proliferating keratinocytes; med: median, NSS: subjects  
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Reactions on stimulus
Clinical observations
Six SS subjects showed a ﬂaring response during tape stripping (fig. 1), while none of 
the NSS subjects developed a ﬂaring reaction (p=0.002). The ﬂaring response did not 
correlate with skin type (p=0.091). A blanching response after one tape strip was 
observed in five SS subjects and three NSS subjects. Clinically assessed erythema 
responses peaked at 0.5 or 8 hours after stimulus. Five subjects in each group showed 
marked erythema and two subjects of each group showed slight edema 0.5 hour after 
stimulus. Six SS subjects and two NSS subjects reported discomfort, mainly burning 
sensations (VAS 2-5) 0.5 hour after stimulus. These sensations disappeared in two of 
six SS subjects 8 hours after stimulus. 24 hours after stimulus only two SS subjects still 
experienced discomfort and only one SS at 72 hours after stimulus, encompassing itch 
and tightness.
Biophysical measurements
With respect to a*value, TEWL and SC hydration, a significant increase compared to 
baseline was observed 0.5 hour after stimulus. Maximum values for a* values and SC 
hydration were reached 0.5 hours after stimulus and for TEWL 0.5 or 8 hours after 
stimulus. Post-stimulus biophysical measurements showed a significantly lower a* 
value in the SS group 0.5 hour after stimulus (p=0.017), table 3. 
Table 3   Continued.
Observed (median, range) Estimated difference between the groups
baseline 0.5 hours 8 hours 24 hours 72 hours 0.5 hours 8 hours 24 hours 72 hours
n med (range) n med (range) n med (range) n med (range) n med (range) mean (95%CI) mean (95%CI) mean (95%CI) mean (95%CI)
Immunologic and vascular markers 
S100 (% of epidermis )
   SS
   NSS
8
8
5.7
5.5
(3.3-8.3)
(3.4-8.2)
8
8
3.4
5.1
(1.0-6.3)
(4.0-5.6)
8
8
3.1
4.4
(1.9-5.1)
(2.9-8.9)
8
8
2.7
3.2
(1.7-4.0)
(2.5-4.5)
8
7
2.7
2.7
(1.7-3.6)
(1.8-4.4)
-1.29
0.00 
(-2.28;-0.31)
(reference)
-1.63
0.00 
(-2.62;-0.65)
(reference)
-0.73
0.00 
(-1.72;0.25)
(reference)
-0.43
0.00 
(-1.44;0.59)
(reference)
CD1a (% of epidermis)
   SS
   NSS
8
8
4.9
4.4
(3.8-8.2)
(3.0-5.8)
8
8
4.9
4.3
(3.8-6.0)
(3.0-5.2)
8
8
4.6
4.7
(2.2-5.5)
(2.9-6.4)
8
8
3.4
2.9
(1.8-5.3)
(2.6-3.7)
8
7
2.3
2.7
(1.5-3.2)
(2.0-3.5)
0.65
0.00 
(-0.22;1.52)
(reference)
-0.31
0.00 
(-1.17;0.54)
(reference)
0.26 
0.00
(-0.59;1.12)
(reference)
-0.60 
0.00
(-0.46;0.32)
(reference)
CD31 (% of dermis)
   SS
   NSS
8
8
3.1
2.4 
(2.3-3.6)
(1.7-3.0)
-
-
n.a.
n.a.
-
-
n.a.
n.a.
-
-
n.a.
n.a.
8
7
3.1
3.4
(2.6-3.6)
(2.2-4.1)
n.a. n.a. n.a. -0.37
0.00 
(-1.06;0.31)
(reference) 
with self-assessed non-sensitive skin; N.a.: not applicable; S100: marker for dendritic cells; SC: stratum 
corneum; SS: subjects with self-assessed sensitive skin; TEWL: transepidermal water loss; Tryptase: marker  
for mast cell protease tryptase.
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Epidermal proliferation and differentiation markers
Extracting the SC resulted in gradual thickening of the viable epidermis (fig. 2). 
Twenty-four hours after stimulus, the estimated mean thickness (µm) of the viable 
epidermis is higher (p<0.001) in the SS subjects compared to the NSS subjects (mean 
difference 29.00 [95% CI 14.98;43.03]), although the estimated number of cycling 
keratinocytes is not significantly different. Subsequently, after 72 hours the viable 
epidermal thickness decreases and is comparable again, while the estimated number 
of cycling keratinocytes is significantly lower (p<0.001) in the SS group (mean 
difference -30.57 [95% CI -47.51;-13.62]). In both groups a relative decrease in cycling 
keratinocytes was observed 24 hours after stimulus, while 72 hours after stimulus the 
number of cycling keratinocytes increased (fig. 2). With respect to spongiosis (fig. 3), 
the estimated extensiveness was stronger 24 and 72 hours after stimulus (p=0.006 
and p<0.001 respectively) in SS subjects compared to NSS subjects (0.72 [95% 
CI 0.22;1.22] for 24 hours and 0.94 [95% CI 0.42;1.46] for 72 hours after stimulus). 
No difference between SS and NSS subjects could be observed in K16 expression and 
hypergranulosis (fig. 4).
Figure 1  Macroscopic image of the skin at baseline, 1 minute, 0.5 hours, 8 hours,  
24 hours and 72 hours after stimulus respectively.
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Immunologic and vascular markers 
The estimated area of S100 cells per mm2 of the viable epidermis was lower in the SS 
subjects 0.5 (p=0.011) and 8 hours after stimulus (p=0.002), (mean difference -1.29 
[95% CI -2.28;-0.31] and -1.63 [95% CI -2.62;-0.65] respectively). The number of mast 
cells remained stable over time and was slightly lower in SS subjects at all time points, 
borderline significant 8 hours (p=0.086) and 24 hours after stimulus (p=0.091). No 
differences in T-cells, PMN’s, endothelial cells and Langerhans’ cells could be detected. 
Figure 2  Mean observed values of the epidermal compartment in NSS subjects 
(bullets) and in SS subjects (triangles) at baseline and at each point of measurement 
after stimulus for a) thickness of the viable epidermis; b) number of proliferating cells 
(Ki67+ cells) per mm basement membrane c) Spongiosis score on 4 point scale (0-3); 
The vertical lines indicate the standard error of the mean.
a
c
b
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Figure 3  Spongiosis in HE stained tissue in a SS subject at 24 hours after stimulus 
(objective magnification x63).
Figure 4  A-C: Representative images of immunoﬂuorescent staining for K16+ cells 
(green) and filaggrin (red) at baseline, 24 hours and 72 hours after stimulus. DAPI was 
used as a nuclear stain (blue). A) Baseline: No K16 expression, and filaggrin is continuously 
expressed in the granular layer. B) 24 hours after stimulus: K16 is expressed suprabasally 
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Discussion 
To identify key drivers in the pathomechanism of SS, we used sequential tape stripping 
as an in vivo model for skin inﬂammation. This study showed that less tapes were 
required to strip off the SC in SS compared to NSS subjects, while the SC was of 
comparable thickness. Clinically, a ﬂaring response was only observed in six out of 
eight SS subjects, while it was not manifested in NSS subjects. Furthermore, the 
estimated mean thickness of the viable epidermis was significantly higher in SS 
subjects compared to NSS subjects 24 hours after stimulus, with significantly less 
cycling keratinocytes in SS subjects. The significantly stronger spongiosis response in 
SS subjects might explain the stronger increase of the viable epidermal thickness in SS 
subjects. The differences observed implies that the questionnaire might be an adequate 
tool to select, for research purposes, SS and NSS subjects. 
The lower number of strips required to strip the SC off in SS subjects could be caused 
by  reduced inter-corneocyte adhesion causing easy detachment of corneocytes. In 
line with our results, Ota et al. (2002) previously proposed that the average projected 
area of corneocytes obtained by tape stripping is a more reliable predicting method 
for self-assessed SS than TEWL or lactic acid stinging test (LAST). (20) Muizzuddin et al, 
(1998) observed that less strips were needed in a SS group to duplicate baseline TEWL 
values. (21) In coherence with this, Sparavigna et al. (2006) observed a correlation 
(r=0.46, p<0.001) between stinging intensity and irregularity skin index (ISI), implying 
a rougher skin in SS. (22) 
Vascular reactivity seems to play a role in the pathomechanism. The strong spongiosis 
in the SS group might explain the relative decrease of Ki67+ cells per mm BM at 24, 
also observed in other studies. (18) Spongiosis might also cause the lower a* values 
measured in SS subjects at several time points. (23, 24) One may speculate on adaptation 
to external manipulations of the SS. 
The hypothesized mechanisms of SS, e.g. skin barrier impairment, hypersensitivity, 
vascular reactivity and atopic predisposition, could not all be confirmed in our study. 
However, results emerged the contribution of impaired corneocyte adhesion and 
the spongiosis and ﬂare response in SS subjects may refer to vascular reactivity. 
Though, other stimuli than a mechanical one might elicit other pathways in the patho-
mechanism. 
and filaggrin is partially extracted by tapestripping. As a positive control at 24 hours, 
perifollicular staining for filaggrin can be observed. C) 72 hours after stimulus: K16 
expression can be observed and filaggrin is expressed more strongly in the granular 
layer; the filaggrin layer thickens.
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Biophysical parameters in our study did not reﬂect differences between SS and NSS 
subjects and did not parallel the conclusion with regard to the skin barrier. Slightly 
lower baseline SC hydration values were found (9, 25, 26), which reached statistically 
significance in one study (27), but also higher baseline values have been reported. (28, 29) 
TEWL at baseline is mainly shown to be higher in SS subjects, (9, 26, 28-31), but rarely 
reaches significance. (26, 32) 
A limitation of the study is the small number of subjects included and the analysis of 
four different stimulated spots in time. Moreover, it is questionable whether translation 
of skin responses on the lower back to facial areas is eligible. 
It has been proposed that SS symptoms have similarities with atopic dermatitis (AD), 
irritant contact dermatitis and physical urticaria and therefore, these diseases were 
excluded in our study. Remarkably, we found strong development of spongiosis 
following tape stripping implying that this model might is interesting for investigating 
dyskeratinization aspects in AD.
In conclusion, the differences observed between these groups of selected subjects 
imply that the used questionnaire is an adequate tool to select subjects for SS reseach. 
The differences as experienced in SS and NSS subjects is reﬂected in the functioning 
of the SC and spongiosis contributing to the overall inﬂammation. Accurate analysis of 
the skin barrier components, such as lipids, natural moisturizing factor and corneo-
desmosomes, and vascular reactivity could provide insights in the SS pathomechanism.
Acknowledgements
Wim Verkruijsse, senior scientist, Philips Research, Eindhoven, the Netherlands; Jan 
Willem Bikker, statistical consultant, CQM consultancy, Eindhoven, the Netherlands; 
Harry van Amerongen, research scientist, Philips Research, Eindhoven, the Netherlands; 
Lisanne Janssen, student, Radboud university medical center, Nijmegen, The Netherlands. 
103
IN VIVO HUMAN MODELS
4
Supplement 1 –Questionnaire
Questionnaire
Previously conducted research shows that many people complain of a sensitive skin in  
certain situations. The aim of currently conducted studies is to investigate what is happening  
in the skin of people who report to have a sensitive skin. 
Explanation for filling out this questionnaire:
- This questionnaire consists of 11 questions.
- We would kindly like to ask you to answer all questions in this questionnaire and to fill out 
one answer or to give one score per question.  
- We would like to advise you to take your time to fill out this questionnaire. Filling out this 
questionnaire takes 10-15 minutes.
Question 1:
How sensitive is your skin to the sun? Which skin type best describes your skin?
Skin color refers to  skin  that is not exposed to the sun.
  Skin type I: I always burn and never tan.  
Characteristics: fair skin,  often freckles, often red to light blond hair, often blue or green eyes. 
  Skin type II: I  usually burn and sometimes tan.  
Characteristics: fair skin, often blond hair,  often blue or green eyes.
  Skin type III: I sometimes burn and usually  tan.  
Characteristics: white to light brown skin, often dark blond to brown hair, often brown eyes.
  Skin type IV: I seldom burn and tan easily. 
Characteristics: light brown skin, often brown hair and brown eyes.
  Skin type V: I have a natural brown skin and tan easily. 
Characteristics: brown skin, often brown or black hair, often brown eyes.
  Skin type VI: I have a natural black skin.
Characteristics: dark brown to black skin, often black hair, often brown eyes.
Question 2: Allergic predisposition
2a. Do you currently have asthma or have you had asthma in the past?
  Yes
  No
2b. Do you currently have hay fever or have you had hay fever in the past?
  Yes
  No
2c. Do you currently have atopic dermatitis or have you had  atopic dermatitis in the past? 
Atopic dermatitis (atopic eczema) is a type of dermatitis which often has a childhood onset. Atopic 
dermatitis is not a  contact dermatitis due to allergy or irritation to substances.
  Yes
  No
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Question 3: 
Do you have a skin disease? 
  Yes
  No
Question 4:
Do you think your skin is more sensitive than the skin of others?
  Yes, my skin is much more sensitive 
  Yes, my skin is a bit more sensitive
  No, my skin is equally sensitive 
  No, my skin is less sensitive 
  I do not know 
Question 5:
How would you usually  qualify your facial skin, regarding skin dryness?
  Normal 
  Dry (the skin can scale) 
  Oily (the skin can shine)
  Combined (dry and oily zones)
How would you usually qualify the skin of your body, regarding skin dryness?
  Normal 
  Dry (the skin can scale) 
  Oily (the skin can shine)
  Combined (dry and oily zones)
Explanation scale and sensations:
A line depicts a scale, in which 0 means no  perception or pain  (or redness/dryness/pimples) 
and 10 is the most discomfortable feeling or pain (or redness/dryness/pimples)  that you can 
imagine. 
On the scale you can indicate the intensity of your sensation or observation following  
a specific situation. If a specific question is not applicable to you, you can indicate that in  
the specific box ‘not applicable’. After you have indicated your sensation, you are asked  
to fill out how long a specific reaction approximately persists. 
Stinging or prickling skin:  The feeling as if needles are pricked into the skin or the feeling as 
if alcohol is patted on a wound.  
Redness  Red spots or streaks occur or a more diffuse redness occurs.
Dryness:  The skin is dry and can scale. To a larger extent, cracks in  
the skin can occur.
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Example: Does your skin react to toiletries, cosmetics or laundry detergents? 
What do you feel and/or see and to what extent?
You would answer: “Yes, often my skin becomes little red and strongly stings.”
General discomfort: 
Redness: 
Stinging feeling: 
6.   Does your skin react to toiletries, cosmetics or laundry detergents? 
What do you feel and/or see and to what extent? 
Examples: shampoo, shower soap, hand soap,   facial lotions, make-up, make-up remover, shaving 
foam, deodorant, perfume,   cream, bodylotions, sunscreen products, washing-powder for the  
laundry etc.
a. General discomfort:
How long does this specific reaction approximately persist? 
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
b. Stinging or prickling feeling:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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c. Dry skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
d. Red skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
7.   Does your skin react to shaving? 
What do you feel and/or see and to what extent? 
Examples: shaving of facial hair, armpits, legs, genital area etc.
  This is not applicable for me
a. General discomfort:
How long does this specific reaction approximately persist? 
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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b. Stinging or prickling feeling: 
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
c. Dry skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
d. Red skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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8.   When you feel emotional or when you feel stressed, does your skin react to this? 
What do you feel and/or see and to what extent? 
a. General discomfort:
How long does this specific reaction approximately persist? 
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
b. Stinging or prickling feeling: 
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
c. Dry skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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d. Red skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
9. Does your skin ever react to heat?   
What do you feel and/or see and to what extent? 
Examples: hot shower, use of sauna  
a. General discomfort:
How long does this specific reaction approximately persist? 
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
b. Stinging or prickling feeling: 
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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c. Dry skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
d. Red skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
10.   Does your skin ever react to cold?   
What do you feel and/or see and to what extent? 
Examples: cycling in winter
a. General discomfort:
How long does this specific reaction approximately persist? 
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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b. Stinging or prickling feeling: 
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
c. Dry skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
d. Red skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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11.   Does your skin ever react to specific clothes or fabrics? 
What do you feel and/or see and to what extent? 
Examples: wool, rough cotton etc. 
General discomfort:
How long does this specific reaction approximately persist? 
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
a. Stinging or prickling feeling: 
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
b. Dry skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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c. Red skin:
How long does this specific reaction approximately persist?  
  I do not experience this 
  Seconds
  Few minutes
  Less than an hour
  Hour(s)
  Day(s)
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a*  CIE spectrum (International Commission on Illumination), a* value denotes red/green values
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BM  basement membrane
BSA   bovine serum albumin
DAB   3,3’-diaminobenzidine tetrahydrochloride
HE  hematoxylin-eosin 
HRP  horseradish peroxidase 
M/I+E  setting of the spectrophotometer: Measurement ø8mm, both SCI and SCE included 
METC  medical ethical committee 
NSS  non-sensitive skin
PBS  phosphate-buffered saline
SCE   specular component excluded
SCI  specular component included
SEM  standard error of the mean
SS  sensitive skin
TEWL  transepidermal waterloss (gm-2h-1)
UV  ultra violet
VAS  visual analogue scale
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Abstract 
Intro In order to identify pathways underlying the sensitive skin (SS) phenomenon, 
we stimulate the skin with sodium dodecyl sulphate (SDS), and use this as an in vivo 
human model to evaluate clinical, biophysical and immunohistochemical skin responses 
of subjects with SS.
Methods Subjects with SS and non-sensitive skin (NSS) were selected based on recall 
perceptions following daily triggers. Two sites on the buttock were exposed to 1% SDS 
for 24h. Skin reactions were evaluated with respect to clinical (discomfort, erythema, 
dryness, edema), biophysical (transepidermal waterloss, stratum corneum (SC) 
hydration and a*value) and immunohistochemical (hematoxylin & eosin, Ki67, CD3, 
elastase, tryptase, S100 and CD31) parameters 24 and 72 hours after stimulation. 
Results 72 hours after stimulus, the stratum corneum was significantly thinner in SS 
subjects compared to NSS subjects. The number of mast cells was significantly lower 
in SS subjects compared to NSS subjects 24 hours after stimulus.
Discussion The selection method seems to adequately distinguish SS from NSS 
subjects. Biophysical measurements seem to have limited value in the identification 
of SS pathophysiology, while there might be anomalies in the SC composition. Future 
research efforts for understanding pathomechanisms of SS should be directed at 
studying SC components and immune responses. 
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Introduction
Sensitive skin is a poorly understood condition, in which subjects report sensations of 
the skin, particularly characterized by stinging, burning or itching. (1-3) Visible signs of 
skin irritation are absent in some individuals with sensitive skin. (1, 3-6) An impaired 
epidermal barrier function is hypothesized by many research groups to be involved in 
the pathophysiology of sensitive skin. 
Maintaining a functional barrier is the role of the stratum corneum (SC), which 
structure protects the body from dehydration, external toxins and bacterial invasion 
and protects the keratinocytes from mechanical disruption. A common conceptual 
model of the SC is the “bricks and mortar” model, in which the corneocytes are 
considered to be the bricks and the intercellular lipids the mortar. (7-9) Differences in 
the nature of these intercellular lipids and/or the corneocytes provide the structural 
basis for the wide variations in permeability of the SC observed between different 
body sites and individuals (10) and possibly underlie the clinical differences between 
sensitive skin and non-sensitive skin.
Amongst a variety of eliciting factors, cosmetics frequently cause sensory skin 
reactions. Irritating compounds can affect the skin by various modes of action. Sodium 
Lauryl Sulphate (SLS) or Sodium Dodecyl Sulphate (SDS) is an anionic surface active 
agents used as an emulsifier in pharmaceutical vehicles and cosmetics as cleansing 
agents, and its degenerative effects are exerted by disrupting the lipid bilayers and by 
denaturation of stratum corneum proteins. (11, 12) These compounds with high irritant 
potential have been applied as provocative agents in clinical studies as an in vivo 
human model to study irritant contact dermatitis and to elicit skin responses in the 
sensitive skin. The impact of single exposure of the skin to SDS on the susceptibility to 
chronic irritant contact dermatitis (CICD) was studied extensively. (13) It was shown 
that together with atopic dermatitis, the irritability after SDS application were 
predisposing factors for CICD and not a high baseline transepidermal water loss 
(TEWL). (14-16) In contrast with CICD, the underlying pathways of the reaction of 
sensitive skin subjects to SDS, are not thoroughly investigated.
In 1991, Kligman already proposed the concept of invisible subclinical irritation, which 
is difficult to objectify. (17) These subclinical changes might occur following mild 
challenges to the skin, are below the threshold levels of clinical irritation, and might be 
solely observed histologically as proposed by Simion et al, 1995. (18) Therefore, immu-
nohistochemical evaluations should be applied to reveal underlying pathways causing 
mild sensory reactions in SS subjects.
The irritation threshold, the lowest SDS concentration that leads to visual skin 
inﬂammation after 4h patching ranges from <0.1% to >20%. (19, 20) The intensity of skin 
irritation depends on the exposure duration and the amount of chemical penetrating 
into the skin. By applying a fixed amount of an irritant, the irritation reaction is only 
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dependent on the penetration rate of the compound through the human skin, which 
on its turn is dependent on: condition of the skin barrier, physicochemical properties 
of the chemical and/or vehicle next to environmental factors as temperature and 
humidity. (21, 22) Therefore evaluation of the model under strict conditions enables 
studying the skin barrier of subjects with sensitive skin.
Previous studies showed inconsistent results with respect to differences in 
non-invasive biophysical measurements following application of SDS (4, 23-27) and 
therefore, further exploration of the value of surfactants in the identification of path-
omechanisms of sensitive skin is required. Not only by repeating experiments 
employing non-invasive biophysical measurements, but, more importantly, by 
involving analytical tools allowing to identify minute differences in the skin structure 
and composition. In our study, we defined sensitive skin and non-sensitive skin 
subjects using a proprietary questionnaire. In all patients, sensitive and non-sensitive 
subjects, the skin is stimulated with SDS to exert acute chemical manipulation of the 
skin barrier and to use this in vivo human skin model for clinical, biophysical and im-
munohistochemical evaluation of responses over time. Our primary objective is to 
investigate whether subjects with sensitive skin react differently to SDS compared to 
subjects with non-sensitive skin. Combining and relating these parameters in percep-
tion-based selected subjects might decisively meet our general objectives, i.e. 
obtaining new knowledge on the role of the barrier and mediators of potential 
inﬂammatory responses in the pathomechanism of sensitive skin. 
Methods
Population selection
Subjects, recruited via student websites were asked to fill out a questionnaire, 
comprising questions on self-assessed skin sensitivity and skin perceptions on recall 
(discomfort, stinging, redness or dryness) following eliciting factors (e.g. toiletries, 
shaving, emotions, heat, cold and clothes). Subjects scored the extend of discomfort 
on a Visual Analogue Scale (VAS) and duration on an ordinal scale (e.g. no experience, 
seconds, minutes, less than one hour, hour(s), day(s)). The investigator scored the 
answers by summing up the VAS scores and durations. Inclusion criteria were: the 
subjects with self-assessed skin sensitivity having high scores and the subjects 
without self-assessed skin sensitivity having low scores (as defined by the upper and 
lower quartiles of the score in a large cohort, n=238); skin type II or III (Fitz-Patrick 
scale), healthy subjects without atopy or skin diseases including contact dermatitis 
and urticaria. Subjects could not apply any cosmetics for at least 24 hours before the 
first visit until the end of study participation and should not use immunosuppressive 
treatments. SS and NSS groups were matched for gender. The study was conducted 
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conform Declaration of Helsinki principles and the study design was approved by the 
local ethics committee. Subjects gave written informed consent.
Stimulation of the skin
In both the SS and NSS groups, two sites on the upper outer quadrant of the left 
buttock of each patient were exposed for 24h to an aliquot of 150µl of 1% sodium 
dodecyl sulphate (of 99% purity) in demineralized water using square patch test 
chambers with an area of 0.6 cm2. The skin was not cleansed in advance, as this might 
affect SC biophysical properties. 1% was selected as it is the maximum tolerated 
concentration in cosmetics, causing only moderate erythema. (28) The patches were 
additionally fixed with tape. One hour prior to evaluation, the patches were removed 
to prevent measuring occlusion effects. (29) Evaluation was done in non-stimulated 
skin at three different time points: baseline, directly after 24 hour stimulation with 
SDS, ’24 hours after stimulus’, and 48h after removal of the patch, ‘72 hours after 
stimulus’.
Biophysical measurements
Prior to any measurements, subjects were acclimated for 20-25 min with the skin 
exposed to the room temperature and relative humidity under standard conditions, 
20-22°C and 40-60% Respectively. Each measurement was performed three times on 
the same skin site and applied in the following order: skin redness, transepidermal 
water loss (TEWL) and statum corneum hydration. Skin redness was measured using 
the Chroma Meter 2600d (Konica Minolta, Tokyo, Japan) calibrated on a white surface 
delivered with the device. The changeable aperture was set at 8mm and settings 
were: UV100%, M/I+E, 65d illuminant and 0.0 sec delay time. The device had brief, 
light contact with the skin to prevent vasoconstriction and subsequent hyperaemia. 
An interval of 30 seconds was applied between each spectrophotometeric 
measurement. TEWL was measured by the AquaFlux AF200 (Biox Systems, London, 
U.K.)  and values were expressed as a mean of three recordings. Intervals of two 
minutes were applied, to make prevent water accumulation on the skin surface due to 
occlusion by the probe. Stratum corneum hydration was measured using the 
Corneometer CM825 (Courage + Khazaka electronic GmbH, Cologne, Germany). 
Intervals of 10 seconds were used and the probe was cleaned with cotton pads 
between measurements. In case longer terminal hairs were present, these were 
carefully cut with scissors to enable adequate skin-probe contact. 
Tissue processing and immunohistochemistry
The skin was cleansed with chloorhexidin 0.5% m/v in alcohol 70% v/v before taking a 
3mm punch biopsy of the skin under local anesthesia with 1% xylocain-adrenalin. 
Tissue was fixed in 10% formalin for subsequent paraffin embedding, and sectioned 
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at 6 µm thickness. Paraffin fixed specimens were deparaffinized and rehydrated. 
Citrate buffer (pH 6.0, 10 min at 100°C) was used to retrieve epitopes for Ki-67 and 
CD31, and  TRIS/EDTA  (50 mM TRIS + 2 mM EDTA, pH 9.0, 10 min at 100°C) for tryptase 
and for CD3 antibodies, EDTA/Tween-20 (10 mM EDTA, + 0.05% Tween-20, pH 8.0, 10 
min at 100°C). The S100 primary antibodies did not require antibody retrieval steps. 3% 
H2O2 in phosphate-buffered saline (PBS) was used to block endogenous peroxidase 
activity for Ki67, CD31, CD3, tryptase and S100 antibodies and preincubation was done 
using 1% bovine serum albumin (BSA) (Dako, Glostrup, Denmark) for 15 minutes before 
application antibodies. For CD3 staining preincubation was done for 30 minutes. 
Anti-human primary antibodies were used for immunohistochemical staining (table 1): 
Ki67 (1:100, clone MIB-1, Dako, Glostrup, Denmark), CD3 (1:100, clone F7.2.38,  Abcam, 
Cambridge, UK), CD31 (1:80, clone JC70A, Dako, Glostrup, Denmark), anti-tryptase 
(1:100,000, clone AA1, Dako, Glostrup, Denmark), and S100 (1:5,000, clone Z0311, Dako, 
Glostrup, Denmark). Sections were incubated overnight at room temperature, 
whereby primary antibodies were dissolved in 1% BSA. Envision anti-mouse (Dako, 
Glostrup, Denmark) was used to amplify antibody visualization, except for S100 
staining, in which horseradish peroxidase (HRP) labeled polymer (Envision anti-rabbit, 
Dako, Glostrup Denmark) was used. 3,3’‐diaminobenzidine tetrahydrochloride (DAB) 
solution (Sigma‐Aldrich, St. Louis, MO) was used as a antibody label. Mayer’s 
hematoxylin (Sigma-Aldrich, Saint Louis, USA) was used as a counterstaining. Slides 
were dehydrated and mounted using Permount (Thermo Fisher Scientific, Waltham, 
USA). 
Semi-quantitatively assessment of immunohistochemical markers
Cells were quantified by using Axiokop 2 MOT microscope (Zeiss) at a magnification of 
×200, Axiocam MRc5 digital camera and AxioVision software rel. 4.8 (Zeiss). Semi-
quantitative analysis of cells was established using macro colour deconvolution and 
color threshold in ImageJ (National Institutes of Health, version 1.46). The epidermal 
thickness was measured by dividing the epidermal area by the length (average of the 
basal membrane (BM) length and the surface length). The thickness of the SC is the 
mean of 10 measurements in a single slide. Spongiosis was assessed by two blinded 
observers (RR, LJ) on a 4 point scale (0, no spongiosis; 1, slight spongiosis in a limited 
area of epidermis; 2, slight spongiosis in a large area of epidermis; 3, strong spongiosis 
in a large area of epidermis). When scores mismatched, consensus was achieved by 
discussion. Ki67 positive cells were expressed as the number of positive cells per mm 
BM length. S100 stainings were expressed as the percentage of the viable epidermis. 
The dermis was assessed from the BM down to 350 µm across the section and CD31, 
CD3, tryptase and elastase positive cells were expressed as the number or percentage 
of the surface per mm2 dermis. 
123
IN VIVO HUMAN MODELS
4
Statistical analysis
Baseline characteristics are presented as median and range, or as frequencies and 
percentages. The t-test was used to analyze differences between skin sensitivity 
groups (sensitive skin and non-sensitive skin) for continuous variables. Pearson’s 
correlations were done to identify relations between continuous variables. Differences 
between the sensitive and non-sensitive groups were analyzed using a linear mixed 
model for repeated measurements adjusted for baseline. The dependent variable was 
the specific variable (biophysical measurement, immunohistochemical evaluation). 
The independent class variables were the skin sensitivity (sensitive and non-sensitive), 
time (baseline, 24 and 72 hours after stimulus) and the value of the specific variable at 
baseline. The estimated mean differences between the two groups with 95% 
confidence intervals (CI), at each point of measurement, is presented. The statistical 
analyses were performed using SAS version 9.2 for Windows (SAS Institute, Cary, NC) 
and IBM SPSS Statistics 20.0 for Windows (IBM Corp. Armonk, NY). A p-value of lower 
than 0.05 was considered statistically significant. 
Table 1   Baseline characteristics of the subjects  with NSS (n=8) and  the subjects 
with SS (n=8).
NSS subjects
n (%) /
median(range)
SS subjects
n (%) /
median(range)
Gender
    Male
    Female
4 
4 
(50.0)
(50.0)
4 
4 
(50.0)
(50.0)
Age (years) 22.5 (19-28) 23.5 (20-32)
Skin type (Fitzpatrick)
    Skin type II
    Skin type III 
5 
3
(62.5)
(37.5)
6 
2 
(75.0)
(25.0)
Facial skin dryness
    Normal
    Dry
    Oily
    Combined
5 
1 
1 
1
(62.5)
(12.5)
(12.5)
(12.5)
1 
3 
0 
4 
(12.5)
(37.5)
(0.0)
(50.0) 
Body skin dryness
    Normal
    Dry
    Oily
    Combined
5 
3 
0 
0 
(62.5)
(37.5)
(0.0)
(0.0)
4 
4 
0 
0 
(50.0)
(50.0)
(0.0)
(0.0)
Questionnaire 28.7 (8-38) 156.9 (70-287)
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Results 
Baseline outcomes
Clinical observations and biophysical measurements 
Eight subjects with SS and eight subjects with NSS skin were included and the median 
age (range) was 23.5 (20-32) and 22.5 (19-28) years respectively (table 1). The average 
score on the questionnaire was 159.4  (range: 70 – 287) for the SS group and 25.8 
(range: 8 – 38) for the NSS group. Note that the questionnaire is used to define SS and 
NSS. Six subjects in the SS group and five subjects in the NSS group had skin type II. 
Four SS and three NSS subjects reported to have a dry skin of the body. None of the 
subjects reacted positive on the dermography test. With respect to the biophysical 
parameters, on average no statistically significant difference at baseline between the 
SS and the NSS group were found (table 2). A negative correlation was found between 
SC hydration and TEWL values (r=-0.537, p=0.032).
Epidermal proliferation, immunologic and vascular markers
No statistically significant differences between the SS and NSS group were found with 
respect to SC thickness, viable epidermal thickness, proliferating keratinocytes, T cells, 
neutrophils, mast cells, dendritic cells, and endothelial cells. 
Skin reactions following SDS application
Clinical observations
Two SS and two NSS subjects showed highest erythema values 24 hours after stimulus, 
while in all other subjects highest erythema responses were observed at 72 hours 
after stimulus. At this latter point of measurement, six SS subjects showed fair 
erythema, while this was visible in only three NSS subjects, figure 1. Other subjects 
showed slight erythema. Twenty-four hours after stimulus five SS subjects showed 
some degree of skin dryness, while none of the NSS subjects showed this. At 72 hours 
after stimulus, skin dryness was observed in seven and three subjects in the SS and 
NSS groups respectively. At 24 hours after stimulus one SS subjects experienced 
burning (VAS 2) and one NSS subjects reported itch (VAS 2). At 72 hours after stimulus, 
these subjects did not experience any complaints. One SS and one NSS subject 
experienced itch sensations 72 hours after stimulus, VAS 5 and VAS 3 respectively. 
Biophysical measurements
In table 2, the observed medians and estimated difference between the groups are 
presented. On average, none of the biophysical measurements were found to be 
statistically significant different between the SS and NSS subjects. A* values increased 
over time and reached maximum values for all SS subjects at 72 hours after stimulus, 
while for NSS subjects the maximum was reached at either 24 hours (n=3) or 72 hours 
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after stimulus (n=5). On average, TEWL increased following SDS stimulus in both 
groups and reached highest values at 72 hours after stimulus, while SC hydration 
decreased and reached lowest values at 72 hours after stimulus. 
Epidermal proliferation markers
With respect to the SC thickness, we found that the mean SC  thicknesses at 72 hours 
after stimulus was statistically significantly lower (p=0.016) in the SS group compared 
to the NSS group (-2.4, 95%CI: (-4.2;-0.5) (table 2). The SC decreased in thickness from 
baseline to 72 hours after stimulus (figure 2). We found a strong correlation between 
SC thickness and TEWL both at 24 hours and 72 hours (r=-0.557, p=0.024 and r=-0.724, 
p=0.002, respectively). With respect to the epidermal proliferation markers, we found 
no statistically significant difference in the amount of spongiosis, in the thickness of 
the viable epidermis and in the number of proliferating keratinocytes between SS and 
NSS subjects. The viable epidermis thickened after stimulation with SDS and reached 
on average maximum values at 72 hours after stimulus. The number of proliferating 
cells increased at 72 hours after stimulus compared to 24 hours after stimulus 
(p<0.0001).  
Figure 1  Clinical observations at baseline (Panel A); at 24 hours after SDS application 
showing fair erythema (Panel B); at 72 hours after SDS application showing slight 
erythema and skin dryness (Panel C).
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Immunologic and vascular markers
With respect to the number of mast cells, we found statistically significantly less mast 
cells in the SS subjects compared to NSS subjects at 24 hours after stimulus (-19.5, 
95%CI: (-36.7;-2.4) (p=0.029), (table 2, figure 2). No statistically significant differences 
are found in the quantity of endothelium tissue, S100+ positive cells, T-cells and 
neutrophils between SS and NSS subjects post-stimulus. 
Figure 2  Mean observed values of three parameters in NSS subjects (solid bullets) 
and in SS subjects (open bullets) at each point of measurement of the thickness of 
the stratum corneum (SC) (Panel A); of the number of tryptase+ cells (mast cells) per 
mm2 dermis (Panel B); of the a* value in arbitrary units (A.U.) (Panel C).  The vertical 
lines indicate one standard error; * p<0.001; ** p<0.05. Note that SDS stimulation of 
the skin was applied to all subjects in each group up to 24 hours since baseline.
A
C
B
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Discussion
Our results show that subjects with SS, selected when reporting strong self-assessed 
reactivity to daily stimuli, show different skin reactions in response to SDS application 
compared to subjects who do not report strong self-assessed reactivity to daily stimuli. 
After application of SDS, the stratum corneum was significantly thinner in SS subjects 
at 72 hours after stimulus compared to NSS subjects. Next to this, the number of mast 
cells was significantly lower in the SS subjects compared to the NSS subjects at 24 
hours after stimulus. Maximum a* values were reached in SS subjects 72 hours after 
stimulus, while in NSS subjects the maximum was reached either 24 or 72 hours after 
stimulus.
Although not as abundant as tape stripping, this stimulus elicits differences in skin 
responses between selected SS and NSS subjects. Reasons for the use of SDS for 
experimental studies is, that it brings no cosmetic inconvenience to the exposed 
subject and no systemic toxicity is mentioned, nor the irritant being a carcinogen or 
sensitizer (30). A relatively low dose of SDS was used, since this simulates the irritating 
effect of cosmetics, frequently reported by SS subjects. A higher concentration of SDS 
might enhance differences in skin reactions between SS and NSS subjects more 
perspicuously, since it is known that there is a correlation between response and 
concentration of SDS, similar to SDS, as found in blood ﬂow measurements after 24 
hours and 48 hours of SDS patching. (31) Notably is that this stimulus is a milder 
stimulus compared to for example tape stripping, and holds a different, yet 
complimentary mode of action.
The lower number of mast cells found in SS after stimulus is in line with the results of 
Richters et al, 2015, studying skin responses to mechanical barrier disruption, in which 
a trend in a lower number of mast cells following stimulus in SS subjects was observed 
compared to NSS subjects. (32) Next to their anti-inﬂammatory functions, mast cell 
proteases are known to have pro-inﬂammatory functions as well and might be 
imbalanced in SS subjects. Another explanation of this lower number of mast cells 
following stimulus in SS subjects might be that immune responses in SS subjects are 
adapted to mild environmental stimuli or that each mast cell releases more 
inﬂammatory mediators. Tryptase, a neutral protease in human mast cell secretory 
granules measured in this study, is predominantly produced by mast cells, but not the 
only protease. Analysis of other proteases might validate these results and place them 
in context. Quatresooz et al, 2009, in contrast showed less CD117+ cells in unchallenged 
skin of SS subjects revealing low current perception thresholds. (33)
The stratum corneum was significantly thinner 72 hours after stimulus in the SS 
subjects compared to the NSS subjects (p=0.016). This could imply differences in 
molecular composition (e.g. amount, type and ratio of lipids and structural proteins) in 
the SC between the SS and NSS groups. These results emerge that the SC is vulnerable 
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to surfactants. Other studies show that the SC is also vulnerable to mechanical 
stimulation, and therefore, SS might be triggered by factors of different nature. As 
TEWL measurements were not able to discriminate between SS and NSS groups, it 
could mean that the structure of components of the SC might be malformed and 
establish a slightly impaired barrier at a level that is beyond sensitivity of the traditional 
non-invasive biophysical methods. 
Also, high inter individual variability is known in the recovery of TEWL following SDS 
exposure, where subjects with high baseline values tended to have higher delta TEWL 
after repeated exposure to SDS. (34) After single exposure to SDS, TEWL and erythema 
increased more strongly in a group with atopic dermatitis (p=0.07 and p=0.03 
respectively). (34, 35) Recalling that about 2-3% of applied SDS solution penetrates, as 
shown by de Jongh et al, (2006) is also supporting this hypothesis. (34) For example, a 
higher delta TEWL therefore might imply a higher penetration rate of SDS. The 
individual susceptibility for irritant contact dermatitis (ICD) is suggested to be 
predicted by brief SDS tests and baseline TEWL by several epidemiological studies. (13) 
Yet, Lofﬂer et al, 2001, and Diogo et al, 2010, could not objectify different skin reactions 
to SDS between SS subjects and NSS subjects. In these studies, subjects were selected 
by questionnaire and self-reported sensitivity to household cleaning products 
respectively (4, 26) In our study, erythema at 72 hours after stimulus tended to be 
higher compared to 24 hours after stimulus in the majority of SS subjects, in contrast 
with NSS subjects and implies a stronger irritable effect of the SDS. However, this is 
not reﬂected by TEWL measurements. 
A limitation of this study is the small number of subjects and next to this, adjacent 
skin sites are assumed to have comparable skin properties. Yet, after removal of the 
SDS patch, an increase in TEWL with respect to baseline values could be observed in all 
subjects. Agner et al. (1993) showed that the occlusive effect on the skin evaluated by 
measurements of TEWL was present until 60 minutes after patch removal. 60-180 
minutes after patch removal, TEWL measurements were constant. (36) This finding 
supports the reliability of our measurements; that we accurately envisage TEWL, and 
not surface water caused by occlusion. Lastly, our results in SDS reactivity may be 
generalized over different ages between 18 and 50, since Agner et al, 1991 show no 
differences between those ages. (37)
In conclusion, the selection questionnaire seems to adequately distinguish SS from 
NSS subjects and therefore seems to be a selection tool for clinical studies. Furthermore, 
frequently used established biophysical skin barrier measurements seem to be of 
limited value in evaluation of differences in skin responses between SS and NSS 
subjects, while there might be impairments in the stratum corneum composition. In 
the future we recommend focusing on identification of mechanisms underlying SS by 
studying stratum corneum components, and cutaneous immune responses. 
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Abstract 
Background Fractional photothermolysis using professional devices is a well-accepted 
and a widely-used technique for skin rejuvenation. Recently, the technology has also 
been implemented in devices for home-use. Yet, a subpopulation of consumers exists 
that reacts excessively to this stimulation and reports ‘sensitive skin’ (SS). 
Objective The goal of this study was to evaluate the response of subjects with SS and 
NSS to fractional non-ablative photothermolysis to provide additional insights in the 
pathophysiology of SS. 
Methods Subjects with SS and non-sensitive skin (NSS), selected using a proprietary 
questionnaire were stimulated by applying a home-use fractional non-ablative photo-
thermolysis device. Self-reported perceptions and objective effects were evaluated 
after 0.5, 8, 24 and 72 hours by clinical, biophysical and immunohistochemical assessment, 
and in vivo reﬂectance confocal microscopy (RCM). 
Results Significantly fewer mast cells were found in SS compared to NSS subjects, 
0.5 and 72 hours after stimulus based on tryptase staining, and SS subjects report 
discomfort more frequently. Immunohistochemical biomarkers revealed new insights 
in the effects of fractional non-ablative photothermolysis, which were supported by 
RCM: peri- and interlesional epidermal proliferation, and changes in keratinocyte 
 differentiation. 
Conclusion Previously, we have already reported that SS could be elicited by mechanical 
and chemical stimuli. Thus, mild yet excessive self-reported perceptions described here 
supports the hypothesis about existence of generalized skin sensitivity. Furthermore, 
it supports a view point suggesting involvement of TRPV1 receptors in this phenomenon. 
While histological evaluation, in line with our previous results points to the role of mast 
cells in SS, overall, however, fractional non-ablative photothermolysis causes only mild 
damage, nearly equal in SS and NSS and could be used as an in vivo model for skin 
regeneration without manipulating the skin barrier. 
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Introduction
One of the key functions of the human skin is the protection of the body from the 
external environment and daily challenges such as mechanical and chemical damage, 
and photo-irradiation. Photoaging of the skin is a process that builds up over the years, 
caused by exposure of the skin to UV-light. Chronological skin aging results in a 
decrease of skin thickness with diminished elasticity, while photodamage manifests 
as rhytids, pigment changes, and laxity and roughness of the skin. (1) Maintaining skin 
integrity and thus its functionality as well as appearance is essential to battle these 
skin alterations. 
To improve the appearance of aged skin, a wide spectrum of techniques has been 
developed. Ablative lasers in fractional or non-fractional forms were used to resurface 
the skin affecting the stratum corneum, the epidermis and portions of the superficial 
dermis, inducing collagen remodeling in the deeper dermis. Their action is based on 
using carbon dioxide (CO2, 10600 nm), or erbium-doped yttrium aluminum garnet 
(Er:YAG, 2940 nm) laser or combined treatment using both of them. Very strongab-
sorption by water molecules leads to high efficacy of treatment, which is however 
associated with rather long downtimes. To minimize recovery times, persistent 
erythema and risks of altered pigmentation associated with these methods, near 
infrared fractional non-ablative laser technologies were introduced. (2) Their 
wavelength is close to the less-strongly absorbing near-infrared band of water at 1450 
nm, where for example solid state lasers such as neodymium-doped yttium aluminum 
garnet (Nd:YAG), erbium laser, or diode lasers are used. (3, 4) Application of these light 
sources in a fractional regime results in isolated microscopic thermal micro-lesions. 
The spared interlesional tissue appears to stimulate the collagen synthesis, resulting 
in improvement of rhytids and dyspigmentation. (3) The technique is implemented in 
home-use devices for skin rejuvenation and is based on the Fraxel® technology. (5)
As is known for chemical challenges (6-11), a subpopulation reacts excessively to these 
photothermolysis stimulations compared to other individuals. Individuals might 
assess themselves as having a ‘sensitive skin’ (SS), including objective and subjective 
symptoms as burning feeling, erythema and edema. The definition of SS as such, 
including its underlying pathways, is not clear in literature. In order to optimize 
light-based treatments, knowledge of SS and its mitigations is obligatory. Since 
burning pain is frequently reported in SS subjects, an overexpression of the transient 
receptor potential vanilloid receptor (TRPV1 receptor) has been hypothesized to play a 
role in the pathophysiology of SS, since inhibition of the receptor has been proposed 
to lead to reduced sensations of SS. (12) This receptor is known to be activated when 
the skin comes in contact with noxious stimuli, such as heat or capsaicin, which results 
in nociceptor mediated burning pain. (13, 14) Therefore, investigating skin reactions to 
thermal factors represents a justified approach to unravel mechanisms of SS. (12) 
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The objective of this study was to evaluate the response of subjects with SS and NSS 
to fractional non-ablative photothermolysis to provide additional insights in the patho- 
physiology of SSin general, To fulfill this goal, we analyzed self-reported perceptions 
and clinical signs together with dynamically performed objective assessment using 
traditional biophysical methods, (immuno)histochemical analysis, and in vivo reﬂectance 
confocal microscopy (RCM). Understanding the phenomenon of SS in relation to 
 photothermolysis could not only provide an answer to the question about existence 
of generalized skin sensitivity, i.e., whether SS can be considered as a container term, 
implying that subjects with SS react to multiple exogenous challenges, but also lead 
to identification of relevant mitigating measures. 
Methods
Volunteers are recruited via student websites and were asked to fill out a questionnaire 
(manuscript submitted) including retrospective assessment of four skin sensations 
and signs (i.e. skin discomfort, stinging, redness or dryness) following six predisposing 
factors (i.e. toiletries, shaving, emotions, heat, cold and clothes). The four sensations 
per predisposing factor were scored on (i) a VAS scale (0-10) regarding severity and (ii) 
on an ordinal scale on duration (0-10). The scores for these 48 items were summed 
resulting in a maximum score of 480. Additionally, subjects were asked whether they 
assessed their skin as much more, slightly more, equally or less sensitive compared to 
others. High and low scores were defined as scores in the upper and lower quartile, 
respectively, as defined by analysis of a larger cohort (n=238). Subjects were included 
in a SS group, when they thought their skin was sensitive and they scored higher than 
the upper quartile cut-off score, and for the NSS subjects vice versa. 
Exclusion criteria were: age below 18 or above 65 years, Fitzpatrick skin type I and >III, 
a skin disease, history of atopic dermatitis, asthma or allergic rhinoconjunctivitis, 
history of allergic or irritant contact dermatitis, use of immunosuppressive drugs. Sun 
exposure (from two weeks) and topical cosmetics or washing (from 24 hours) on the 
lower back and buttocks was not allowed until the end of participation. The study was 
conducted in conformity with the Declaration of Helsinki principles and approved by 
the local ethics committee.
Procedure and stimulus
In our study, a vertical single stroke was applied with a commercially available CE 
marked, in conformity with the directions of the European Union, 1435 nm non-ablative 
fractional photothermolysis home-use laser device (RéAura SC5000, Philips Electronics 
Nederland B.V.)to induce standardized thermal damage by means of single stimulation 
to the skin parallel to the cranial end of the intergluteal cleft. The device delivers 20 
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microthermal zones per cm2 per pass with 9mJ per pulse. These properties were 
measured using a power meter and visual observation of the thermal lesions . The 
specific body site was chosen to minimize the burden of potential scarring following 
skin punch biopsies. No coupling gel or pretreatment of the skin was applied, since 
these measures might affect skin properties, such as stratum corneum hydration and 
transepidermal waterloss and thus affect read-outs for biophysical methods, 
compromising validity of the study. The device had appropriate contact with the skin 
during the stimulus procedure, as monitored using the light indicators on the device. 
Evaluation
All measurements were performed at an ambient temperature of 20-22 °C and 40-60% 
humidity, to which subjects acclimatized for 30 minutes, in four areas of approximately one 
cm2, at 0.5, 8, 24 and 72 hours after stimulus. A non-stimulated adjacent skin region 
was used as a reference. Incidental terminal hairs were cut with scissors close to the 
skin surface. Clinical macroscopic images were taken at every time point. Additionally, 
the investigator scored erythema as accepted in dermatological practice (no erythema, 
slight erythema, marked erythema, fair red erthema, dark red erythema), dryness (no 
dryness, mild dryness, moderate dryness, severe dryness), edema (no edema, slight 
edema, severe edema) and the subject scored general discomfort, stinging, itching, 
tightness and burning on a Visual Analogue Scale (VAS 0-10). Dermographism on the 
back with a pencil was applied to assess atopic predisposition. 
Biophysical evaluation, including transepidermal waterloss (TEWL), SC (stratum corneum) 
hydration and skin redness, was performed in the corresponding order, using the 
AquaFlux AF200 (Biox Systems, London, U.K.), the Corneometer (Courage + Khazaka) 
and the Chroma Meter 2600d (Konica Minolta, Tokyo, Japan). Each measurement was 
performed three times at each timepoint on the same skin site, with an interval of one 
minute, 30 seconds and 30 seconds respectively to prevent occlusion of the skin and 
vasoconstriction and subsequent hyperaemia. Values included in the analysis were 
the mean of three recordings. The measurements of the Chroma meter were applied 
using an 8mm aperture. 
In addition, RCM (Vivascope 1500 system, Lucid Inc, Rochester, NY, USA), a non-invasive 
imaging device, which uses a near infrared laser for in vivo examination of the skin at 
sub-cellular resolution, was applied in two additional subjects at 0.5, 8, 24 and 72 hours 
after stimulation in order to characterize microthermal zones (MTZ’s).  Dermoscopic 
pictures of the stimulated skin were taken using a macro camera (Vivacam; Lucid Inc) 
and confocal images were taken using Vivascan 7.0 software (Lucid Inc). To indicate 
the MTZ, horizontal mapping (8x8 mm) was performed at the level of the SC, stratum 
granulosum (SG), stratum spinosum (SSp), dermo-epidermal junction (DEJ) and 
papillary dermis. Vertical VivaStacks (steps of 4,5µm with images of 500x500µm) 
mapped the clinical MTZ lesions and the additional MTZ’s identified in the VivaBlocks. 
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Immunohistochemistry and quantification
Skin sites were cleaned with chlorhexidin 0.5% m/v in alcohol 70% v/v and subsequently 
injected with 1% xylocain-adrenalin. Thereafter punch biopsies (3mm) of the skin were 
taken. The formalin fixed tissues were paraffin embedded and sectioned at 6 µm. 
Sections were screened under the microscope in order to identify microthermal zones 
(MTZ’s). The MTZ’s were not detectable in all obtained tissues. Tissues were dewaxed 
in histosafe (Adamas, Rhenen, The Netherlands) and rehydrated in subsequently 
decreasing concentrations of alcohol (100 to 50%). Tissues were stained with 
hematoxylin and eosin, and with Ki67, CD31, tryptase, CD3 and K16 antibodies. Tissues 
were stained with hematoxylin for 10 minutes and eosin for 90 seconds. Ki-67, K16 and 
CD31 antigens were retrieved using citrate buffer (pH 6.0, 10 min at 100°C) and CD3 
and  tryptase antibodies using EDTA/Tween-20 (10 mM EDTA, + 0.05% Tween-20, 
pH 8.0, 10 min at 100°C). Endogenous peroxidase activity was blocked using 3% 
H2O2 in phosphate-buffered saline (PBS) before the tissues were preincubated with 
1% bovine serum albumin (BSA) in PBS (Dako, Glostrup, Denmark) for 15 minutes 
before application of the primary antibodies. The preincubation of CD3 antibodies 
was done for 30 minutes. The anti-human primary antibodies used for immuno-
histochemical staining were: Ki67 (1:100, clone MIB-1, Dako, Glostrup, Denmark), 
CD3 (1:100, clone F7.2.38, Abcam, Cambridge, UK), K16 (1:50, Clone LL025, Sanbio B.V., 
Uden, The Netherlands), tryptase (1:100000, Clone AA1, Dako, Glostrup, Denmark) 
and CD31 (1:80, clone JC70A, Dako, Glostrup, Denmark), all dissolved in 1% BSA in PBS. 
Sections were incubated overnight at room temperature. Envision anti-mouse 
labeled polymer (Dako, Glostrup, Denmark) was used to amplify visualization with 
3,3’‐diaminobenzidine tetrahydrochloride (DAB) solution (Sigma‐Aldrich, St. Louis, MO). 
Mayer’s hematoxylin (Sigma-Aldrich, Saint Louis, USA) was used as a counterstaining. 
Slides were dehydrated and mounted using Permount (Thermo Fisher Scientific, 
Waltham, USA). 
Subsequently, the positively stained cells were quantified using Axiokop 2 MOT 
microscope (Zeiss) at a magnification of ×200, Axiocam MRc5 digital camera and 
AxioVision software rel. 4.8 (Zeiss) and ImageJ (National Institutes of Health, version 
1.46). Macro colour deconvolution and color threshold in ImageJ (National Institutes 
of Health, version 1.46) were used for the quantitative analysis. Epidermal thickness 
was measured by dividing the area of the epidermis area by its length (average of the 
basal membrane (BM) length and the surface length). For Ki67, the number of positive 
nuclei was expressed per mm BM length, for CD31 and tryptase, positive cells or 
surface was expressed per mm2 dermis (depth 350 µm).
Statistical analysis
To analyze differences between SS and NSS subjects, the Mann-Whitney test for 
non-parametric independent variables  was used for continuous variables. Statistical 
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analyses were performed using IBM SPSS Statistics 20.0 for Windows (IBM Corp. 
Armonk, NY). p-value < 0.05 was considered statistically significant. 
Results
Population characteristics
In total, eight SS and eight NSS subjects were included, with sensitive skin questionnaire 
scores of 168.8 (119-316) and 41.4 (8-55), respectively. Sexes were equally distributed 
and subjects had a median (range) age of 20 (19-24) years in the SS group and 21.5 
(20-24) years in the NSS group. Five SS and six NSS subjects had skin type II, the others 
had skin type III. Three SS subjects assessed their facial skin as dry, and six assessed 
their body skin as dry. Dermographism was positive in one SS subject, showing wheal 
and ﬂare reaction. With respect to these characteristics, the groups did not differ 
significantly. 
Clinical and biophysical parameters
Representative images of skin reactions of SS subjects following stimulus are shown 
in figure 1. Five SS subjects showed fair erythema 0.5 hours after stimulus, other 
subjects showed slight erythema. 24 hours after stimulus in two NSS subjects the 
erythema had disappeared, and at 72 hours in all subjects except for a significant 
subgroup of three SS subjects. Edema occurred 0.5 hours after stimulus in four subjects 
in each group and was still visible in one NSS subject at 8 hours after stimulus. Skin 
dryness was observed in one SS and in one NSS subject at 72 hours after stimulus. 0.5 
hours after stimulus, four SS subjects experienced stinging (VAS 2-7), four SS subjects 
experienced burning (VAS 2-8), one SS subject experienced itch (VAS 2) and one SS 
subject experienced tightness (VAS 6). Three subjects experienced these sensations 
still in lesser extent at 8 hours after stimulus and at 24 hours only one SS subject still 
experienced perceptions. Of the NSS group only one subject experienced stinging 
(VAS 1), at 8 hours after stimulus. No differences in biophysical measurements could 
be found between SS and NSS subjects (table 1).
Immunohistochemistry and RCM
Perilesional skin (around the MTZ’s)
0.5 hours after stimulus MTZ’s were possible to detect, with more intense hematoxylin 
and eosin staining in a vertical direction of the epidermis and dermis (Figure 2). In the 
papillary dermis, damaged and dilated capillaries were observed and dermal-epidermal 
clefting. 8 hours after stimulus, microscopic epidermal necrotic debris (MEND) formed 
and disorganization and destruction were predominant. The dermis showed 
inﬂammatory infiltrates and abnormal fibrotic fibers. In some biopsies, perilesional 
142
CHAPTER 4
spongiosis have been observed. 24 hours after stimulus, MEND’s were gradient. Again 
the damaged capillaries corresponded to the localization of the MTZ and extensive 
infiltrates of inﬂammatory cells were observed. The SC and basement membrane 
were destroyed and the morphology of the epidermis had dramatically changed. 72 
hours after stimulus, MEND’s were partially shed off and inﬂammatory infiltrate and 
spongiosis were still observed. Perilesional hypergranulosis and hyperproliferation 
were visible and perilesional changes in keratinocyte differentiation were observed 
(figure 3). With respect to RCM evaluations, the MTZ’s were detected at all time points 
from the upper SC to the deeper dermis. Half an hour after stimulation, the low 
reﬂecting area (black round structure of 200 µm in diameter) was observed (figure 2). 
Extremely low reﬂectance signal could either be associated with absence of material 
in the zone or to presence of material with an homogenous refractive index. As the 
corresponding histological images clearly show presence of nucleated cellular material 
with nearly absent cytoplasm, the low reﬂectance could be originating from 
accumulation of denatured proteins and cells, lacking cytoplasm and therefore 
refractive index contrast. This area is surrounded by a highly reﬂecting halo, originating 
either due to changes in protein rigidity or accumulation of liquids, introducing 
refractive index variation and thus leading to high reﬂection around the primary 
damaged zone. At 8 hours, heterogeneous material (mainly protein debris) is present 
Figure 1  An example of a macroscopic image of the skin of a SS subject at 0.5, 8, 24, 
and 72 hours after stimulus. The stimulus (10mm wide) was applied to the skin as can 
be seen in vertical direction in the image.
143
IN VIVO HUMAN MODELS
4
Ta
bl
e 1
   O
bs
er
ve
d v
alu
es
 (m
ed
ian
, ra
ng
e)
 of
 bi
op
hy
sic
al 
pa
ra
m
et
er
s a
nd
 im
m
un
o h
ist
oc
he
m
ica
l m
ar
ke
rs 
in
 SS
 an
d N
SS
 su
bj
ec
ts
 at
 
ba
se
lin
e a
nd
 0
.5,
 8,
 24
 an
d 7
2 h
ou
rs 
af
te
r s
tim
ul
at
ion
 of
 th
e s
kin
 w
ith
 fr
ac
tio
na
l p
ho
to
th
er
m
ol
ys
is.
Ob
se
rve
d (
m
ed
ian
, ra
ng
e)
ba
se
lin
e
0.5
 ho
ur
8 h
ou
rs
24
 ho
ur
s
72
 ho
ur
s
TE
W
L (
gm
-2 h
-1 )
   S
S
   N
SS
10
.5
10
.5
10
.7
(7.
2-1
4.7
)
(7.
2-1
4.7
)
(7.
6-
13.
4)
11.
7
10
.1
12.
4
(8
.5-
14
.6)
(8
.5-
13.
9)
(9
.8-
14
.6)
13.
4
12.
6
14
.6
(7.
9-
18
.2)
(7.
9-
18
.2)
(8
.4-
18
.0)
12.
7
11.
4
16
.3
(8
.6-
19
.2)
(8
.6-
17.
6)
(9
.6-
19
.2)
13.
8
12.
6
16
.9
(7.
6-
23
.7)
(7.
6-
23
.7)
(8
.3-
22
.5)
SC
 hy
dr
at
ion
 (A
U)
   S
S
   N
SS
20
.2
19
.4 21.
2
(14
.3-
35
.4)
(14
.3-
25
.0)
(17
.6-
35
.4)
19
.9
18
.6
21.
0
(13
.2-
41
.8)
(13
.2-
22
.3)
(16
.6-
41
.8)
22
.8
22
.0
24
.4
(15
.1-
37
.9)
(20
.2-
23
.6)
(15
.1-
37
.9)
21.
0 21.
7
20
.2
(7.
2-3
9.2
)
(17
.4-
24
.1)
(7.
2-3
9.2
)
18
.9
18
.9 19
.1
(7.
7-3
0.9
)
(14
.4-
25
.2)
(7.
7-3
0.9
)
a*
 va
lue
s (
AU
)
   S
S
   N
SS
5.3 5.1 5.7
(3.
4-
8.1
)
(3.
8-
6.7
)
(3.
4-
8.1
)
7.7 8.1 7.5
(4
.4-
12.
1)
(5.
6-
12.
1)
(4
.4-
10
.2)
7.0 7.0 7.0
(4
.6-
11.
3)
(4
.6-
10
.5)
(4
.6-
11.
3)
5.6 5.5 6.0
(2.
7-8
.3)
(4
.1-
8.1
)
(2.
7-8
.3)
5.2 5.1 5.6
(2.
4-
8.1
)
(3.
9-
6.7
)
(2.
4-
8.1
)
Via
ble
 ep
ide
rm
al 
th
ick
ne
ss
 (µ
m
)
   S
S
   N
SS
67
.2
64
.8 73
.7
(54
.2-
92
.7)
(57
.6-
73
.9)
(54
.2-
92
.7)
74
.9 73
.5
75
.6
(58
.8-
95
.4)
(58
.8-
90
.4)
(6
7.0
-9
5.4
)
69
.7
68
.3
78
.2
(46
.0
-10
8.0
)
(46
.0
-10
8.0
)
(6
8.1
-9
9.1
)
80
.8
74
.4
82
.4
(54
.1-
117
.2)
(54
.1-
117
.2)
(57
.0
-9
7.8
)
90
.0
89
.7
98
.5
(58
.8-
115
.1)
(58
.8-
115
.1)
(79
.0
-11
3.4
)
Ki6
7 (
nu
cle
i/m
m
 BM
)
   S
S
   N
SS
9.7 9.7 9.7
(3.
8-
22
.4)
(3.
8-
22
.4)
(6
.6-
14
.0)
11.
4 15.
1 9.1
(4
.6-
19
.2)
(9
.6-
18
.4)
(4
.6-
19
.2)
11.
6
14
.0 10
.1
(7.
1-1
9.5
)
(10
.9-
17.
6)
(7.
1-1
9.5
)
12.
7
14
.1 11.
7
(6
.3-
26
.1)
(7.
5-2
1.6
)
(6
.3-
26
.1)
18
.3
16
.7
19
.0
(8
.6-
32
.0)
(11
.4-
24
.8)
(8
.6-
32
.0)
CD
31 
(ar
ea
/m
m
² d
er
m
is)
   S
S
   N
SS
2.2 2.2 1.8
(1.2
-3.
4)
(1.
4-
2.6
)
(1.2
-3.
4)
2.0 2.0 1.9
(1.3
-2.
6)
(1.7
-2.
6)
(1.3
-2.
6)
2.4 2.4 2.3
(1.6
-3.
5)
(1.7
-3.
3)
(1.6
-3.
5)
2.3 2.3 2.8
(1.7
-4
.9)
(1.7
-3.
5)
(1.7
-4
.9)
2.5 2.4 2.6
(1.6
-4
.2)
(1.9
-3.
0)
(1.6
-4
.2)
Try
pt
as
e (
nu
m
be
r/m
m
² d
er
m
is 
)
   S
S
   N
SS
67
.6
58
.9
73
.9
(49
.2-
128
.9)
(50
.1-7
6.4
)
(49
.2-
128
.9)
64
.6
47
.9
70
.5
(29
.8-
122
.6)
(29
.8-
79
.3)
(6
1.9
-12
2.6
)
56
.1
54
.6
65
.6
(34
.5-
119
.4)
(39
.7-
82
.1)
(34
.5-
119
.4)
55
.3
51.
0
68
.0
(21
.2-
115
.8)
(21
.2-
10
6.8
)
(49
.4-
115
.8)
70
.3
57
.9 77
.3
(31
.8-
121
.7)
(31
.8-
92
.3)
(6
2.0
-12
1.7
)
AU
: a
rb
itr
ar
y u
ni
ts
; B
M
: b
as
em
en
t m
em
br
an
e; 
 N
SS
: n
on
-se
ns
iti
ve
 sk
in
; S
S: 
se
ns
iti
ve
 sk
in
; S
ig
ni
fic
an
t d
iff
er
en
ce
s b
et
w
ee
n S
S a
nd
 N
SS
 su
bj
ec
ts
 w
er
e f
ou
nd
 fo
r t
he
 nu
m
be
r 
of
 tr
yp
ta
se
 p
os
iti
ve
 ce
lls
 at
 0
.5 
(p
=0
.0
21
)  a
nd
 72
 h
ou
rs
 af
te
r s
tim
ul
us
 (p
=0
.0
21
).
144
CHAPTER 4
Figure 2  Images of HE stained samples and RCM images at different depths in the 
skin at different time points following ReAura stimulation.
Images of HE stained samples (objective magnification 20x) (1), and RCM images at the level of the stratum 
corneum and granulosum (2), the level of the stratum spinosum (3), the level of the dermo-epidermal 
junction (4), the level of the papillary dermis (5) at 0.5 hours (A), 8 hours (B), 24 hours (C) and 72 hours (D) after 
stimulation with ReAura. 1A: microthermal zone (square), damaged capillaries (*), microscopic epidermal 
necrotic debris (MEND) formation (**) 1B: necrotic debris, MEND (**), dermal-epidermal clefting (black arrow); 
1C: MEND (**), inﬂammatory infiltrate (***), dermal-epidermal clefting (arrow); 1D: MEND almost shed off 
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Figure 3  Images of stained skin samples at different time points following ReAura 
stimulation.
Images of Ki67 (1A-D), CD31 (2A-D), CD3 (3A-D) and K16 (4A-D) stained samples at 0.5 hours (A), 8 hours (B), 24 
hours (C) and 72 hours (D) after stimulation with ReAura. The objective magnification for Ki67, CD31 and K16 
was 20x, for CD3 10x. Ki67 staining showed depletion of cycling keratinocytes in the MTZ, while at 72 hours 
perilesional keratinocyte hyperproliferation was observed. CD31 staining showed diffuse distribution of 
endothelial cells in the MTZ after stimulus, showing damage of capillaries. T cell infiltrates can be observed 
at 24 and 72 hours after stimulus. Changes in keratinocyte differentiation are visible perilesional at 72 hours 
after stimulus.
(**), inﬂammatory infiltrate (***), and hypergranulosis (arrow). 2A-5A: MTZ appears as a round black structure 
surrounded by a high refractive halo; 2B-5B: Heterogenous material (debris) is present central in the 
hyporefractive thermal damage (250-300µm in diameter) in the SC, surrounded by a high refractive halo; 
2C-5C: The lesion has an hourglass shape, convergent at the level of the basal and spinous layer showing 
migration of keratinocytes; 2D-5D: The lesion has the same shape as at 24 hours, showing re-epithelialization 
and migration of keratinocytes. Collagen changes in the papillary dermis are visible.
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in the hyporefractive area. A vertical hourglass shape convergent at the level of the 
basal and spinous layer, showing re-epithelialization and migration of keratinocytes 
comprising a healthy cytoplasm, was detected at 24 hours, even more evident at 
72 hours. Furthermore, at 72 hours collagen changes were seen, comparable to solar 
elastosis. (15)
Interlesional skin (between MTZ’s)
The number of proliferating keratinocytes and the viable epidermal thickness increased at 
24 and 72 hours compared to baseline (figure 4). The percentage of the dermis covered 
by CD31+ cells slightly increased over time, possibly due to diffuse distribution of 
damaged endothelial cells. Infiltration of inﬂammatory cells could be observed from 
8 hours after stimulus. The number of mast cells slightly increased at 72 hours.
Figure 4  Mean viable epidermal thickness, proliferating keratinocytes, mast cells 
and a* values in SS and NSS subjects at different time points following ReAura 
stimulation.
A) Viable epidermal thickness (µm); B) Ki67+ cells per mm basement membrane; C) Tryptase positive cells 
per mm² dermis; D) a* values (AU) in SS (open bullets) and NSS subjects (bullets) expressed as the mean 
(± standard error).
A
C D
B
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Interlesional skin (between MTZ’s) – SS versus NSS subjects
Only the number of mast cells per mm² dermis was lower in the SS subjects compared 
to the NSS subjectsat 0.5 hours (p=0.021), 24 hours (p=0.074) and 72 hours (p=0.021) 
after stimulus (table 1 and figure 4)
Discussion
The objective of this study was to provide insights into the pathomechanism of SS, 
and, specifically in response to fractional non-ablative photothermolysis by identifying 
a potential link between self-reported symptoms and physiological processes 
triggered by this stimulus in SS and NSS subjects. Acute effects of fractional photo-
thermolysis were expressed mainly as necrotic debris and capillary damage, while 
secondary effects were perilesional spongiosis, vasodilatation, and increased 
proliferation and differentiation of keratinocytes. Interlesionally, we observed slightly 
increased proliferation and subsequent epidermal thickening. Differences between SS 
and NSS subjects were more frequently reported skin perceptions and a lower number 
of mast cells. 
The mechanisms causing SS have been extensively explored in clinical studies, but 
exact eliciting factors of key drivers remain unknown. Tape stripping and sodium 
dodecyl sulphate (SDS) stimulation of the skin of SS subjects, showed differences in 
objective parameters, while the subtle skin responses to the thermal stimulus applied 
in this study, were characterized only by unpleasant perceptions of SS subjects. Slight 
increase in keratinocyte proliferation and epidermal thickness was observed in all 
subjects, but no evident perilesional inﬂammatory reaction could be detected; 
infiltrate of T cells developed solely in the deeper dermis. Only ﬂaring and increased a* 
values occur at 0.5 and 8 hours after stimulation, interpreted as vasodilatation. The 
human thermoreceptor hTRPV1 was found to contribute to SS (16) and TRPV1 
antagonists showed a decrease in symptoms experienced following application of 
capsaicin. (12) This specific burning feeling seems to be elicited by photothermolysis as 
well, most evident in the SS group. 
The effects of fractional photothermolysis reported until now were mainly focusing 
on cell viability and connective tissue conditions. Laubach et al, 2006, described 
histological features of the forearm after stimulation with a near infrared 1500 nm 
laser and included markers for proliferation (proliferating cell nuclear antigen), 
physical stress and myofibroblasts. (17) In addition to their dynamic analysis, in this 
study we identified and described local changes in keratinocyte differentiation, 
endothelium destruction, and infiltrate type and extent. These additional early 
alterations in skin physiology indicating onset of micro-wound healing and skin 
regeneration could be used in the future when evaluating photothermolysis based 
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treatments or similar regenerative technologies. To the best of our knowledge, this is 
the first study with RCM examining non-ablative fractional photothermolysis induced by 
infrared lasers targeting the dermis. We observed re-epithelialization at 24 and 72 hours 
after stimulus and collagen changes were observed. RCM dynamic characterization of 
fractional CO2 laser healing processes also show spatiotemporal closure of laser-ablated 
channels (18) and crusted holes with edematous rings following fractional ablative 
photothermolysis have been described. (19) Bencini et al, 2012 described non-ablative 
fractional photothermolysis effects on acne scars and showed that 30 minutes after 
treatment, spongiosis, lymphocytes and homogeneously highly refractive material 
were visible. (20) A limitation of this study is the relatively small study population, and 
the estimation of the distance between the tissue and the MTZ. The latter could bias 
the quantification of the biomarkers interlesionally. Immunohistochemical evaluation 
also showed small but statistically significant differences in amount of mast cells 
between SS and NSS, as was reported before (21), suggesting one would need to 
further examine the role of mast cells in SS to understand its pathomechanism. 
The number of mast cells measured in NSS subjects is in line with other studies. (22, 23) 
We hypothesize a faster degranulation of mast cells underlying the lower number of 
mast cells observed in SS subjects compared to NSS subjects. Another explanation 
could be that SS subjects have developed a protecting mechanism, an increase of 
reaction thresholds, to prevent unpleasant skin sensations at continuously following 
very mild skin challenges.
Conclusion
In conclusion, differences between SS and NSS subjects were observed with respect to 
skin perceptions, which were elicited by the mild thermal challenge. This supports the 
hypothesis, that the pathomechanism of SS can be triggered by factors of different 
origin. Non-ablative fractional photothermolysis is a highly controlled thermal stimulus, 
only causing mild localized skin damage and inﬂammation, and onset of healing 
processes which appears of same extent in SS and NSS subjects. Therefore, this 
stimulus could be a suitable in vivo human model for regenerative processes in the 
skin without manipulation of the skin barrier. Furthermore, this novel characterization 
of non-ablative fractional photothermolysis in a dynamic way helps understanding its 
effects and directing to applications. 
149
IN VIVO HUMAN MODELS
4
References
1. Kim KH, Geronemus RG. Nonablative laser and light therapies for skin rejuvenation. Archives of facial 
plastic surgery. 2004;6(6):398-409.
2. Narurkar VA. Global Total Nonsurgical Rejuvenation: Lasers and Light-Based Systems in Combination with 
Dermal Fillers and Botulinum Toxins. In: Ahluwalia GS, editor. Cosmetic Applications of Laser and 
Light-based Systems. Norwich, NY, USA: William Andrew Inc. ; 2009. p. 281-9.
3. Zelickson B, Walgrave S. Skin Rejuvenation Using Fractional Photothermolysis: Efficacy and Safety. In: 
Ahluwalia GS, editor. Cosmetic Applications of Laser and Light-based Systems. Norwich, NY, USA: William 
Andrew Inc. ; 2009. p. 255-70.
4. Khan MH, Sink RK, Manstein D, Eimerl D, Anderson RR. Intradermally focused infrared laser pulses: thermal 
effects at defined tissue depths. Lasers in Surgery & Medicine. 2005;36(4):270-80.
5. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for 
cutaneous remodeling using microscopic patterns of thermal injury. Lasers in surgery and medicine. 
2004;34(5):426-38.
6. Basketter DA, Griffiths HA. A study of the relationship between susceptibility to skin stinging and skin 
irritation. Contact dermatitis. 1993;29(4):185-8.
7. Bowman JP, Floyd AK, Znaniecki A, Kligman AM, Stoudemayer T, Mills OH. The use of chemical probes to 
assess the facial reactivity of women, comparing their self-perception of sensitive skin. Journal of cosmetic 
science. 2000;51.
8. Coverly J, Peters L, Whittle E, Basketter DA. Susceptibility to skin stinging, non-immunologic contact 
urticaria and acute skin irritation; is there a relationship? Contact dermatitis. 1998;38(2):90-5.
9. Lammintausta K, Maibach HI, Wilson D. Mechanisms of subjective (sensory) irritation. Propensity to 
non-immunologic contact urticaria and objective irritation in stingers. Dermatosen in Beruf und Umwelt 
Occupation and environment. 1988;36(2):45-9.
10. Marriott M, Holmes J, Peters L, Cooper K, Rowson M, Basketter DA. The complex problem of sensitive skin. 
Contact dermatitis. 2005;53(2):93-9.
11. Wu Y, Wang X, Zhou Y, Tan Y, Chen D, Chen Y, et al. Correlation between stinging, TEWL and capacitance. 
Skin research and technology : official journal of International Society for Bioengineering and the Skin. 
2003;9(2):90-3.
12. Kueper T, Krohn M, Haustedt LO, Hatt H, Schmaus G, Vielhaber G. Inhibition of TRPV1 for the treatment of 
sensitive skin. Experimental dermatology. 2010;19(11):980-6.
13. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426(6966):517-24.
14. Dhaka A, Viswanath V, Patapoutian A. Trp ion channels and temperature sensation. Annual review of 
neuroscience. 2006;29:135-61.
15. Longo C, Casari A, Beretti F, Cesinaro AM, Pellacani G. Skin aging: in vivo microscopic assessment of 
epidermal and dermal changes by means of confocal microscopy. Journal of the American Academy of 
Dermatology. 2013;68(3):e73-82.
16. Jourdain R, Bastien P, de Lacharriere O, Rubinstenn G. Detection thresholds of capsaicin: a new test to 
assess facial skin neurosensitivity. Journal of cosmetic science. 2005;56(3):153-66.
17. Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers in 
surgery and medicine. 2006;38(2):142-9.
18. Banzhaf CA, Wind BS, Mogensen M, Meesters AA, Paasch U, Wolkerstorfer A, et al. Spatiotemporal closure 
of fractional laser-ablated channels imaged by optical coherence tomography and reﬂectance confocal 
microscopy. Lasers in surgery and medicine. 2015.
19. Shin MK, Park JM, Lim HK, Choi JH, Baek JH, Kim HJ, et al. Characterization of microthermal zones induced 
by fractional radiofrequency using reﬂectance confocal microscopy: a preliminary study. Lasers in surgery 
and medicine. 2013;45(8):503-8.
20. Bencini PL, Tourlaki A, Galimberti M, Longo C, Pellacani G, De Giorgi V, et al. Nonablative fractional photo-
thermolysis for acne scars: clinical and in vivo microscopic documentation of treatment efficacy. 
Dermatologic therapy. 2012;25(5):463-7.
150
CHAPTER 4
21. Richters RJ, Uzunbajakava NE, Falcone D, Hendriks JC, Jaspers EJ, van de Kerkhof PC, et al. Clinical, 
biophysical and immunohistochemical analysis of skin reactions to acute skin barrier disruption. 
A comparative trial between subjects with sensitive skin and subjects with non-sensitive skin. The British 
journal of dermatology. 2015.
22. Janssens AS, Heide R, den Hollander JC, Mulder PG, Tank B, Oranje AP. Mast cell distribution in normal adult 
skin. Journal of clinical pathology. 2005;58(3):285-9.
23. Weber A, Knop J, Maurer M. Pattern analysis of human cutaneous mast cell populations by total body 
surface mapping. The British journal of dermatology. 2003;148(2):224-8.
151
IN VIVO HUMAN MODELS
4

Detailed analysis of the stratum corneum 
in sensitive skin
 
5.1  “ Sensitive skin: assessment of the skin barrier using confocal  
Raman micro-spectroscopy.”
5.2  “ Development of a novel approach to study corneodesmosomes  
and stratum corneum adhesion.”
5
Abbreviations
AD atopic dermatitis
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TRP Transient Reception Potential
VAS score Visual Analogue Scale score
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Abstract 
Background/Aims Sensitive skin (SS), a frequently reported condition in the Western 
world, has been suggested to be underlined by an impaired skin barrier. The aim of this 
study was to investigate the skin barrier molecular composition in SS subjects  using 
confocal Raman micro-spectroscopy (CRS) and to compare it with that of subjects 
with non-sensitive skin (NSS), atopic dermatitis (AD) and allergic rhinoconjunctivitis 
(AR), who frequently report SS.  
Methods Subjects with SS (n=29), NSS (n=30), AD (n=11) and AR (n=27) were included. 
Stratum corneum (SC) thickness, water, ceramides/fatty acids, and Natural Moisturiz-
ing Factor (NMF) was measured by CRS next to TEWL, sebum levels and capacitance, 
on the ventral forearm, thenar and cheek. 
Results No differences between SS and NSS subjects were found regarding SC thick-
ness, water and NMF content, yet a trend towards lower ceramides/fatty acids was 
observed in the cheek. Compared to AD, the SS group showed higher ceramides/fatty 
acids content in the forearm, whereas no differences emerged with AR. Correlation 
of macroscopic biophysical techniques and CRS was weak, yet CRS confirmed well-
known lower content of NMF and water and thinner SC in subjects with filaggrin 
 mutations. 
Conclusion The skin barrier in SS is not impaired in terms of SC thickness, water, 
NMF and ceramides/fatty acids content. Failure of biophysical techniques to follow 
alterations in molecular composition of skin barrier revealed by CRS emphasizes 
a strong need in sensitive and specific tools for in vivo skin barrier analysis.
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Introduction
The skin protects our internal milieu from the external environment, due to its low 
permeability, mainly established by specific properties of the stratum corneum (SC). 
(1) The cells of the SC are the result of epidermal differentiation, a gradual maturation 
process of the basal keratinocytes ascending to the cornified layer of the squamous 
epithelium, functioning as corneocytes. (1-4) Next to a tough and resilient organization 
of the ﬂattened corneocytes, the envelope of proteins and lipids surrounding each 
corneocyte also plays a crucial role in preventing penetration and diffusion of foreign 
substances through the skin and loss of internal water. The currently accepted model 
of the stratum corneum, although a subject to change, (5-7) also contains the 
intercellular lipid lamellae, a product originating from the lamellar bodies of the 
stratum granulosum, and consisting of ceramides, fatty acids and cholesterol. Located 
between the corneocytes, it contributes to the overall skin barrier function (3, 8-12). 
Furthermore, water soluble intracorneocyte substances collectively known as Natural 
Moisturizing Factor (NMF) contribute to the overall skin barrier function by binding 
water and limiting water loss from the skin. (1) Impairment of the skin barrier may 
result in penetration of allergens and pathogens contributing to skin diseases like for 
example atopic dermatitis, and allergic and irritant contact dermatitis.
Sensitive skin (SS) is a condition characterized by perception of skin discomfort 
following mild stimuli, frequently without objective signs of skin irritation. (13-18) This 
skin condition has been shown to be highly prevalent in the Western World but, 
despite extensive research in the past years, no consensus on its definition and path-
omechanisms has been reached. (19) Impaired skin barrier function has been suggested 
to underlie SS (13, 20, 21), leading to proposals of association of SS with atopic 
conditions. (22-24) The assessment of the skin barrier is being traditionally performed 
by means of transepidermal water loss (TEWL), which is indirect macroscopic 
biophysical techniques. The hydration of the SC, indirectly measured based on 
capacitance, has also been proposed to be lower in facial areas of SS subjects (25) and 
of subjects perceiving stinging responses following application of lactic acid on the 
nasolabial folds. (20) However, other studies, also using macroscopic biophysical 
techniques, did not find such differences between a SS and a non-sensitive skin (NSS) 
group. (14, 18, 20, 26, 27) This inconsistency between outcomes could be on one hand 
due to the fact that subjects were included in tests using different criteria, since a 
definition of SS is still lacking. It might also be possible that indirect assessments of 
barrier function and hydration by means of TEWL and capacitance lacks sensitivity 
and specificity if barrier function impairment in SS is only subtle.
Over the last years, confocal Raman micro-Spectroscopy (CRS) has emerged as a 
powerful tool for the direct and non-invasive assessment of the molecular components 
of the skin, also at a high spatial and temporal resolution. CRS is an optical technique 
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based on the principle of inelastic (Raman) scattering: when a monochromatic laser 
beam is focused in the skin, incident photons interact with the vibrational levels of the 
molecules transferring to them a part of their energy. The exact amount of energy 
required to excite a vibrational mode is dependent on the masses of the atoms 
involved in the vibration and on the chemical bonds between them. The resulting 
Raman spectra are thus molecule-specific and contain detailed information on their 
type and amounts. (28) In addition, by using the principle of confocal detection, only 
the light scattered from the laser focus is detected, providing spatially-resolved 
information, which approaches a sub-cellular resolution. (29) Raman spectroscopy has 
already found its strong position in non-invasive skin analysis for many applications, 
ranging from detection of non-melanoma skin cancer (30) to evaluation of skin barrier 
composition in atopic dermatitis. (31, 32) As CRS is able to detect differences at the 
molecular level and at a high spatial resolution, it could provide a breakthrough in the 
evaluation of barrier function involvement in SS, so far not possible with macroscopic 
biophysical techniques. (33)
The primary objective of this study was to evaluate the SC molecular composition 
using CRS in subjects with SS and to compare the results with those measured on 
people with NSS, atopic dermatitis (AD) and allergic rhinoconjunctivitits (AR). The 
underlying hypothesis was that the mechanism of SS could be based on aberrant 
properties of the SC and could share interface with atopic conditions.  The second 
objective was to perform a comparative study of the penetration kinetics of a solution 
of glycerol (1%) in water in SS and NSS subjects in order to establish whether faster 
penetration of topicals due to impaired skin barrier might occur in SS. Gained 
knowledge would be then of high value for clinicians and the cosmetic and 
pharmaceutical industry developing solutions for the individuals with SS.
Methods
Subject selection
Inclusion criteria for this study were an age between 18 and 65 years and skin type II or 
III (Fitzpatrick scale). Subjects could not use immunosuppressive drugs. Starting from 
two days before the test, subjects were advised not to use toiletries (e.g. personal care 
and cosmetic products) in the areas to be investigated and not to excessively expose 
these areas to sunlight or use artificial tanning methods. Four groups of subjects were 
included. Subjects with SS and subjects with NSS were selected based on a percep-
tion-based questionnaire, as previously described in detail. (34, 35) Brieﬂy, potential 
participants filled in questions on self-assessed skin sensitivity and on skin perceptions 
(i.e. discomfort, stinging, redness, dryness) following exogenous and endogenous 
triggers (i.e. toiletries, shaving, heat, cold, clothes, emotions). The severity of reactions 
159
DETAILED ANALYSIS OF THE STRATUM CORNEUM IN SENSITIVE SKIN
5
to each trigger and the correspondent duration were scored on a Visual Analogue 
Scale (VAS) and on an ordinal scale (no reaction, seconds, minutes, less than one hour, 
hour(s), day(s)), respectively. The scores of each trigger were summed together, and 
the final score was compared to a upper and lower quartile determined in advance by 
distributing the questionnaire in a large study cohort. (36) If the final score was above 
the upper quartile and the subject reported SS, he/she was included in the group with 
SS. If the final score was below the lower quartile and the subject reported NSS, he/
she was included in the group with NSS. In addition, subjects in both the SS and NSS 
groups did not have a history of skin diseases in particular, atopic dermatitis, or other 
concomitant diseases including asthma and allergic rhinoconjunctivitis in particular. 
The other two groups included in the study were subjects with allergic rhinoconjunc-
tivitis (AR) using oral histamine antagonists when experiencing symptoms and not 
having a history of asthma, urticaria, AD or other (skin) diseases; and subjects with 
moderate to severe AD (three item severity score - TIS - ≥3) not having a history of 
asthma, urticaria, allergic rhinoconjunctivitis or other (skin) diseases, currently using 
no therapy or using solely topical corticosteroids. Subjects with AR and AD did not fill 
in the full-length questionnaire, but were asked if they perceived their skin as sensitive 
or non-sensitive. The study was conducted conform to the Declaration of Helsinki 
principles and was approved by the local ethics committee. Experiments were 
performed at the department of Dermatology of the Radboud university medical 
center in Nijmegen, the Netherlands, between January and March 2015. 
Instrumentation
Three body sites were measured: (i) the mid-ventral forearm, (ii) the lateral side of the 
thenar eminence of the arm, and (iii) the malar eminence of the right cheek on the 90 
angle crosspoint of the ala of the nose and the lateral canthus of the eye. Forearm and 
thenar measurements were performed in the non-dominant arm. AD subjects did not 
have active lesions on these body sites. Subjects were acclimatized for 20 minutes in a 
temperature and relative humidity-controlled room (temperature: 21 ± 1 °C, relative 
humidity of 50 ± 10%). 
In vivo CRS measurements were performed using the gen2-SCA performance model of 
RiverD International B.V., Rotterdam, The Netherlands. The device has an axial 
resolution of 5 µm and is equipped with a 785 nm laser source for measurements in 
the 400-1800 cm-1 spectral region and a 671 nm laser source for measurements in the 
2400-4000 cm-1 spectral region. The laser power complies with the maximum 
permissible levels for skin as defined by the international laser safety standard (IEC 
60285-1:2007; <30mW for 785nm, and <20mW for 671nm). In the 400-1800 cm-1 
region, spectra of the cheek and forearm were acquired at 4 µm steps along the axial 
direction up to 28 µm depth using a 5 s acquisition time per point, whereas the thenar 
spectra were acquired at 15 µm steps up to 180 µm depth using a 5 s acquisition time 
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until 100 µm and a 7 s  - until 180 µm. In the 2400-4000 cm-1 region, spectra of the 
cheek and forearm were acquired at 4 µm steps up to 40 µm depth using a 2 s 
acquisition time per point, whereas of the thenar spectra were acquired at 15 µm steps 
up to 180 µm depth during 2 s until 100 µm and during 5 s until 180 µm. Ten measurements 
per body site were performed in each spectral region.
Macroscopic biophysical techniques included: (i) capacitance for indirect measurement 
of SC hydration (Corneometer CM825, Courage + Khazaka); (ii) TEWL for indirect 
assessment of skin barrier (Aquaﬂux AF200, Biox); (iii) sebumeter for indirect measurement 
of sebum level at the skin surface (Sebumeter SM815, Courage + Khazaka). Three 
measurements per body site were performed, except for the SC hydration of the cheek 
which was measured five times. The sebum measurements were performed on the side 
contralateral to the one used during CRS and were not performed on the thenar.
Penetration kinetics of glycerol
200 µl of a 1% solution of glycerol in demineralised water was applied to the 
non-dominant volar forearm during one minute, where a plastic ring with a diameter 
of 13 mm was used to prevent spreading of the substance over the skin surface. The 
solution was wiped off using a tissue afterwards. Measurements in the 400-1800 cm-1 
spectral region were performed every 60 seconds during the subsequent 15 minutes 
using axial steps of 4 µm, up to 28 µm depth.
Calculation of parameters from CRS measurements
Concentration profiles of SC molecular components relative to keratin were obtained 
using SkinTools 2.0 software (RiverD International B.V., Rotterdam, the Netherlands) 
using a previously reported fitting algorithm. (28) Brieﬂy, the algorithm consists of a 
least square fitting of the Raman spectra obtained in vivo to a library of Raman spectra 
of SC molecular components obtained in vitro, resulting in a set of fit coefficients for 
the SC constituent spectra. The fit coefficients are subsequently normalized to the fit 
coefficient for the keratin spectrum in order to compensate for the loss of signal 
intensity for increasing skin depths. (28) For the measurement of concentration 
profiles of glycerol, the Raman spectrum of the 1% glycerol solution in water was 
obtained in vitro and subsequently added to the library of Raman spectra. Obvious 
outliers in the concentration profiles (due for example to presence of cosmic rays or 
high background ﬂuorescence in the corresponding Raman spectra) were removed. 
The average thickness of the SC was calculated from the water concentration profiles 
using an implementation in Matlab (The Mathworks, MA, USA) of the method of 
Bielfeldt S. et al., 2009 (37), in which the SC thickness was defined as the intercept of 
two straight lines delineating the boundary between the stratum corneum and the 
epidermis. The average water content in the SC was expressed as area-under-the-
curve (AUC) of the water profiles from 4 µm depth to the SC thickness for the cheek 
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and forearm and from 10 µm depth to the SC thickness in the thenar. The average 
levels of ceramides/fatty acids (treated in SkinTools as a single variable, ”ceramides”) 
and of NMF between 4 and 12 µm depth for the forearm, 4 and 8 µm depth for the 
cheek and 10 and 50 µm depth for the thenar were calculated from the corresponding 
average concentration profiles. These intervals were chosen in order to avoid 
inﬂuences from skin surface contamination (e.g. sebum) and from washout/
desquamation effects at the skin surface, as well as to avoid Raman signals from the 
viable epidermis (38). The presence of filaggrin mutations was established according 
to the method of O’Regan et al., 2010 (32), in which the cut-off point of 1.07 A.U. used 
for filaggrin mutations (either FLG-/- or FLG+/-) versus no filaggrin mutation (FLG+/+) 
was derived from the mean NMF level between 30 and 50 µm measured on the thenar. 
Statistical analysis
Results are presented as number (percentage) or as median (minimum-maximum). 
Differences between the groups (SS, NSS, AR and AD) were analyzed using the 
Mann-Whitney exact test for non-parametric independent values. Correlations were 
done using Spearman’s rho. Statistical analyses were performed with SPSS Statistics 
(v. 20, IBM SPSS Inc., USA). A p-value ≤ 0.05 was considered statistically significant. 
Missing values were excluded from the analyses. No corrections for multiple comparisons 
were applied.
Results
Group characteristics
In total, 29 subjects were included in the SS, 30 subjects  - in the NSS, 27 subjects  - in 
the AR and 11 subjects in the AD group. The group characteristics are presented in 
Table 1. There were no significant differences with respect to age, gender, Fitzpatrick 
skin type and presence of FLG mutations between the groups. Self-assessed facial and 
body skin differed between SS and NSS subjects, with the former reporting more 
frequently dry or combined (concomitant presence of dry and oily parts) skin, and the 
latter reporting more frequently normal skin (p=0.007 and p=0.000, respectively). 
Self-assessed sensitive skin was reported by two-thirds of AR subjects and by all AD 
subjects. The measurements of four subjects in the volar forearm, of one subject in 
the cheek and of two subjects in the thenar were excluded, because of artefacts found 
in the Raman spectra most possibly caused by exogenous agents on the skin. 
Macroscopic biophysical measurements
Macroscopic biophysical measurements of the forearm, cheek and thenar are reported 
in Tables 2-4. In the forearm, SS and AR had lower TEWL compared to NSS and AD (SS 
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vs. NSS: p=0.076, SS vs. AD: p=0.082, AR vs. NSS: p=0.038, AR vs. AD: p=0.044). Similar 
findings were found in the thenar (SS vs. NSS: p=0.016, SS vs. AD: p=0.058, AR vs. NSS: 
p=0.050, AR vs. AD: p=0.071). No further difference between the groups was found 
with respect to TEWL measured on the cheek and with respect to SC hydration (based 
on capacitance measurement) and sebum level measured on either body site. 
Table 1   Population characteristics.
NSS, n (%) or
median (range)
SS, n (%) or
median (range)
AR, n (%) or
median (range)
AD, n (%) or
median (range)
Self-assessed sensitive skin 30 (100.0) 29 (100.0) 27 (100.0) 11 (100.0)
   SS
   NSS
0
30
(0.0) 
(100.0)
29
0
(100.0)
(0.0)
18
9
(66.7)
(33.3)
11
0
(100.0)
(0.0)
Gender
    Male
    Female
14 
16
(46.7)
(53.3)
11 
18 
(37.9)
(62.1)
11 
16 
(40.7)
(59.3)
5 
6 
(45.5)
(54.5)
Age (years) 21.5 (18-28) 21.0 (18-32) 23.0 (19-29) 23.0 (20-27)
Skin type (Fitzpatrick)
    Skin type II
    Skin type III 
22 
8 
(73.3)
(26.7)
21 
8 
(72.4)
(27.6)
19 
8 
(70.4)
(29.6)
8 
3 
(72.7)
(27.3)
FLG mutations
    FLG-/- or FLG+/- 
    FLG+/+
      missing
Facial skin dryness
    Normal
    Dry
    Oily
    Combined (dry and oily)
3
26
1
17
4
1
8
(10.0)
(86.7)
(3.3)
(56.7)
(13.3)
(3.3)
(26.7)
3
25
1
6
9
2
12
(10.3)
(86.2)
(3.4)
(20.7)
(31.0)
(6.9)
(41.4)
1
26
0
(3.7)
(96.3)
(0.0)
n.a.
3
8
0
(27.3)
(72.7)
(0.0)
n.a.
Body skin dryness
    Normal
    Dry
    Oily
    Combined (dry and oily)
25
4
0
1
(83.3)
(13.3)
(0.0)
(3.3)
9
15
0
5
(31.0)
(51.7)
(0.0)
(17.2)
n.a. n.a.
Questionnaire score  29.5 (0.0-62.0) 157.8 (70.3-287.0) n.a. n.a.
SS: sensitive skin; NSS: non-sensitive skin; AR: allergic rhinoconjunctivitis; AD: atopic dermatitis; 
FLG-/-: homozygous filaggrin mutation; FLG+/-: heterozygous filaggrin mutation; FLG+/+: no filaggrin muta-
tion; n.a: questions about facial and body skin dryness and the questionnaire to determine skin sensitivity 
were not asked/distributed in the AR and AD groups.
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Molecular composition measured by confocal Raman  
micro-spectroscopy
The average concentration profiles of water, NMF and ceramides in the forearm and 
cheek for all groups are shown in Figure 1. The SC thickness, SC water content, and 
average NMF and ceramides levels in the forearm, cheek and thenar are reported in 
Tables 2-4. Numerical values of water, NMF and ceramides at each depth and body site 
can be found in the supplementary material (Tables S1-S3). 
Figure 1  Average concentration profiles of water (a, d), Natural Moisturizing Factor 
(b, e) and ceramides/fatty acids (c, f) at different depths (µm) measured on the volar 
forearm (a-c) and cheek (d-f).
Profiles represent medians (range). NSS = non-sensitive skin (red), SS = sensitive skin (blue), AR = allergic 
rhinoconjunctivitis (brown), AD = atopic dermatitis (green).
a
c
e
b
d
f
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Table 2   Measurements Forearm.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Biophysical measurements
   TEWL [g/m2h] 29 13.2 (7.1-21.9) 27 11.4 (5.8-17.7) 26 11.3 (7.0-16.2) 11 13.8 (8.9-28.4) 0.076 0.082 n.s. n.s. 0.038 0.044
   SC hydration [a.u.] 29 31.7 (19.4-55.6) 27 33.9 (16.7-57.7) 26 31.7 (19.4-53.4) 11 31.3 (18.1-39.0) n.s. n.s. n.s. n.s. n.s. n.s.
   Sebum [a.u.] 29 1.0 (0.0-152.0) 27 0.3 (0.0-142.3) 26 1.5 (0.0-138.7) 11 1.0 (0.0-92.3) n.s. n.s. n.s. n.s. n.s. n.s.
CRS parameters
   SC thickness [µm] 29 16.6 (13.5-24.2) 27 16.4 (13.7-23.5) 26 16.9 (14.2-20.3) 11 16.5 (13.6-19.3) ns. ns. ns. ns. ns. ns.
   AUC Water 4-SC [a.u.] 29 621.2 (478.6-1010.0) 27 600.5 (503.9-852.3) 26 619.7 (518.2-735.1) 11 582.4 (491.8-719.1) ns. ns. ns. ns. ns. ns.
   Average NMF 4-12µm [a.u.] 29 1.1 (0.5-1.8) 27 1.0 (0.7-1.8) 26 1.0 (0.6-1.7) 11 0.9 (0.6-1.3) ns. ns. ns. ns. ns. ns.
   Average Cer 4-12µm [a.u.] 29 43.8 (27.0-81.5) 27 45.1 (38.8-68.9) 26 44.4 (24.6-58.5) 11 40.9 (36.2-54.1) ns. 0.007 ns. ns. ns. ns.
Table 3   Measurements Cheek.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Biophysical measurements
   TEWL [g/m2h] 30 23.8 (12.8-40.8) 28 22.7 (10.2-37.5) 27 23.0 (13.1-40.9) 11 23.2 (15.3-42.7) ns. ns. ns. ns. ns. ns.
   SC hydration [a.u.] 30 37.9 (9.0-62.3) 28 30.7 (7.3-54.4) 27 29.8 (16.2-59.0) 11 36.7 (18.5-88.2) ns. ns. ns. ns. ns. ns.
   Sebum [a.u.] 30 48.3 (0.3-290.0) 28 50.8 (0.0-209.3) 27 46.7 (0.0-373.0) 11 31.0 (4.3-215.7) ns. ns. ns. ns. ns. ns.
CRS parameters
   SC thickness [µm] 30 14.1 (11.6-17.3) 28 14.0 (10.8-21.5) 27 14.3 (12.0-19.1) 11 13.7 (12.6-15.9) ns. ns. ns. ns. ns. ns.
   AUC Water 4-SC [a.u.] 30 516.9 (417.7-639.1) 28 507.5 (393.4-780.4) 27 512.1 (425.5-777.3) 11 482.9 (433.9-623.5) ns. ns. ns. ns. ns. ns.
   Average NMF 4-8µm [a.u.] 30 0.9 (0.5-1.3) 28 0.8 (0.5-1.5) 27 0.8 (0.4-1.3) 11 0.8 (0.4-1.0) ns. ns. ns. 0.091 ns. ns.
   Average Cer 4-8µm [a.u.] 30 82.2 (47.5-142.9) 28 72.1 (45.1-155.1) 27 72.0 (35.4-143.2) 11 66.3 (39.2-92.0) 0.077 ns. ns. 0.097 ns. ns.
AD: atopic dermatitis; AR: allergic rhinoconjunctivitis; a.u.: arbitrary units; AUC: area-under-curve; Cer: 
 ceramides/fatty acids; CRS: confocal Raman micro-spectrosocpy;  gw/100gt: grams of water/100 grams of wet 
AD: atopic dermatitis; AR: allergic rhinoconjunctivitis; a.u.: arbitrary units; AUC: area-under-curve; Cer: 
ceramides/fatty acids; CRS: confocal Raman micro-spectrosocpy;  gw/100gt: grams of water/100 grams of wet 
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Table 2   Measurements Forearm.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Biophysical measurements
   TEWL [g/m2h] 29 13.2 (7.1-21.9) 27 11.4 (5.8-17.7) 26 11.3 (7.0-16.2) 11 13.8 (8.9-28.4) 0.076 0.082 n.s. n.s. 0.038 0.044
   SC hydration [a.u.] 29 31.7 (19.4-55.6) 27 33.9 (16.7-57.7) 26 31.7 (19.4-53.4) 11 31.3 (18.1-39.0) n.s. n.s. n.s. n.s. n.s. n.s.
   Sebum [a.u.] 29 1.0 (0.0-152.0) 27 0.3 (0.0-142.3) 26 1.5 (0.0-138.7) 11 1.0 (0.0-92.3) n.s. n.s. n.s. n.s. n.s. n.s.
CRS parameters
   SC thickness [µm] 29 16.6 (13.5-24.2) 27 16.4 (13.7-23.5) 26 16.9 (14.2-20.3) 11 16.5 (13.6-19.3) ns. ns. ns. ns. ns. ns.
   AUC Water 4-SC [a.u.] 29 621.2 (478.6-1010.0) 27 600.5 (503.9-852.3) 26 619.7 (518.2-735.1) 11 582.4 (491.8-719.1) ns. ns. ns. ns. ns. ns.
   Average NMF 4-12µm [a.u.] 29 1.1 (0.5-1.8) 27 1.0 (0.7-1.8) 26 1.0 (0.6-1.7) 11 0.9 (0.6-1.3) ns. ns. ns. ns. ns. ns.
   Average Cer 4-12µm [a.u.] 29 43.8 (27.0-81.5) 27 45.1 (38.8-68.9) 26 44.4 (24.6-58.5) 11 40.9 (36.2-54.1) ns. 0.007 ns. ns. ns. ns.
Table 3   Measurements Cheek.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Biophysical measurements
   TEWL [g/m2h] 30 23.8 (12.8-40.8) 28 22.7 (10.2-37.5) 27 23.0 (13.1-40.9) 11 23.2 (15.3-42.7) ns. ns. ns. ns. ns. ns.
   SC hydration [a.u.] 30 37.9 (9.0-62.3) 28 30.7 (7.3-54.4) 27 29.8 (16.2-59.0) 11 36.7 (18.5-88.2) ns. ns. ns. ns. ns. ns.
   Sebum [a.u.] 30 48.3 (0.3-290.0) 28 50.8 (0.0-209.3) 27 46.7 (0.0-373.0) 11 31.0 (4.3-215.7) ns. ns. ns. ns. ns. ns.
CRS parameters
   SC thickness [µm] 30 14.1 (11.6-17.3) 28 14.0 (10.8-21.5) 27 14.3 (12.0-19.1) 11 13.7 (12.6-15.9) ns. ns. ns. ns. ns. ns.
   AUC Water 4-SC [a.u.] 30 516.9 (417.7-639.1) 28 507.5 (393.4-780.4) 27 512.1 (425.5-777.3) 11 482.9 (433.9-623.5) ns. ns. ns. ns. ns. ns.
   Average NMF 4-8µm [a.u.] 30 0.9 (0.5-1.3) 28 0.8 (0.5-1.5) 27 0.8 (0.4-1.3) 11 0.8 (0.4-1.0) ns. ns. ns. 0.091 ns. ns.
   Average Cer 4-8µm [a.u.] 30 82.2 (47.5-142.9) 28 72.1 (45.1-155.1) 27 72.0 (35.4-143.2) 11 66.3 (39.2-92.0) 0.077 ns. ns. 0.097 ns. ns.
tissue; NMF: natural moisturizing factor; ns: no statistically significant difference; NSS: non-sensitive skin; 
SC: stratum corneum; SS: sensitive skin; TEWL: transepidermal water loss.
tissue; NMF: natural moisturizing factor;  ns: no statistically significant difference; NSS: non-sensitive skin; SC: 
stratum corneum; SS: sensitive skin; TEWL: transepidermal water loss.
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No significant differences in SC thickness and SC water content were found between 
the groups at either body site. 
With respect to the average NMF at 4-12 µm measured on the forearm, no significant 
differences emerged between the groups, yet it is possible to observe a trend towards 
lower levels in the AD subjects compared to the other subjects (see Figure 1). Similarly, 
in the cheek, AD subjects showed a trend to lower average NMF at 4-8 µm compared 
to NSS subjects (p=0.091). AR subjects tended to have higher average NMF in the 
thenar at 10-50 µm compared to NSS subjects (p=0.076).
With respect to the average ceramides/fatty acids at 4-12 µm measured on the 
forearm, SS subjects showed higher levels compared to AD subjects (p=0.007), 
whereas no differences emerged between the other groups. 
Table 4   Measurements Thenar.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Biophysical measurements
   TEWL [g/m2h] 29 39.6 (21.8-80.6) 28 29.9 (19.4-67.8) 27 32.6 (16.5-58.6) 11 39.9 (21.1-60.8) 0.016 0.058 ns. ns. 0.050 0.071
   SC hydration [a.u.] 29 32.8 (15.2-82.2) 28 27.0 (9.1-42.5) 27 33.0 (15.3-47.9) 11 29.9 (13.9-56.3) ns. ns. ns. ns. ns. ns.
CRS parameters
   SC thickness [µm] 29 97.6 (57.1-159.1) 28 97.4 (40.1-159.6) 27 111.7 (43.9-149.7) 11 96.7 (41.4-144.2) ns. ns. ns. ns. ns. ns.
   AUC Water 10-SC  [a.u.] 29 3702.2 (2176.8-6659.5) 28 3741.9 (1401.8-6642.8) 27 4140.7 (1629.3-5609.8) 11 3840.5 (1447.8-5263.0) ns. ns. ns. ns. ns. ns.
   Average NMF 10-50µm 
  [a.u.]
29 1.7 (1.1-2.2) 28 1.8 (1.1-2.6) 27 1.9 (1.1-2.5) 11 1.9 (0.9-2.0) ns. ns. ns. ns. 0.076 ns.
Table 5   Measurements of glycerol (1% in demineralized water) applied on the volar 
forearm for 1 minute.
n
NSS
median (range) n
SS
median (range)
Glycerol content [a.u.]
   1 minute 22 1274 (835-2205) 20 1039 (783-1545) 0.030
   2 minutes 21 1243 (808-2259) 20 1038 (646-1962) ns.
   3 minutes 20 1208 (785-2016) 20 994 (672-1925) ns.
a.u.: arbitrary units;  ns: no statistically significant difference; NSS: non-sensitive skin; SS: sensitive skin.
AD: atopic dermatitis; AR: allergic rhinoconjunctivitis; a.u.: arbitrary units; AUC: area-under-curve; Cer: 
ceramides/fatty acids; CRS: confocal Raman micro-spectrosocpy;  gw/100gt: grams of water/100 grams of wet 
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In the cheek SS subjects tended to have lower average ceramides at 4-8 µm compared 
to NSS subjects, yet these values were again higher than in subjects with AD (p=0.097). 
This trend is more pronounced at the skin surface (see Figure 1). Ceramides were not 
detectable in the thenar.
Presence of filaggrin mutations 
In total, ten subjects were found to be carriers of FLG mutations (either FLG-/- or FLG+/-) 
(Table 1). Differences between subjects with FLG-/- or FLG+/- and subjects with FLG+/+ 
were present in the forearm, with the former having lower NMF levels (p=0.017) and a 
trend towards lower water content and thinner SC (p=0.071 and p=0.058, respectively). 
Similarly, in the thenar, subjects with FLG-/- or FLG+/- had lower NMF levels, lower water 
content and thinner SC (p=0.000) compared to subjects with FLG+/+. The results 
found in the cheek are consistent with these findings, albeit no significant differences 
were present. Numerical results can be found in the supplementary material (Table S4). 
Correlations between macroscopic biophysical measurements and CRS
A moderate to weak negative correlation was found between TEWL and NMF levels in 
the forearm (rho=-0.220, p=0.034, n=93), in the cheek (rho=-0.408, p=0.000, n=96) 
and in the thenar (rho=-0.208, p=0.044, n=95). In the thenar, TEWL weakly correlated 
also with the SC water content (rho=0.207, p=0.044, n=95) and with the SC thickness 
(rho=0.202, p=0.050, n=95). Of note, the weak correlation with the SC water content 
remained also when controlling for the corresponding SC thickness. No further correlations 
were found between TEWL and SC water content, SC thickness or ceramides levels 
measured on the forearm and cheek. 
Table 4   Measurements Thenar.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Biophysical measurements
   TEWL [g/m2h] 29 39.6 (21.8-80.6) 28 29.9 (19.4-67.8) 27 32.6 (16.5-58.6) 11 39.9 (21.1-60.8) 0.016 0.058 ns. ns. 0.050 0.071
   SC hydration [a.u.] 29 32.8 (15.2-82.2) 28 27.0 (9.1-42.5) 27 33.0 (15.3-47.9) 11 29.9 (13.9-56.3) ns. ns. ns. ns. ns. ns.
CRS parameters
   SC thickness [µm] 29 97.6 (57.1-159.1) 28 97.4 (40.1-159.6) 27 111.7 (43.9-149.7) 11 96.7 (41.4-144.2) ns. ns. ns. ns. ns. ns.
   AUC Water 10-SC  [a.u.] 29 3702.2 (2176.8-6659.5) 28 3741.9 (1401.8-6642.8) 27 4140.7 (1629.3-5609.8) 11 3840.5 (1447.8-5263.0) ns. ns. ns. ns. ns. ns.
   Average NMF 10-50µm 
  [a.u.]
29 1.7 (1.1-2.2) 28 1.8 (1.1-2.6) 27 1.9 (1.1-2.5) 11 1.9 (0.9-2.0) ns. ns. ns. ns. 0.076 ns.
tissue; NMF: natural moisturizing factor;  ns: no statistically significant difference; NSS: non-sensitive skin; SC: 
stratum corneum; SS: sensitive skin; TEWL: transepidermal water loss.
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Skin hydration measured with capacitance was not found to correlate with the SC 
water content in either the forearm, cheek or thenar. On the other hand, in the forearm 
capacitance correlated weakly with the water content in the middle part of the SC 
(4-12 µm) and with the water content up to the upper epidermis (4-32 µm) (rho=0.222, 
p=0.032, and rho=0.207, p=0.046, n=93, respectively). In the cheek, capacitance 
weakly correlated only with the NMF levels (rho=0.223, p=0.029, n=96). 
Figure 2  The Raman spectrum of 1% glycerol in water (light green) and the average 
difference Raman spectra of the skin where glycerol signal was clearly detectable.
The difference spectrum was obtained by subtraction of the Raman spectrum where the glycerol signal was 
not detectable from the spectrum, where glycerol was detected using SkinTools 2.0 software. Different 
Raman spectra are shown (a) 1 minute, (b) 2 minutes and (c) 3 minutes after glycerol application. All spectra 
were measured on the skin surface (0-4 µm). The Raman spectrum of glycerol (light green) is superimposed 
on the difference spectra for clarity. All major bands of the Raman spectrum of glycerol can be seen in the 
difference spectra, confirming the presence of glycerol in the Raman spectra in which the glycerol signal was 
detectable. At later time points, the Raman spectrum of glycerol could not be distinguished anymore in the 
difference spectrum.
a
b
c
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Penetration kinetics of glycerol
Presence of glycerol could only be detected only at the skin surface (0-4 µm) and in the 
first three minutes following application (see Figure 2). Measured levels of glycerol on 
subjects with NSS and SS are reported in Table 5. NSS subjects showed consistently 
higher values of glycerol than subjects with SS, reaching statistical significance at one 
minute after application (p=0.030). In both groups, glycerol levels declined slightly 
from the first to the third minute after application. 
Discussion
The main objective of this study was to investigate whether the barrier function is 
aberrant in SS by directly measuring the molecular composition of the SC by means of 
CRS. A comparison with the molecular composition of the SC of subjects with NSS, AD 
and AR was made, together with the indirect assessment of the skin barrier by means 
of TEWL and capacitance. 
In line with literature, also in this study SS subjects reported more frequently dry facial 
and body skin compared to people with NSS. However, we did not find a strong 
evidence to support a hypothesis of impaired skin barrier in SS in terms of SC water- 
and NMF levels in either the forearm, cheek or thenar. SC thickness was also not 
different between the groups, in line with our previous findings. (21)
Interestingly, however, is that ceramides/fatty acids showed a trend towards lower 
levels in the cheek of SS subjects to NSS group, whereas marginal and non-significant 
higher values were found in the forearm. Several studies that have suggested the role 
of an impaired skin barrier function in SS (13, 20, 21) in particular demosntrated lower 
ceramides in the facial skin of subject with SS (27). This hypothesis about weaker SC 
barrier is also supported by previous clinical studies performed by our group, in which 
the same perception-based questionnaire was used to select volunteers with SS and 
NSS.  (21, 34, 35) In those clinical studies, the SC of subjects with SS was shown to be 
more vulnerable to chemical and mechanical stimuli than the SC of subjects with NSS, 
suggesting an impaired barrier. 
Additional mechanisms than the ones investigated in this study might thus play the 
major role in the barrier function impairment in SS, including reduced inter-corneo-
cyte adhesion, different organization of lipids in the intercellular lamellae and increased 
inﬂammatory reactions and altered number of mast cells in response to a range of 
stimuli, previously reported by our group. (21, 35)
In addition to barrier function impairment via alterations in molecular balance of NMF, 
ceramides and water, an involvement of the family of transient receptor potential 
(TRP) channels has been hypothesized to play a role in SS. (39) TRP channels are sensory 
receptors activated by a variety of external stimuli and known to mediate a range of 
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skin sensations including pain, itch and burning feeling. Increased levels or an 
upregulated sensitivity of these receptors might account for the previously reported 
increased perception of SS to a variety of stimuli.  (21, 35) Thus,  one could also speculate that 
the more frequent self-reported perception of skin dryness in SS subjects might be primarily 
mediated by these receptors, because of the lack of significant differences in SC water 
content and NMF levels in SS compared to NSS subjects demonstrated here.
Less clear is the possible association of SS with atopic conditions, as proposed previously. 
(22-24) While we clearly detected lower NMF and water and thinner SC in subjects 
with filaggrin mutations, which is well-documented in literature (31,32), however, despite 
frequently reporting SS, in line with previous findings (36), no differences emerged 
between AR and NSS and SS subjects, at least with respect to the inspected parameters. 
Moreover, even higher ceramides/fatty acids levels found in the forearm of SS subjects 
compared to AD, together with the observation that FLG mutations do not seem to be 
reported more frequently in the SS group compared to the NSS, do not support the 
hypothesis of SS being a subclinical form of AD. (39) This is also supported by the lack 
of association between SS and the dysbiosis of the cutaneous microbiota found in a 
previous study, in contrast with AD, known to be characterized by overabundance of 
Straphylococcus aureus. (39, 40) Yet should TRP receptor family be involved in 
underlying SS sensations, this could suggest at least one common interface with AD, 
where these receptors were shown to mediate sensory discomfort and inﬂammation, 
at least in murine model. (39, 41-43)
In our previous clinical studies we showed a reduced number of mast cells and a 
reduced number of tapes required to strip off the total SC in the lower back of SS 
compared to NSS. (21, 34)  It could be tempting to speculate that the stronger expression 
of ceramides in the forearm of SS subjects might be due to a compensating mechanism 
of the primary defect in activation of the innate immune system or impaired intercor-
neocyte adhesion. (34, 35, 44, 45) This hypothesis might not be valid for the cheek, 
which is characterized by a higher number of mast cells compared to other body sites 
and thus not needing a compensatory mechanism. (46) 
Despite the different results on ceramides levels between the forearm and cheek, we 
are of the opinion that the response of SS is rather universal. Farage et al, 2009, (47) 
evaluated answers to determine whether people claiming SS in general also claimed 
to have SS at specific body sites. Most responses of descriptions of facial and body skin 
were consistent with the perception of SS in general (60.7% and 68.4% of responders, 
respectively) or varied by one degree out of four with respect to severity (36.7% and 
31.3% of responders, respectively). Our previous findings also support the hypothesis 
of a generalized SS based on possible altered immune responses in SS. (21)
The second objective of this study was to investigate whether topicals penetrate 
faster through the skin of subjects with SS compared to subjects with NSS as a result 
of possible barrier function impairment. We found consistently higher levels of glycerol 
171
DETAILED ANALYSIS OF THE STRATUM CORNEUM IN SENSITIVE SKIN
5
in the superficial layers of the SC of NSS subjects compared to SS subjects in the first 
three minutes after application. This might imply a faster spreading of glycerol on the 
superficial skin of SS because of barrier function impairment. Our results clearly 
demonstrate that CRS has the potential to detect differences in such assessment 
provided that a sufficiently longer application time is chosen for the exogenous 
substance to be applied. (48)
As the last remark, we confirm the difficulty of finding correspondences between the 
measurements performed with the macroscopic biophysical methods, TEWL and 
capacitance, and the molecular composition of the SC measured with CRS, as 
demonstrated by the lack of correlations thereof found in this study. In previous 
studies, the skin barrier function of SS subjects was predominantly analyzed at 
baseline or after stimulation using these macroscopic biophysical methods and 
significant differences between SS and NSS subjects could rarely be detected.  (13, 14, 
16, 18, 20, 26, 49, 50) A range of limitations of these easy-to-use, rapid measurements 
are known (33), and our study demonstrates that more sensitive and specific tools for 
the in vivo analysis of the skin barrier in general and in SS in particular are needed.  
In conclusion, we propose that SS is not a subclinical form of AD and that the skin 
barrier is not impaired in terms of SC thickness and in terms of water, NMF and 
ceramides content. Treatments of SS solely based on hydration and ceramides supple-
mentation seem not to correspond to the identified SC properties, although benefits 
have been reported. More research efforts should be directed at unraveling the role of 
the cutaneous nervous system, in particular the involvement of TRP channels, on the 
onset of subjective perceptions of sensitive and dry skin. Among other mechanisms to 
be investigated in SS, we include the role of an altered immune response and inter-cor-
neocyte adhesion. 
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Table S1   Supplementary table Forearm.
n NSS
median (range)
n SS
median (range)
n AR
median (range)
n AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Water levels [gw/100gt]
    0 29 31.3 (23.3-41.2) 27 30.4 (21.9-41.6) 26 30.6 (23.2-37.1) 11 29.3 (23.3-35.8) ns. ns. ns. ns. ns. ns.
    4 29 33.1 (26.8-40.5) 27 32.7 (23.2-39.7) 26 31.8 (25.3-38.0) 11 32.5 (28.0-37.8) ns. ns. ns. ns. ns. ns.
    8 29 41.4 (37.3-49.0) 27 42.4 (28.4-50.8) 26 40.2 (33.5-49.5) 11 43.1 (38.0-49.8) ns. ns. ns. ns. ns. ns.
   12 29 54.4 (45.4-60.8) 27 54.8 (37.3-62.1) 26 53.8 (43.9-60.7) 11 55.6 (47.5-60.5) ns. ns. ns. ns. ns. ns.
   16 29 62.8 (52.2-65.8) 27 63.2 (48.7-65.9) 26 62.9 (55.1-66.1) 11 62.8 (58.0-65.3) ns. ns. ns. ns. ns. ns.
   20 29 66.0 (58.2-67.9) 27 66.2 (59.0-68.3) 26 65.9 (61.9-68.1) 11 65.6 (62.7-67.8) ns. ns. ns. ns. ns. ns.
   24 29 66.9 (61.3-68.9) 27 67.4 (64.3-68.8) 26 66.9 (64.3-69.2) 11 67.0 (64.3-68.7) ns. ns. ns. ns. ns. ns.
   28 29 67.7 (62.8-68.9) 27 68.1 (66.0-69.2) 26 67.4 (65.5-69.6) 11 67.1 (65.5-68.6) ns. ns. ns. ns. ns. ns.
   32 29 68.2 (65.9-69.2) 27 68.5 (66.7-70.2) 26 67.8 (66.0-69.8) 11 67.2 (66.2-69.0) ns. ns. ns. ns. ns. ns.
NMF levels [a.u.]
    0 29 1.2 (0.6-1.7) 27 1.2 (0.8-1.8) 26 1.2 (0.8-1.7) 11 1.2 (0.7-1.7) ns. ns. ns. ns. ns. ns.
    4 29 1.3 (0.7-1.9) 27 1.4 (0.9-2.0) 26 1.4 (0.7-2.0) 11 1.2 (0.7-1.7) ns. 0.095 ns. ns. ns. ns.
    8 29 1.1 (0.6-2.0) 27 1.1 (0.7-2.0) 26 1.0 (0.6-1.9) 11 0.9 (0.6-1.4) ns. ns. ns. ns. ns. ns.
   12 29 0.6 (0.3-1.4) 27 0.6 (0.5-1.4) 26 0.6 (0.4-1.5) 11 0.5 (0.4-0.8) ns. ns. ns. ns. ns. ns.
   16 29 0.5 (0.3-0.9) 27 0.4 (0.3-0.8) 26 0.4 (0.3-0.8) 11 0.4 (0.3-0.5) ns. ns. ns. ns. ns. ns.
Ceramides levels [a.u.]
    0 29 57.8 (27.3-121.7) 27 57.2 (38.5-108.8) 26 61.0 (38.1-97.1) 11 57.5 (37.1-96.8) ns. ns. ns. ns. ns. ns.
    4 29 54.3 (29.5-107.5) 27 56.9 (44.6-90.6) 26 56.7 (32.5-80.3) 11 52.7 (39.6-69.4) ns. ns. ns. ns. ns. ns.
    8 29 41.9 (24.4-77.6) 27 44.3 (38.8-65.4) 26 42.1 (17.9-55.9) 11 38.6 (30.3-50.1) 0.059 0.001 0.065 ns. ns. ns.
   12 29 35.0 (21.1-59.2) 27 38.6 (27.5-50.8) 26 34.4 (23.5-47.4) 11 33.4 (25.8-43.0) 0.064 0.004 0.060 0.096 ns. ns.
   16 29 29.8 (18.4-44.8) 27 31.3 (21.9-39.8) 26 28.5 (20.7-42.1) 11 26.8 (21.8-32.0) ns. 0.019 ns. 0.064 ns. ns.
AD: atopic dermatitis; AR: allergic rhinoconjunctivitis; a.u.: arbitrary units; gw/100gt: grams of water/100 grams 
of wet tissue; NMF: natural moisturizing factor;  ns: no statistically significant difference; NSS: non-sensitive 
skin; SS: sensitive skin.
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Table S1   Supplementary table Forearm.
n NSS
median (range)
n SS
median (range)
n AR
median (range)
n AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Water levels [gw/100gt]
    0 29 31.3 (23.3-41.2) 27 30.4 (21.9-41.6) 26 30.6 (23.2-37.1) 11 29.3 (23.3-35.8) ns. ns. ns. ns. ns. ns.
    4 29 33.1 (26.8-40.5) 27 32.7 (23.2-39.7) 26 31.8 (25.3-38.0) 11 32.5 (28.0-37.8) ns. ns. ns. ns. ns. ns.
    8 29 41.4 (37.3-49.0) 27 42.4 (28.4-50.8) 26 40.2 (33.5-49.5) 11 43.1 (38.0-49.8) ns. ns. ns. ns. ns. ns.
   12 29 54.4 (45.4-60.8) 27 54.8 (37.3-62.1) 26 53.8 (43.9-60.7) 11 55.6 (47.5-60.5) ns. ns. ns. ns. ns. ns.
   16 29 62.8 (52.2-65.8) 27 63.2 (48.7-65.9) 26 62.9 (55.1-66.1) 11 62.8 (58.0-65.3) ns. ns. ns. ns. ns. ns.
   20 29 66.0 (58.2-67.9) 27 66.2 (59.0-68.3) 26 65.9 (61.9-68.1) 11 65.6 (62.7-67.8) ns. ns. ns. ns. ns. ns.
   24 29 66.9 (61.3-68.9) 27 67.4 (64.3-68.8) 26 66.9 (64.3-69.2) 11 67.0 (64.3-68.7) ns. ns. ns. ns. ns. ns.
   28 29 67.7 (62.8-68.9) 27 68.1 (66.0-69.2) 26 67.4 (65.5-69.6) 11 67.1 (65.5-68.6) ns. ns. ns. ns. ns. ns.
   32 29 68.2 (65.9-69.2) 27 68.5 (66.7-70.2) 26 67.8 (66.0-69.8) 11 67.2 (66.2-69.0) ns. ns. ns. ns. ns. ns.
NMF levels [a.u.]
    0 29 1.2 (0.6-1.7) 27 1.2 (0.8-1.8) 26 1.2 (0.8-1.7) 11 1.2 (0.7-1.7) ns. ns. ns. ns. ns. ns.
    4 29 1.3 (0.7-1.9) 27 1.4 (0.9-2.0) 26 1.4 (0.7-2.0) 11 1.2 (0.7-1.7) ns. 0.095 ns. ns. ns. ns.
    8 29 1.1 (0.6-2.0) 27 1.1 (0.7-2.0) 26 1.0 (0.6-1.9) 11 0.9 (0.6-1.4) ns. ns. ns. ns. ns. ns.
   12 29 0.6 (0.3-1.4) 27 0.6 (0.5-1.4) 26 0.6 (0.4-1.5) 11 0.5 (0.4-0.8) ns. ns. ns. ns. ns. ns.
   16 29 0.5 (0.3-0.9) 27 0.4 (0.3-0.8) 26 0.4 (0.3-0.8) 11 0.4 (0.3-0.5) ns. ns. ns. ns. ns. ns.
Ceramides levels [a.u.]
    0 29 57.8 (27.3-121.7) 27 57.2 (38.5-108.8) 26 61.0 (38.1-97.1) 11 57.5 (37.1-96.8) ns. ns. ns. ns. ns. ns.
    4 29 54.3 (29.5-107.5) 27 56.9 (44.6-90.6) 26 56.7 (32.5-80.3) 11 52.7 (39.6-69.4) ns. ns. ns. ns. ns. ns.
    8 29 41.9 (24.4-77.6) 27 44.3 (38.8-65.4) 26 42.1 (17.9-55.9) 11 38.6 (30.3-50.1) 0.059 0.001 0.065 ns. ns. ns.
   12 29 35.0 (21.1-59.2) 27 38.6 (27.5-50.8) 26 34.4 (23.5-47.4) 11 33.4 (25.8-43.0) 0.064 0.004 0.060 0.096 ns. ns.
   16 29 29.8 (18.4-44.8) 27 31.3 (21.9-39.8) 26 28.5 (20.7-42.1) 11 26.8 (21.8-32.0) ns. 0.019 ns. 0.064 ns. ns.
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Table S2   Supplementary table Cheek.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Water levels [gw/100gt]
    0 30 32.7 (10.6-43.2) 28 33.2 (15.4-45.0) 27 31.5 (18.0-42.1) 11 32.6 (24.8-35.4) ns. ns. ns. ns. ns. ns.
    4 30 36.4 (22.5-45.4) 28 36.1 (19.4-49.5) 27 35.3 (22.8-44.6) 11 36.1 (28.6-39.6) ns. ns. ns. ns. ns. ns.
    8 30 49.2 (38.9-57.4) 28 49.5 (29.5-61.9) 27 47.8 (35.1-56.6) 11 49.1 (42.6-53.7) ns. ns. ns. ns. ns. ns.
   12 30 61.4 (50.8-66.0) 28 60.7 (41.8-67.5) 27 60.9 (48.3-65.1) 11 61.3 (57.7-64.3) ns. ns. ns. ns. ns. ns.
   16 30 66.5 (59.6-69.3) 28 66.4 (56.7-69.3) 27 66.7 (57.2-69.5) 11 66.0 (64.0-68.5) ns. ns. ns. ns. ns. ns.
   20 30 68.6 (62.3-70.6) 28 68.2 (64.9-71.1) 27 68.8 (64.3-71.4) 11 68.3 (67.1-71.1) ns. ns. ns. ns. ns. ns.
   24 30 69.5 (62.9-71.8) 28 69.6 (67.2-72.1) 27 69.8 (67.5-72.6) 11 69.5 (68.7-71.7) ns. ns. ns. ns. ns. ns.
   28 30 69.9 (63.4-72.9) 28 70.1 (68.0-72.5) 27 70.5 (68.0-73.7) 11 70.2 (69.4-72.6) ns. ns. ns. ns. ns. ns.
   32 30 70.4 (63.9-72.9) 28 70.3 (68.7-72.7) 27 70.6 (68.3-74.3) 11 70.5 (68.9-73.4) ns. ns. ns. ns. ns. ns.
NMF levels [a.u.]
    0 30 0.9 (0.5-1.4) 28 0.9 (0.5-1.5) 27 0.8 (0.4-1.4) 11 0.9 (0.4-1.2) ns. ns. ns. ns. 0.080 ns.
    4 30 1.0 (0.6-1.4) 28 0.9 (0.5-1.7) 27 0.9 (0.5-1.5) 11 0.9 (0.4-1.1) ns. ns. ns. ns. ns. ns.
    8 30 0.7 (0.4-1.3) 28 0.7 (0.4-1.2) 27 0.6 (0.4-1.1) 11 0.6 (0.3-0.8) ns. ns. ns. 0.065 ns. ns.
   12 30 0.4 (0.3-0.9) 28 0.4 (0.3-0.7) 27 0.4 (0.3-0.9) 11 0.4 (0.3-0.5) ns. ns. ns. 0.057 ns. ns.
   16 30 0.4 (0.3-0.6) 28 0.4 (0.3-0.7) 27 0.4 (0.3-0.6) 11 0.3 (0.3-0.5) ns. ns. ns. 0.080 ns. ns.
Ceramide levels [a.u.]
    0 30 111.7 (63.2-175.4) 28 99.5 (49.9-192.7) 27 96.7 (43.7-233.4) 11 77.6 (41.5-150.3) ns. ns. ns. ns. 0.095 ns.
    4 30 103.6 (60.3-180.3) 28 92.2 (52.0-191.6) 27 86.9 (43.0-177.7) 11 79.7 (43.4-116.9) ns. ns. ns. 0.085 ns. ns.
    8 30 60.7 (31.9-105.5) 28 53.7 (38.2-118.6) 27 54.2 (28.0-108.7) 11 52.9 (35.1-67.2) 0.086 ns. ns. 0.097 ns. ns.
   12 30 42.1 (26.0-69.8) 28 39.8 (29.2-64.0) 27 40.2 (23.2-79.8) 11 39.1 (32.7-48.0) ns. ns. ns. ns. ns. ns.
   16 30 35.8 (21.0-55.8) 28 32.5 (23.3-55.7) 27 34.1 (21.6-59.8) 11 33.5 (27.3-41.4) ns. ns. ns. ns. ns. ns.
AD: atopic dermatitis; AR: allergic rhinoconjunctivitis; a.u.: arbitrary units; gw/100gt: grams of water/100 grams 
of wet tissue; NMF: natural moisturizing factor;  ns: no statistically significant difference; NSS: non-sensitive 
skin; SS: sensitive skin.
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Table S2   Supplementary table Cheek.
n
NSS
median (range) n
SS
median (range) n
AR
median (range) n
AD
median (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Water levels [gw/100gt]
    0 30 32.7 (10.6-43.2) 28 33.2 (15.4-45.0) 27 31.5 (18.0-42.1) 11 32.6 (24.8-35.4) ns. ns. ns. ns. ns. ns.
    4 30 36.4 (22.5-45.4) 28 36.1 (19.4-49.5) 27 35.3 (22.8-44.6) 11 36.1 (28.6-39.6) ns. ns. ns. ns. ns. ns.
    8 30 49.2 (38.9-57.4) 28 49.5 (29.5-61.9) 27 47.8 (35.1-56.6) 11 49.1 (42.6-53.7) ns. ns. ns. ns. ns. ns.
   12 30 61.4 (50.8-66.0) 28 60.7 (41.8-67.5) 27 60.9 (48.3-65.1) 11 61.3 (57.7-64.3) ns. ns. ns. ns. ns. ns.
   16 30 66.5 (59.6-69.3) 28 66.4 (56.7-69.3) 27 66.7 (57.2-69.5) 11 66.0 (64.0-68.5) ns. ns. ns. ns. ns. ns.
   20 30 68.6 (62.3-70.6) 28 68.2 (64.9-71.1) 27 68.8 (64.3-71.4) 11 68.3 (67.1-71.1) ns. ns. ns. ns. ns. ns.
   24 30 69.5 (62.9-71.8) 28 69.6 (67.2-72.1) 27 69.8 (67.5-72.6) 11 69.5 (68.7-71.7) ns. ns. ns. ns. ns. ns.
   28 30 69.9 (63.4-72.9) 28 70.1 (68.0-72.5) 27 70.5 (68.0-73.7) 11 70.2 (69.4-72.6) ns. ns. ns. ns. ns. ns.
   32 30 70.4 (63.9-72.9) 28 70.3 (68.7-72.7) 27 70.6 (68.3-74.3) 11 70.5 (68.9-73.4) ns. ns. ns. ns. ns. ns.
NMF levels [a.u.]
    0 30 0.9 (0.5-1.4) 28 0.9 (0.5-1.5) 27 0.8 (0.4-1.4) 11 0.9 (0.4-1.2) ns. ns. ns. ns. 0.080 ns.
    4 30 1.0 (0.6-1.4) 28 0.9 (0.5-1.7) 27 0.9 (0.5-1.5) 11 0.9 (0.4-1.1) ns. ns. ns. ns. ns. ns.
    8 30 0.7 (0.4-1.3) 28 0.7 (0.4-1.2) 27 0.6 (0.4-1.1) 11 0.6 (0.3-0.8) ns. ns. ns. 0.065 ns. ns.
   12 30 0.4 (0.3-0.9) 28 0.4 (0.3-0.7) 27 0.4 (0.3-0.9) 11 0.4 (0.3-0.5) ns. ns. ns. 0.057 ns. ns.
   16 30 0.4 (0.3-0.6) 28 0.4 (0.3-0.7) 27 0.4 (0.3-0.6) 11 0.3 (0.3-0.5) ns. ns. ns. 0.080 ns. ns.
Ceramide levels [a.u.]
    0 30 111.7 (63.2-175.4) 28 99.5 (49.9-192.7) 27 96.7 (43.7-233.4) 11 77.6 (41.5-150.3) ns. ns. ns. ns. 0.095 ns.
    4 30 103.6 (60.3-180.3) 28 92.2 (52.0-191.6) 27 86.9 (43.0-177.7) 11 79.7 (43.4-116.9) ns. ns. ns. 0.085 ns. ns.
    8 30 60.7 (31.9-105.5) 28 53.7 (38.2-118.6) 27 54.2 (28.0-108.7) 11 52.9 (35.1-67.2) 0.086 ns. ns. 0.097 ns. ns.
   12 30 42.1 (26.0-69.8) 28 39.8 (29.2-64.0) 27 40.2 (23.2-79.8) 11 39.1 (32.7-48.0) ns. ns. ns. ns. ns. ns.
   16 30 35.8 (21.0-55.8) 28 32.5 (23.3-55.7) 27 34.1 (21.6-59.8) 11 33.5 (27.3-41.4) ns. ns. ns. ns. ns. ns.
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Table S3   Supplementary table Thenar.
n
NSS
med (range) n
SS
med (range) n
AR
med (range) n
AD
med (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Water levels [gw/100gt]
   0 29 28.6 (11.4-38.4) 28 26.5 (13.4-41.6) 27 24.0 (13.5-37.2) 11 20.6 (10.5-37.3) ns. ns. ns. ns. ns. ns.
  10 29 32.1 (20.7-42.4) 28 31.8 (20.5-40.1) 27 31.0 (21.1-37.7) 11 29.3 (21.1-45.6) ns. ns. ns. ns. ns. ns.
  20 29 34.4 (28.4-40.3) 28 34.9 (29.8-41.8) 27 33.7 (26.6-41.4) 11 33.7 (25.4-43.8) ns. ns. ns. ns. ns. ns.
  30 29 37.9 (32.6-44.2) 28 36.9 (32.1-51.0) 27 36.5 (31.1-51.4) 11 37.0 (30.0-51.1) ns. ns. ns. ns. ns. ns.
  40 29 38.0 (34.2-48.0) 28 38.3 (33.8-60.9) 27 38.1 (32.7-62.0) 11 38.9 (32.0-62.6) ns. ns. ns. ns. ns. ns.
  50 29 39.1 (35.0-57.0) 28 39.9 (35.2-63.7) 27 39.8 (33.3-65.1) 11 39.9 (31.7-65.8) ns. ns. ns. ns. ns. ns.
  60 29 42.5 (35.6-62.0) 28 42.4 (36.6-65.9) 27 41.3 (33.8-67.4) 11 41.5 (33.1-67.1) ns. ns. ns. ns. ns. ns.
  70 29 45.6 (36.4-63.5) 28 45.9 (37.6-67.5) 27 43.3 (34.4-69.0) 11 41.7 (34.3-67.9) ns. ns. ns. ns. ns. ns.
  80 29 51.3 (37.3-64.5) 28 52.1 (38.6-68.7) 27 45.5 (34.7-70.0) 11 49.0 (34.6-68.7) ns. ns. ns. ns. ns. ns.
  90 29 58.3 (38.3-65.5) 28 57.5 (39.6-69.3) 27 50.4 (34.3-71.1) 55.5 (35.6-70.0) ns. ns. ns. ns. ns. ns.
  100 29 61.3 (39.4-66.7) 28 61.5 (40.5-69.9) 27 55.7 (34.0-71.8) 58.3 (38.2-71.5) ns. ns. ns. ns. ns. ns.
  120 29 65.6 (41.0-67.7) 28 63.6 (42.6-71.9) 27 61.5 37.0-73.1) 61.9 (43.8-73.1) ns. ns. ns. ns. ns. ns.
  150 29 66.8 (56.1-70.2) 28 65.7 (47.4-74.1) 27 64.6 (45.2-74.6) 65.8 (50.4-75.2) ns. ns. ns. ns. ns. ns.
NMF levels [a.u.]
    0 29 1.4 (0.9-3.0) 28 1.5 (1.0-2.6) 27 1.6 (0.9-2.3) 11 1.5 (0.8-2.5) ns. ns. ns. ns. ns. ns.
   10 29 1.8 (1.2-2.2) 28 1.8 (1.2-2.4) 27 2.0 (1.1-2.5) 11 1.9 (0.9-2.2) ns. ns. ns. ns. 0.043 ns.
   20 29 1.8 (1.1-2.2) 28 1.9 (1.3-2.5) 27 2.0 (1.1-2.6) 11 1.9 (0.9-2.3) ns. ns. ns. ns. 0.063 ns.
    30 29 1.8 (1.1-2.2) 28 1.9 (1.0-2.6) 27 2.0 (1.1-2.5) 11 1.9 (0.8-2.3) ns. ns. ns. ns. 0.069 ns.
    40 29 1.8 (0.7-2.2) 28 1.8 (0.5-2.6) 27 1.9 (1.0-2.56) 11 1.9 (0.5-2.1) ns. ns. ns. ns. ns. ns.
    50 29 1.7 (0.5-2.1) 28 1.7 (0.4-2.4) 27 1.8 (0.8-2.4) 11 1.7 (0.4-2.0) ns. ns. ns. ns. ns. ns.
AD: atopic dermatitis; AR: allergic rhinoconjunctivitis; a.u.: arbitrary units; gw/100gt: grams of water/100 grams 
of wet tissue; NMF: natural moisturizing factor;  ns: no statistically significant difference; NSS: non-sensitive 
skin; SS: sensitive skin.
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Table S3   Supplementary table Thenar.
n
NSS
med (range) n
SS
med (range) n
AR
med (range) n
AD
med (range)
SS vs NSS SS vs AD SS vs AR NSS vs AD NSS vs AR AD vs AR
Water levels [gw/100gt]
   0 29 28.6 (11.4-38.4) 28 26.5 (13.4-41.6) 27 24.0 (13.5-37.2) 11 20.6 (10.5-37.3) ns. ns. ns. ns. ns. ns.
  10 29 32.1 (20.7-42.4) 28 31.8 (20.5-40.1) 27 31.0 (21.1-37.7) 11 29.3 (21.1-45.6) ns. ns. ns. ns. ns. ns.
  20 29 34.4 (28.4-40.3) 28 34.9 (29.8-41.8) 27 33.7 (26.6-41.4) 11 33.7 (25.4-43.8) ns. ns. ns. ns. ns. ns.
  30 29 37.9 (32.6-44.2) 28 36.9 (32.1-51.0) 27 36.5 (31.1-51.4) 11 37.0 (30.0-51.1) ns. ns. ns. ns. ns. ns.
  40 29 38.0 (34.2-48.0) 28 38.3 (33.8-60.9) 27 38.1 (32.7-62.0) 11 38.9 (32.0-62.6) ns. ns. ns. ns. ns. ns.
  50 29 39.1 (35.0-57.0) 28 39.9 (35.2-63.7) 27 39.8 (33.3-65.1) 11 39.9 (31.7-65.8) ns. ns. ns. ns. ns. ns.
  60 29 42.5 (35.6-62.0) 28 42.4 (36.6-65.9) 27 41.3 (33.8-67.4) 11 41.5 (33.1-67.1) ns. ns. ns. ns. ns. ns.
  70 29 45.6 (36.4-63.5) 28 45.9 (37.6-67.5) 27 43.3 (34.4-69.0) 11 41.7 (34.3-67.9) ns. ns. ns. ns. ns. ns.
  80 29 51.3 (37.3-64.5) 28 52.1 (38.6-68.7) 27 45.5 (34.7-70.0) 11 49.0 (34.6-68.7) ns. ns. ns. ns. ns. ns.
  90 29 58.3 (38.3-65.5) 28 57.5 (39.6-69.3) 27 50.4 (34.3-71.1) 55.5 (35.6-70.0) ns. ns. ns. ns. ns. ns.
  100 29 61.3 (39.4-66.7) 28 61.5 (40.5-69.9) 27 55.7 (34.0-71.8) 58.3 (38.2-71.5) ns. ns. ns. ns. ns. ns.
  120 29 65.6 (41.0-67.7) 28 63.6 (42.6-71.9) 27 61.5 37.0-73.1) 61.9 (43.8-73.1) ns. ns. ns. ns. ns. ns.
  150 29 66.8 (56.1-70.2) 28 65.7 (47.4-74.1) 27 64.6 (45.2-74.6) 65.8 (50.4-75.2) ns. ns. ns. ns. ns. ns.
NMF levels [a.u.]
    0 29 1.4 (0.9-3.0) 28 1.5 (1.0-2.6) 27 1.6 (0.9-2.3) 11 1.5 (0.8-2.5) ns. ns. ns. ns. ns. ns.
   10 29 1.8 (1.2-2.2) 28 1.8 (1.2-2.4) 27 2.0 (1.1-2.5) 11 1.9 (0.9-2.2) ns. ns. ns. ns. 0.043 ns.
   20 29 1.8 (1.1-2.2) 28 1.9 (1.3-2.5) 27 2.0 (1.1-2.6) 11 1.9 (0.9-2.3) ns. ns. ns. ns. 0.063 ns.
    30 29 1.8 (1.1-2.2) 28 1.9 (1.0-2.6) 27 2.0 (1.1-2.5) 11 1.9 (0.8-2.3) ns. ns. ns. ns. 0.069 ns.
    40 29 1.8 (0.7-2.2) 28 1.8 (0.5-2.6) 27 1.9 (1.0-2.56) 11 1.9 (0.5-2.1) ns. ns. ns. ns. ns. ns.
    50 29 1.7 (0.5-2.1) 28 1.7 (0.4-2.4) 27 1.8 (0.8-2.4) 11 1.7 (0.4-2.0) ns. ns. ns. ns. ns. ns.
182
CHAPTER 5
Table S4   Supplementary table Filaggrin mutations.
n
FLG+/+
median (range) n
FLG+/- and FLG-/-
median (range)
CRS parameters Forearm
   SC thickness [µm] 82 16.5 (13.5-24.2) 10 15.7 (14.1-17.9) 0.058
   AUC Water 4-SC [gw/100gt] 82 612.7 (478.6-1010.0) 10 584.4 (505.8-674.9) 0.071
   Average NMF 4-12µm [a.u.] 82 1.0 (0.6-1.8) 10 0.9 (0.5-1.2) 0.017
   Average Cer 4-12µm [a.u.] 82 44.7 (24.6-81.5) 10 44.4 (33.9-56.0) 1
CRS parameters Cheek
   SC thickness [µm] 84 14.1 (10.8-21.5) 10 13.7 (11.6-14.5) ns.
   AUC Water 4-SC [gw/100gt] 84 508.9 (393.4-780.4) 10 491.8 (417.7-562.7) ns.
   Average NMF 4-8µm [a.u.] 84 0.8 (0.4-1.5) 10 0.7 (0.5-1.2) ns.
   Average Cer 4-8µm [a.u.] 84 74.7 (35.4-155.1) 10 75.7 (45.1-87.2) ns.
CRS parameters Thenar
   SC thickness [µm] 85 101.9 (40.1-159.6) 10 66.9 (41.4-120.2) 0.000
   AUC Water 10-SC 
[gw/100gt]
85 3917.7 (1401.8-
6659.5)
10 2500.0 (1447.8-4279.1) 0.000
   Average NMF 10-50µm 
[a.u.]
85 1.9 (1.1-2.6) 10 0.9 (0.6-1.1) 0.000
a.u.: arbitrary units; AUC: area-under-curve; Cer: ceramides/fatty acids; CRS: confocal Raman micro-spectro-
socpy;   FLG-/-: homozygous filaggrin mutation; FLG+/-: heterozygous filaggrin mutation; FLG+/+: no filaggrin 
mutation; gw/100gt: grams of water/100 grams of wet tissue;  ns: no statistically significant difference; NMF: 
natural moisturizing factor; SC: stratum corneum.
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Abbreviations
BSA  bovine serum albumin
CE cornified envelope
DSG1 Desmoglein 1
PBS phosphate-buffered saline
SC stratum corneum
SEM standard error of the mean
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Abstract 
Intro The stratum corneum reﬂects the epidermal condition and consists of hightly 
organized corneocytes and interstitial components. In this study, we aim to develop 
a novel method to analyze corneodesmosome components in terms of distribution 
and organisation using an easy to apply non-invasive method by using double sided 
adhesive tape. Next to this, since an aberrant skin barrier might contribute to the 
pathomechanism of sensitive skin (SS), we aimed to investigate adhesion of corneo - 
cytes in SS subjects and to compare these properties to subjects with non-sensitive 
skin (NSS). 
Methods Corneocytes of the volar forearm and upper outer quadrant of the left buttock 
of ten subjects with SS and eight subjects with NSS were extracted. Glass slides 
with double sided adhesive tape were subsequently applied to extract the corneocytes 
of different depths of the stratum corneum and were directly stained with anti- 
desmoglein 1 (DSG1) antibody. 
Results A decrease in the area of extracted corneocytes and the quantity of DSG1 was 
observed in depth. A trend towards an increased area of corneocytes extracted per 
tape was observed for the SS group, compared to the NSS group. 
Discussion We developed an easy-to-apply novel approach to investigate the stratum 
corneum adhesion in depth. As has been proposed before, a different structure and 
composition of the stratum corneum have been hypothesized to play a role in the 
development of SS. Our results support the hypothesis that SS partially underlies an 
impaired skin barrier condition. In the future, applications in different skin conditions 
and skin diseases are required in order to optimize and validate this protocol.
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Introduction
The epidermis is the outermost layer of the skin, encompassing a complex organization 
of cells contributing to its vital role as protector of the internal environment of the 
body for pathogens of the external environment and dehydration. The latter function 
of the skin has been called “la raison d’être” of the epidermis. (1) The last decades, 
studies have been published proposing that an aberrant skin barrier function might 
contribute to the pathomechanism of sensitive skin (SS) (2-9), a highly prevalent skin 
condition characterized mainly by perceptions of discomfort of the skin following 
eliciting factors usually causing limited discomfort in individuals. (10-14)
The stratum corneum (SC) is the product of epidermal differentiation and can rapidly 
adapt to the conditions of the environment and skin trauma. The SC typically consists of 
12-16 layers of ﬂat corneocytes with a mean thickness of 1 µm (15) and each corneocyte 
simplistically is an insoluble protein complex consisting primarily of highly organized 
keratin macrofibrillar matrix encapsuled by an insoluble cornified cell envelope (CE) 
and covalently attached a series of lipids. (16) The ceramides are an important 
determinant of the unusual physical properties of these SC lipid bilayers. (16-18) Via 
cell-cell junctions, corneodesmosomes, the corneocytes are connected to each other 
and highly controlled degradation of these corneodesmosomes results in desquamation. 
(19, 20) The major components of corneodesmosomes are corneodesmosin, desmoglein 1 
(DSG1) and desmocollin 1. DSG1 is the known antigen of pathogenic autoantibodies 
in pemphigus foliaceus, a blistering disease characterized by splits in the upper layers 
of the epidermis. (21) 
Tape stripping is a frequently used method to extract corneocytes from the skin and 
many methods have been developed to quantify the amount of cells extracted and to 
quantify absorbed topical substances: weighing, protein content, optical spectroscopy, 
microscopy and TEWL. (22) The amount of SC extracted per tape is decreasing in 
depth. (22) 
In this study, we aim to (i) develop a novel method to analyze corneodesmosome 
components in terms of distribution and organisation using an easy to apply non- 
invasive method by using double sided adhesive tape, and (ii) to characterize adhesion 
of corneocytes in SS subjects and to compare these properties to subjects with 
non-sensitive skin (NSS). We hypothesized that the corneodesmosome quality or 
quantity is impaired in subjects with SS, causing easy disruption of the skin barrier and 
induction of skin perceptions. (23, 24) Knowledge on the currently unknown underlying 
pathways of SS might enable allocation of mitigations for these unsatisfactory skin 
perceptions. 
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Methods
Subject selection 
Participants gave written informed consent and the study was conducted according 
to the Declaration of Helsinki. Subjects with sensitive skin and subjects with non- 
sensitive skin were invited for participation via student websites and were selected 
using a questionnaire on skin conditions and skin sensitivity (24) and were matched 
for age and gender. Exclusion criteria were history of skin disease or atopic predisposition 
(a history of allergic rhinoconjunctivitis, atopic dermatitis or asthma), or severe xerosis 
and subjects could not apply a cosmetic product on the skin site 24h prior to the 
experiment. Tapes were required from optically healthy skin. 
Sample collection: Slides, tapes, pressure and storage variables
Samples of stratum corneum (SC) were collected using 19mm x 50 mm double-sided 
plastic adhesive tape (Scotch 3M, St Paul, USA) from the spool fixed on Superfrost Plus 
microscope slides (Thermo Fisher Scientific, Waltham, USA). The investigator used 
gloves when handling the slides and tape, to prevent contamination of the tapes 
with human material and the slide with tape was only used when the tape was 
homogeneously sticking to the slide, without air and creases. Samples were collected 
from the middle of the volar forearm in a marked area by pressing the slide with tape 
on the skin for two seconds and subsequently removing the slide in longitudinal 
direction. This procedure was repeated ten times using a new tape on the exact same 
body site by alternately lifting each longitudinal edge, preventing unilateral extraction 
of corneocytes. Removal was done in one movement without interruption. The skin of 
the forearm is barely extended. 
Microscope slides without electrostatic attraction  (Thermo Fisher Scientific, Waltham, 
USA) were used as alternative. 
Tapes were applied using the glass slides, in order to equalize pressure distribution. 
Manual pressure in the centre of the slide was given. One investigator applied the 
slides using different pressure grades: (i) slight pressure, (ii) moderate pressure, (iii) 
strong pressure. The room temperature was kept between 20 and 22 °C and between 
40 and 60 % relative humidity. 
After removal of the tapes at 20°C, the tapes were directly stored in a closed box to 
prevent the adhesion of volatile particles of the environment to the tape. The freshly 
extracted corneocytes were stored directly at (i) 20°C, (ii) 4°C or (iii) -80°C and were 
stored (i) one hour, (ii) one day, (iii) seven days and (iv) 28 days. The storage was done 
in three subjects. 
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Anti-Desmoglein-1 antibody variables
Corneocyte samples
The slides with freshly obtained corneocytes were rinsed in 1% phosphate buffered 
saline (PBS) for 10 minutes at room temperature and a central area was marked by 
water repellent inc (Dako pen, Dako, Glostrup, Denmark). Goat serum 20% in 1% BSA in 
PBS (Vector Laboratories Inc., Burlingame, USA) was used as a blocking agent for 15 
minutes to minimize aspecific binding of the primary antibody. Incubation with 25 µl 
of the primary antibody, mouse anti-human DSG1 (LifeSpan BioSciences Inc., Seattle, 
WA, USA) was done for 60 minutes before application of IgG1 goat anti-mouse Alexa 
Fluor 594 (red) or 488 (green) (Thermo Fisher Scientific, Waltham, USA) 1:200. Before 
and after incubation with the secondary antibody, the tissue was rinsed in 1% PBS for 
two times five minutes. The tissue was mounted with Fluoromount-G (eBioscience 
Inc., San Diego, CA, USA). 
A concentration series was performed for the DSG1 antibody: 1:1, 1:5, 1:10 and 1:15 
diluted in 1% bovine serum albumin (Dako, Glostrup, Denmark) in 1% PBS (PBS/1% 
BSA). The primary and secondary antibodies were also applied on tapes without 
corneocytes in combination and separately, and additionally solely the secondary 
antibody was applied on tape with corneocytes. Strip number one to ten were stained 
for DSG1. The method was duplicated in two subjects. 
Full thickness skin tissue
Skin punch biopsies of 3mm diameter were excised from abdominal human skin, fixed 
in 10% formalin solution for four hours and stored in 70% alcohol before being 
imbedded in paraffin and sliced at 6 µm. The slides with paraffin embedded tissue 
were deparaffinized and rehydrated using histosafe and alcohol. Citrate buffer was 
used to retrieve antigens (pH 6.0, 10 min at 100°C). Preincubation was done using 
PBS/1% BSA for 15 minutes before application of the DSG1 antibody 1:1 for 60 minutes 
at room temperature. IgG1 goat anti-mouse Alexa Fluor 594 (red) 1:200 was used for 
visualization for 30 minutes. Finally, slides were dehydrated and mounted using 
Fluoromount-G. 
Reference keratin variables
Corneocyte samples
Pan cytokeratin antibody (AE1/AE3, Merck Millipore, Billerica, MA, USA) diluted 1:1 
detecting CK1-8, CK10, CK14-16, and CK19, cytokeratin 10 antibody 1:5 (RKSE60, 
Monosan, Uden, the Netherlands) detecting cytokeratin 10 and pan cytokeratin 
antibody 1:10 (OSCAR, LifeSpan BioSciences Inc., Seattle, WA, USA) detecting various 
cytokeratins were used to identify a reference for the DSG1 staining. Tapes with 
corneocytes (tape numbers one until ten) were rinsed in PBS for 10 minutes at room 
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temperature and a central area was marked by water repellent inc (Dako, Glostrup, 
Denmark). Goat serum 20% (Vector Laboratories Inc., Burlingame, USA) in PBS/1% BSA 
(was used as a blocking agent for 15 minutes. 
Incubation with 25 µl of the primary antibody, mouse anti-human DSG1 antibody 1:5, 
was done for 60 minutes before application of IgG1 goat anti-mouse Alexa Fluor 594 
(Thermo Fisher Scientific, Waltham, USA) 1:200 for 30 minutes. Before and after 
incubation with the secondary antibody, the tissue was rinsed in PBS for two times 
five minutes. Mounting was done with Fluoromount-G (eBioscience Inc., San Diego, 
CA, USA).
The pancytokeratin antibody was applied in the following concentrations: 1:1, 1:10 and 
1:25 in PBS/1% BSA. Furthermore, as a permeabilisation step of the cornified envelopes 
the following agents were used: Tween 20 0.5%, alcohol 70% or acetone for 5 minutes 
prior to application of goat serum and the antibody. 
Full thickness skin tissue 
Skin punch biopsies of 3mm diameter were excised, retrieved, prepared and mounted 
as in the DSG1 protocol and the pancytokeratin antibody (OSCAR, LifeSpan BioSciences 
Inc. Seattle, WA, USA) was applied for 60 minutes in the concentrations 1:10, 1:25, 1:50 
and 1:100 and IgG2a goat anti-mouse Alexa Fluor 488 and IgG Alexa Fluor 594 1:200 
for 30 minutes (figure 1).
Other reference variables
On tape numbers 2, 6 and 9 polyclonal rabbit anti-human loricrin antibody 1:500 
(Biolegend, San Diego, CA, USA), involucrin antibody (BT-601, Biomedical Technologies 
Inc., Stoughton, MA, USA) 1:1, and polyclonal rabbit anti-filaggrin antibody (Covance, 
Richmond, USA) 1:100 were applied for 60 minutes and visualized with goat anti-mouse 
Alexa Fluor 488 1:200. Stripped corneocytes (strips number 5) were rinsed in PBS for 10 
minutes and thereafter stained with: eosin 0.2% (Merck Diagnostica, Darmstadt, 
Germany) for 1 minute, eosin 1% for 2 minutes, eosin 1% for 5 minutes, hematoxylin 
(Sigma‐Aldrich, St. Louis, MO, USA), trypane blue (BDH Chemicals ltd.) for 5 minutes, 
trypane blue for 10 minutes and Lucifer yellow CH dipotassium salt solution, 1 µM, 
(Sigma‐Aldrich, St. Louis, MO, USA) for 10 minutes. Eosin stained cells were directly or 
after drying mounted with Permount or Fluoromount-G. Fluoromount-G was used for 
mounting when the other reference agents were used.
Quantitative assessment and statistical analysis
Quantification was done using Axiokop 2 MOT microscope (Zeiss) at a magnification 
of 200x, Axiocam MRc5 digital camera and AxioVision software rel. 4.8 (Zeiss). For 
DSG1, bandpass 525/50 nm emission filter for green or band pass 620/60 nm emission 
filter for red were used with 2 seconds illumination. Images were converted to 8-bit 
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images and the number of pixels was counted in Fiji (National Institutes of Health, 
version 2.35). DSG1 quantity was expressed as percentage of positive pixels per image. 
SC surface was expressed as percentage of positive area of Lucifer yellow per image. 
Statistical significance of the differences in distribution patterns was tested using 
paired samples T tests and correlations were tested using Pearson’s rho. The investigator 
was blinded when analyzing the images. 
Results
Participants
In total, 30 subjects responded to the study invitation and 18 subjects were included 
for participation, since there was no skin disease and the skin sensitivity fitted the SS 
(n=10) or NSS (n=8) criteria. In the SS group nine females and one male participated, 
in the NSS group three and eight respectively and the age was between 21 and 
37 years. Five subjects in the NSS and one in the SS group had skintype 3 according 
to Fitzpatrick, the others had skintype 2.
Figure 1  DSG1 (1:5) in full thickness human abdominal skin as a reference. DSG1 
positivity can be observed in the viable epidermis and the stratum corneum.
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Slides, tapes and extraction
Microscope slides without electrostatic attraction  (Thermo Fisher Scientific, Waltham, 
USA) showed the same level of adherence of the tape compared to Superfrost Plus 
microscope slides. The application of the slides using different pressure grades did 
scarcely result in differences in the amount of corneocytes removed,  however strong 
pressure resulted in clumps of corneocytes. The slight pressure given by the investigator 
however, seemed to fit the optimal adhesive bond of the tape. The skin of the forearm 
is barely extended, and therefore, the velocity of the removal of the slide did not seem 
to be a variable in the amount of corneocytes removed. 
DSG1
The DSG1 staining showed damaged corneocytes due to crystal formations when 
stored at -80°C. Storage of tissue at 20°C and 4°C showed the same results. Tissue that 
was not stored, stored for 1 day, 7 days or 28 days did result in the same staining quality. 
The signal reduced in all concentrations from tape 1 to tape 10. In concentrations 1:10 
and 1:15, a very weak signal was visible from tape 5 onwards, while the 1:1 concentration 
Figure 2  A) DSG1 and Lucifer Yellow double staining showing the DSG1 positivity  
in the periphery of the corneocytes; B) Lucifer Yellow labeling the corneocytes;  
C) DSG1 positivity in the periphery of the corneocytes forming hexagonal structures; 
D) corneocytes illuminated with visible light.
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gave a very strong signal in tapes 1 to 5. The concentration of 1:5 was found to give the 
optimal signal, still detectable in tape 10. Full thickness skin tissue shows positive 
staining for DSG1 in the suprabasal epidermis and in the SC and therefore, slides of full 
thickness skin can be used as a reference. DSG1 was found in a punctuate pattern in 
the peripheral part of every corneocyte in the cell-cell contact areas, forming a 
hexagonal pattern (figure 2, 3).
Keratins and other reference variables
Cytokeratin 10, pan cytokeratin and pan cytokeratin (AE1/AE3) antibodies showed a 
positive signal in a patchy pattern, localized in the periphery of the corneocytes. The 
Figure 3  Double staining of the first three tapes in a single subject, with optimized 
settings of the camera. Left 20x objective magnification, right 10x objective 
magnification.
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upper layers of corneocytes showed a lower signal compared to the deeper layers 
extracted by the tapes. Permeabilisation did not result in stronger expression of 
keratin signal. In the full thickness skin, the stratum corneum showed a positive signal 
for keratins with Alexa Fluor 594. None of the barrier proteins did result in a positive 
signal in the cell stainings. Hematoxylin did not stain the corneocytes. Eosin did stain 
the corneocytes but 0.5 hours after mounting, the colour seemed to leak out the 
corneocytes, faster in the lower concentrations of eosin. Trypane blue for 10 minutes 
resulted in an intenser staining compared to 5 minute incubation. The trypane blue 
staining also appeared red ﬂuorescence when band pass 620/60 nm emission filter 
was used. After one day however, the staining lost intensity and initially lacked 
sensitivity. Lucifer yellow was expressed strongly, with sufficient specificity and 
sensitivity for the corneocytes and the staining intensity was stable for hours after 
mounting. The expression of DSG1 seems to be specific, since keratin expression in 
depth was the opposite of the DSG expression. 
Final protocol for corneocyte surface and DSG1 staining
Tapes on microscope slides without electrostatic attraction were chosen using slight 
pressure by always the same investigator using gloves (RR). 10 tapes were subsequently 
extracted from the mid volar forearm and the upper outer quadrant of the lower back, 
and were stored at 20°C for maximum 28 days. The protocol was applied on 60 slides 
per session. Slides were washed in PBS for 10 minutes, subsequently marked by 
Dako-pen (Dako, Glostrup, Denmark), antigens were blocked using a 50 µl  drop goat 
serum 20% (Vector Laboratories Inc., Burlingame, USA) in PBS/1% BSA in the centre of 
the tape, which was soaked off using a pipette after 15 minutes. Subsequently the 
same spot was incubated with 25 µl of mouse anti-human DSG1 antibody 1:5 (LifeSpan 
BioSciences Inc., Seattle, WA, USA) for 60 minutes. After 10 minutes of washing in PBS, 
IgG1 goat anti-mouse Alexa Fluor 594 (Thermo Fisher Scientific, Waltham, USA) 1:200 
was applied for 30 minutes in darkness. After 10 minutes of washing in PBS, Lucifer 
yellow, 1 µM, was applied in darkness for 10 minutes. After being dipped in PBS, 
mounting was done using Fluoromount-G (eBioscience Inc., San Diego, CA, USA).
Dynamics in the skin
The amount of SC extracted between the corresponding tape numbers was 
significantly higher in the arm, compared to the back (p<0.05 for each tape number). 
The median (range) of SC area extracted of the 10 subsequent tapes was 24% (11-46) 
for the forearm, and 59% (31-88) for the back. Over the depth in the skin, a reduction 
of the amount of SC extracted was observed by tape number (table 1, figure 3). 
There was a correlation between the area of extracted corneocytes per tape 
(percentage of total surface) and the amount of DSG1 for the upper layers of the 
stratum corneum for both the forearm (tapes 2 to 6) and the back (tape 1 to 6). The 
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amount of DSG1 reduced by tape number (table 1, figure 2 and 3) and the strongest 
reduction was shown in the upper layers of the SC and in the forearm. A trend towards 
a stronger decrease in extracted area of corneocytes in relation to the DSG1 quantity 
was observed for the forearm, showing that the first two tapes comprise relatively 
less DSG1. (figure 4).
Differences between SS and NSS subjects 
Between SS and NSS subjects, there was no difference between (i) the mean of SC 
area extracted of the 10 subsequent tapes (p=0.118); (ii) the % of SC extracted by each 
tape number; and (iii) the amount of DSG1 expressed by each tape number. However, 
Figure 4  A: the area of corneocytes extracted per tape for the forearm and back 
(n=18); B: the amount of DSG1 extracted per tape for the forearm and back (n=18).
Figure 5  A: the amount of SC and DSG area extracted per tape in SS and NSS subjects 
for the forearm; B: the amount of SC and DSG area extracted per tape in SS and NSS 
subjects for the back. Bright red line: DSG1 in SS; The dark red line: DSG1 in NSS;  
The bright green line: corneocyte area in SS; The dark green line: corneocyte area in NSS.
A
A
B
B
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a trend towards an increased SC and DSG1 area extracted by each tapestrip could be 
observed in SS subjects compared to NSS subjects, with the largest differences 
observed for the superficial layers of the SC for the forearm. (figure 5). 
Discussion
In this study, we investigated the distribution pattern of DSG1 and intercorneocyte 
adhesion in the stratum corneum in depth and we developed a novel protocol to 
quantify these parameters which is reproducible, non-invasive, cheap, and easy-to- 
apply. Corneocytes can be extracted from the easy accessible forearm at room 
temperature, cells can be stored at room temperature for a few weeks and fixation is 
not required for the intensity of the binding of the DSG antibodies. The protocol is 
suitable to evaluate stratum corneum components in different depths and the 
corneocyte organization can be observed. In addition, this protocol can be used as a 
basis to investigate additional stratum corneum parameters. Next to this, a trend 
towards increased amounts of SC extracted by a single tape strip can be observed for 
SS subjects compared to NSS subjects, implying an impaired SC adhesion in SS, in line 
with literature. (23-25)
The corneodesmosomes are important to the structural integrity of the SC, which 
determines mainly the skin barrier and reﬂects the epidermal condition. Normal 
human SC shows a pattern in the transverse plane of the corneocyte tapes, which the 
hexagonal form of the corneocytes is identified, lined by desmoglein on the intercor-
neocyte areas. This network is also visible in longitudinal plane of biopsy tissues. 
Desmoglein can be observed as continue or more patchy dense structures on the 
corneocyte membranes. Results of Oyama et al, 2010 (26) support our findings with 
respect to the peripheral distribution pattern in the superficial layers of the SC in 
normal skin. They show also that in psoriasis skin, a less clear hexagonal pattern of 
DSG1 could be observed, reﬂecting the dyskeratinization in psoriasis vulgaris. (26) 
Naoe et al, 2010 and Igawa et al, 2011 proved that DSG1 distribution in the upper layers 
is peripheral, whereas in the deepest layers of the SC DSG1 is distributed over the 
entire corneocyte surface. (20, 27) Higher levels of DSG1 in the first tape strip correlated 
with higher levels of TEWL (r=0.516 p<0.01). (20) In our study, we could not show a 
clear change in distribution pattern of DSG1 in the corneocytes, hence we observed a 
decrease in expression in depth. In all corneocyte layers, DSG1 was predominantly 
expressed in the periphery of the corneocytes. However, we may have not extracted 
these deepest layers of SC, in which a homogenous expression of DSG1 was described 
previously. To estimate the depth of the investigated corneocytes, we translated the 
results of another study to these parameters, in which we removed the total stratum 
corneum using 31,5 tapestrips on average. (24) Knowing that this extraction of 
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corneocytes is non-linear, using 10 tape strips we should remove about 40-70% of the 
stratum corneum, a depth of 6-10 micron in a SC of 14 micron thickness. 
A stronger decrease in extracted area of corneocytes in relation to the DSG1 quantity 
was observed for the forearm. This means that the upper corneocytes show relatively 
more DSG1 compared to deeper layers of the SC, as is in line with literature. Absolutely, 
the amount of DSG deceased in depth as well. The decreased expression of DSG1 in the 
deeper layers of the SC seems not to be determined by an insufficient antigen 
attainability in depth, since keratin expression showed opposite distributions in SC 
depth. Lucifer yellow was chosen for practical reasons, however, keratins could also be 
used as a reference in order to verify the relative adhesiveness in terms of DSG 
expression and could be measured accurately by using Confocal Raman Spectroscopy. 
Weighing of the tapes could be another reference, since we can only investigate the 
area of corneocytes, but not the number of corneocytes. 
The amount of SC extracted between the corresponding tape numbers was significantly 
higher in the arm, compared to the back. 
In summary, we developed an easy-to-apply novel approach to investigate the stratum 
corneum adhesion in depth. As has been proposed before, a different structure and 
composition of the stratum corneum have been hypothesized to play a role in the 
development of SS. A trend towards a higher amount of SC extracted by a single tape 
in depth in the skin was observed for SS compared to NSS, supporting the hypothesis 
that SS underlies an impaired skin barrier condition. In the future, applications in 
different skin conditions and skin diseases are required in order to optimize and 
validate this protocol.  
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Conclusions and general discussion
As sensitive skin (SS) is highly prevalent in the Western world and has impact on the 
quality of life, understanding the physiological reality of this condition and its careful 
management is of high importance. The diversity of skin properties and of the 
perception of skin symptoms by individuals, due to genetic, environmental, social and 
cultural factors, presents a challenge for scientists and dermatologists in the search 
for the definition and the cause of SS. The aim of this project ‘establish a uniform 
definition of SS’ corresponds to one of the goals of the World Health Organization 
(WHO), who’s priority is moving towards universal health coverage. The WHO had 
defined International Classifications in order to facilitate the storage, retrieval, analysis 
and interpretation of data and their comparison with populations over time and 
between populations, and to facilitate the compilation of internationally consistent 
data. (1) Approaches focusing on identifying pathomechanisms causing perceptions of 
skin discomfort designated as SS could enable an evidence-based diagnosis and 
tailoring of treatment to patients – approach highly aspired in the times of personalized 
medicine. 
Definitions and subject selection
Several research groups have tried to define SS. Kligman et al, 2006 (2) used a novel 
nomenclature for SS, by proposing its different subtypes defined by clinical 
presentation or possible underlying etiology as following: (i) ‘subjective irritation’ 
refers to an irritant response without visible clinical signs; (ii) ‘neurosensory irritation’ 
signifies neutrally mediated responses such as itching, stinging, burning, tightness; 
(iii) ‘chemosensory’ relates to sensory responses induced by chemicals in contrast to 
physical, mechanical and environmental factors; and (iv) ‘psychophysical irritation’ 
implies a psychological component. Willis et al (3) described several clinical forms 
depending on the intensity of clinical symptoms: (i) ‘very sensitive skin’, dry or fatty, 
bitterly reacting to exogenous factors, i.e. cosmetic products, environmental factors 
and endogenous features. The clinical symptoms are acute and permanent and both 
triggered determining psychological reactions; (ii) ‘environmentally sensitive skin’, 
often clear, dry and thin skin, essentially reactive to environmental factors, i.e. heat 
and rapid temperature changes, with frequent bouts of ﬂushing; and (iii) ‘cosmetically 
sensitive skin’, essentially reactive to cosmetics. This intolerance is often limited to 
some identifiable cosmetic products. Farage et al, 2006, also propose a heterogeneous 
phenomenon with multiple etiologic aspects. (4) 
Following this already undertaken research direction could fuel more rapid gain of 
deeper knowledge about sensitive skin and facilitate comparison of experiment 
results.
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In chapter 2, we aimed to overview morphologic, physiologic and biophysical charac-
teristics of SS to critically appraise the quality and reliability of diagnostic tests for SS 
at baseline and/or following provocation, to identify knowledge gaps and unmet 
needs, and to formulate recommendations for our research. Next to this, available 
provocations and objective methods in the identification of pathways underlying SS 
were also evaluated. We chose an approach by solely reviewing studies, which have 
included subjects based on perception, e.g. burning, stinging, itching, general skin 
discomfort etcetera, for this selection might correspond better to the key symptoms 
of SS compared to reactions of redness or dryness following one stimulus only. This 
self-reported skin sensitivity was determined (i) by skin reactions, including sensations 
following application of specific stimuli or (ii) by questionnaire. Inclusion of subjects 
who predominantly experience redness following a certain provocation or following 
daily used toiletries or friction, might cause clinical susceptibility bias. It is known that 
skin diseases like atopic dermatitis or atopic predisposition, irritant contact dermatitis, 
allergic contact dermatitis or urticaria cause the symptoms of redness following certain 
contacts. Therefore, including sensations in the selection of study populations was at 
least mandatory for the inclusion of the study in our systematic literature review. 
We observe that existing heterogeneity of study designs reported so far complicates 
the comparison of results as various selection methods of limited sensitivity and 
specificity have been used. In addition to the arbitrary definition of a subject with SS, 
we noted that in the included studies ethnicities, skin types and comorbidities of the 
study population are not always specified, or that subjects with various skin types and 
comorbidities in particular are included. It is known that a darker skin has slightly 
different properties compared to the more fair Caucasian skin: more cell layers in the 
stratum corneum, possibly more coherent and a higher electrical resistance. (5-7) Next 
to this, since individuals with SS more frequently report to have a skin disease, 
including contact allergy, compared to the non-sensitive population, skin diseases can 
be a potential confounder in SS research. (8) In the general Japanese population for 
example, 31 % is suffering from a skin disorder, while among subjects declaring to have 
a SS, 43% reports to have a skin disorder. (9) With respect to the prevalence of specific 
skin diseases in this population, only significant differences between SS and NSS 
subjects were found with respect to atopic dermatitis (3, 10) (23.5% and 4.7%, 
respectively). (9)  Atopic dermatitis, has aberrant barrier properties (11-16) and 
therefore might potentially bias the barrier parameters in the SS. For atopic dermatitis 
is a very common inﬂammatory disease with a prevalence of 5-30% in children and 
2-10% in adults (17) and even non-lesional atopic skin might has different skin 
properties compared to healthy skin, it is important to take this into consideration in 
population selection processes. Next to atopic dermatitis, this also holds in particular 
for contact dermatitis. 
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It is hard to overestimate the role of careful selection of SS subjects for clinical studies. 
Next, while applying non-invasive measurements for objective quantification of 
barrier impairments in SS it is of crucial importance to follow strict adherence to the 
user manual and guidelines. (18, 19) Even in this case of following guidelines, one has 
to take into account that the major limitation of transepidermal water loss 
measurements (TEWL) and electrical techniques such as skin capacitance or 
conductance is that they are indirect and thus are not measuring the skin structure 
and the molecular composition of the skin barrier. What further complicated data 
interpretation obtained using such traditional biophysical techniques is that these 
parameters are inﬂuenced by both intrinsic and extrinsic factors. (20) Since the 
differences between in skin properties between SS and non-sensitive skin (NSS) are 
expected to be subtle, accurate application of these measurements is highly important 
as a minimum condition to obtain sensible information. In order to enable this, 
guidelines describe for example to perform the measurement in controlled 
environments regarding temperature and relative humidity on acclimatized subjects 
on suitable skin areas not exposed to cosmetics in advance. (13, 21-23) These measures 
have been addressed in only a fraction of studies. Unfortunately, the majority of 
dermatological community and skin scientists are still not paying sufficient attention 
to the fact that TEWL, skin capacitance and conductance are indirect methods, where 
the measurement outcome is impacted by many factors and thus, may not have a 
straightforward relation with a parameter in question, eg skin hydration. Getting 
better quality data thus requires not only new, specific, and direct methods for skin 
barrier quantification by also a change of attitude/mentality of dermatologists and 
skin research scientists.
As a final part of our systematic literature review (24), the translation from skin 
perceptions to objective measurements was made and showed that the strongest 
evidence exists for the role of an impaired skin barrier in SS, although the limitations 
described. This impaired barrier might cause sensory perceptions and vascular 
reactivity might develop subsequently. However, strong evidence and consistence on 
pathways underlying SS were still lacking at this moment.
Subject characteristics
In chapter 3 we aimed to define characteristics of subjects reporting SS, the symptom 
profile and discriminative factors for SS. We propose using a questionnaire capturing 
reactions of subjects to multiple provocations to include subjects for clinical studies 
instead of skin reactions to a single provocation only. Inclusion of subjects reacting to 
multiple stimuli could prevent measuring irritant or allergic contact dermatitis or heat 
intolerance for example. The hypothesis of multiple etiologies underlying SS would 
not be farfetched as also proposed by Maibach and Farage. (4) By including subjects 
with subjectively severe SS and subjects with subjectively no complaints of SS for 
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clinical studies, potential differences might become highlighted. Though, which 
factors and which symptoms are most discriminative between a SS and NSS group? 
First we investigated the role of patient factors on SS, by exploring characteristics of 
the individual reporting to have a SS, compared to individuals reporting to have a 
relatively NSS. In particular, concomitant skin diseases were addressed. The question 
remains whether skin diseases are predisposing conditions for SS, or the primary 
cause. Our results show that subjects with SS generally react to multiple stimuli and 
skin reactions are rather polymorph. This study confirmed the high prevalence of skin 
diseases in SS, compared to NSS subjects. Since the symptom profile of SS is rather 
non-specific, these results are not surprising. 
Next, using the questionnaire results, we aimed at better understanding of the 
magnitude that skin diseases play in the prevalence of self-reported SS perceptions. 
Atopic dermatitis and contact dermatitis in particular were significantly more prevalent 
in the group with SS compared to NSS. Asthma and allergic rhinoconjunctivitis in 
addition were significantly more prevalent in the SS group, however, we did not 
analyze its independent contribution to predict sensitivity. Very likely, this observation 
coincides with atopy. The fact that of the subjects with SS 41% has or has had atopic 
dermatitis, and the fact that 48% has or has had a skin disease other than atopic 
dermatitis, means that still one out of two subjects with SS does not have any of these 
conditions. Therefore, other mechanisms than skin diseases only may underlie SS. This 
directs again to the exclusion of skin diseases in explorative studies on the physiology of 
SS or at observing these subjects as a separate group. Next to atopic conditions, also 
urticaria should be ruled out when transient itching, burning, and tingling are reported 
by a patient, for these symptoms may overlap at presentation. Non-immunologic or 
immunologic urticaria appear within minutes after cutaneous or mucosal contact 
with the eliciting agent and are frequently characterized by local wheal-and-ﬂare 
reaction. A patient is sometimes able to address a specific inducing substance, while 
SS might be elicited by multiple triggers. The question whether contact dermatitis 
underlies SS is challenging. Higher skin susceptibility in for example nickel sensitizations 
are reported. (25) Either sensitizations can be caused by a potential impaired skin 
barrier function in SS allowing potential allergens to penetrate the skin, or the 
susceptibility can be caused by skin reactions following sensitization. However, again 
SS might be elicited by multiple substances, while in contact dermatitis often a single 
substance or group of substances account for the symptoms. 
Compared with patients of the general Dutch population, patients with skin diseases 
in primary care are known to have a significantly lower psychological and social 
well-being. (26) This impact also comprises health-related quality of life, which in its 
turn also adversely affects compliance with care and satisfaction. Since it has been 
found that disease severity and disease duration significantly predicted psychological 
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wellbeing, it is important that future research pays attention to chronic conditions, 
that frequently cause chronic physical symptoms of itch, pain and fatigue and which 
are accompanied by other comorbidities and chronic disease. Few studies have been 
performed on the quality of life in subjects with SS. (27)
Skin sensations
SS has a predominantly subjective character, as stinging, burning, itching and 
sensations of tightness are reported, implying that neurons of subjects with a SS 
dysfunction and easily respond to mild stimuli. In our survey described in chapter 3, 
we also quantified skin perceptions of subjects with SS more in detail. We found that 
in particular the severity of ‘sensations’ as general discomfort and stinging are the 
most discriminative for self-reported SS. 
Stander et al, 2008, address the role of the neural system and neuromediators in skin 
sensitivity to explain increased skin sensations. (28) Differences in pain perceptions 
were observed in subjects with SS by fMRI. (29) Skin discomfort induced by lactic acid 
lead to activation of different parts of the cerebral cortex. Quatresooz et al, 2009, also 
measured the current perception threshold (CPT) in subjects with reactive and 
non-reactive skin and concluded that some subjects with reactive skin and a lower 
CPT showed a higher density of mast cells in the dermis. (30) This is in line with the 
findings of Kim et al, 2008, who detected a lower CPT to 5 Hz electric current on the 
forearm in subjects with SS compared to subjects with NSS. (31) 5-Hz is a selective 
stimulator of the C-fibers of sensory nerves. (31) C-fibers are unmyelinated fibers, 
playing a role in the perception of pain, itch and warmth. Additionally, an inverse 
correlation was shown between clinical detection thresholds of capsaicin and SS 
indexed by questionnaire. (32) When the skin comes in contact with capsaicin, noxious 
heat or low pH, transient receptor potential vanilloid 1 (TRPV1) is activated (33, 34) and 
results in nociceptor mediated burning pain. An overexpression of this receptor could 
play a key role in the pathomechanism of SS, as inhibition of this receptor by the 
application of a selective antagonist, trans-4-tert-butylcyclohexanol, results in reduced 
burning sensations following application of a capsaicin emulsion. (35) In order to relate 
perceptions of skin dryness to this hypothesis, a perception of skin dryness might be 
related to feelings of skin tightness, prickling or burning.
Diffuse or localized sensitive skin? 
Another question arises, whether subjects with SS have skin sensation rather diffuse 
or localized. Many studies on SS have been performed on the forearm (24), while SS is 
predominantly reported in the face and moreover, cosmetics eliciting SS are mainly 
used at that particular body site. Farage et al, 2009, (36) reported that people claiming 
to have SS also claimed to have SS at several specific body sites. Most responses of 
descriptions of facial and body skin were consistent with the perception of SS in 
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general (61% and 68% of responders, respectively) or varied by one degree out of four 
with respect to severity (37% and 31% of responders, respectively). The questionnaire 
we have conducted, described in chapter 3, supports these results. 
Clinical studies performed in different body regions cannot be easily compared, since 
skin barrier function, skin permeability and vascular responses cause variability. In a 
study of Distante et al, 2002, facial areas were mapped in detail, where the chin and 
the paranasal sites showed highest laser Doppler ﬂux and highest TEWL values, and 
the forehead and cheeks showed the lowest capacitance. (37) Between stingers – 
subjects reporting stinging sensations following the application of lactic acid on the 
skin – and non-stingers however, no significant differences were found for the 
properties of facial areas. 
In our clinical studies on human subjects described in chapter 4, we performed 
investigations on the upper side of the buttocks. We chose this particular body site to 
decrease the burden of potential scar formation following multiple skin punch 
biopsies. In the survey described in chapter 3, we observed that 35% of SS subjects, 
compared to 15% of NSS subjects, reported that the legs were one of the most five 
sensitive body parts, and 7% and 4% assessed the legs as the most sensitive body part, 
respectively. Subjects with SS also report to have SS on the lower back or buttock 
although not as often as on the face. This justifies our choice of the studied body site. 
To strengthen our study, we included subjects who do report sensations of SS, not 
specifically on the face.
Which mechanisms underlie sensitive skin? 
We aimed to gain insight in underlying pathways by developing a novel approach on 
subject selection and dynamic analysis, including clinical, biophysical and immunohis-
tochemical parameters in chapter 4. Our view is that to achieve this, translation of 
self-reported perceptions to biophysical properties and detailed histological data 
could be the best approach to investigate this dominantly subjective skin condition. 
Subjects with SS should be selected in a perception-based manner through a 
questionnaire spanning a range of provocations, including those of chemical, 
mechanical and thermal origin and including multiple signs and symptoms.
We chose an approach encompassing reproducible in vivo skin models in order to 
enhance skin reactions in the subject with SS. Processes were studied over time, in a 
dynamic fashion. We chose immunohistochemical analysis both as a reference for 
dimensions of the skin layers to compare it with for example non-invasive measurements 
of the stratum corneum thickness (performed using confocal Raman spectroscopy) 
and as a source of information on cell- and molecular biological manifestations of 
changes accompanying SS. The former enables further research by non-invasive 
analysis of the skin barrier for example. However, of note, differences in biophysical 
measurements between subjects do not necessarily reﬂect differences in skin sensitivity 
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since these parameters have high inter-individual variability in the general population. 
Additional parameters measuring the same process could strengthen specific 
pathways and might explain previously described inconsistencies in study outcomes.
Comparative data would have been superior in clarifying the issue of whether SS 
exists as an objective entity. Ideally, we would evaluate several stimuli intra-individu-
ally. Since we are limited to five or six punch biopsies in each subject, we rather chose 
to investigate skin response to one selected stimulus dynamically in time rather than 
observed one-time response to multiple stimuli. 
The skin barrier
We have investigated characteristics of the skin barrier and the stratum corneum, 
such as thickness, water-holding capacity and conductance in several studies. When 
we combine data obtained on all 48 subjects in the clinical studies, in which we have 
also included immunohistochemical analysis and compare the SS subjects (n=24) with 
the NSS subjects (n=24), we find no significant differences in the thickness of the 
stratum corneum (p=0.336, Mann-Whitney test for non-parametric distributions). 
The median SC thickness (in µm) ± SEM of the SS and NSS groups are respectively 
14.9±0.9 and 13.5±0.8. Measurements using Confocal Raman Microspectroscopy, 
described in chapter 5, confirm this finding: there is no significant difference in the 
stratum corneum thickness between the SS and NSS groups for the foream (p=0.231) 
and for the cheek (p=0.850). The median SC thickness (in µm) ± SEM in the forearm for 
the SS and NSS group is 16.4 ±0.4 and 16.8±0.5, respectively, and in the cheek 14.1±0.4 
and 14.1±0.2, respectively. 
Similarly to the SC thickness, with respect to skin barrier function measurements, 
TEWL and SC hydration, no differences between a SS and a NSS group were found in 
any of our studies reported in chapter 4 and 5. Additionally, when we combine all 
subjects 48 subjects participated in the clinical studies, in which we have included 
immunohistochemical analysis and compare the SS subjects (n=24) with the NSS 
subjects (n=24), we find no significant differences in TEWL or SC hydration between 
the SS and NSS groups: (p=0.284 and p=0.228, respectively, Mann-Whitney test for 
non-parametric distributions). With respect to the average NMF at the SC depth of 
4-12 µm on the forearm and the cheek, no significant differences emerged between 
the SS and NSS groups in the CRS study. Next to this, immunohistochemical results 
confirmed that the percentage of the granular layer expressing filaggrin of the viable 
epidermis is 5.1 ± 0.8 and 5.6 ± 0.7 respectively in SS and NSS subjects (n=8 in each 
group) with no significant difference. 
We propose that the skin barrier in SS is not impaired in terms of SC thickness and in 
terms of water, NMF and ceramide/fatty acids content. Treatments of SS solely based 
on hydration and ceramides supplementation seem not to correspond to the identified 
SC properties, although benefits have been reported.
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Although at baseline there seems to be no differences in stratum corneum thickness 
and composition, apparently the stratum corneum of sensitive subjects seems to be 
more easily damaged compared to that of NSS subjects. Less tapes are required to 
strip off the total stratum corneum in SS subjects and following 1% SDS application 
during 24 hours on the lower back, the stratum corneum thinned more strongly in the 
SS group. We hypothesized that a reduced inter-corneocyte adhesion causes easy 
detachment of corneocytes. Ota et al. (2002) previously proposed that the average 
projected area of corneocytes obtained by tape stripping is higher in SS subjects 
compared to NSS subjects. (38) In addition, Muizzuddin et al, (1998) observed that less 
strips were needed in a SS group to duplicate baseline TEWL values. (39) We aimed to 
investigate the corneodesmosomes in SS subjects by extracting human corneocytes 
from the skin using adhesive tapes (chapter 5). However, in this small explorative 
study, we were unable to detect statistically significant differences in the number or 
surface of corneocytes extracted and the expression of Desmoglein-1 between SS and 
NSS subjects, however a trend towards increased numbers in SS subjects compared to 
NSS subjects could be observed. A recent study by Raj et al, 2016, did find an increased 
number of smaller and immature corneocytes in a capsaicin sensitive group, compared 
to a less sensitive group. (40)
Skin of stingers with self-reported SS appears to be rougher since FFT evaluation of 
tapes after tape-stripping the stratum corneum in 243 stingers reveals lower contents 
of cells. (41) This also implies a more irregular, rougher and possibly less hydrated skin 
as well as impaired intercorneocyte adhesion. Objectively measured skin elasticity 
shows no correlation to hypersensitivity. (42)
In our studies, we have conducted a questionnaire including questions on self-perceived 
SS and questions on skin dryness. In total, 20% of subjects who reported to have some 
kind of skin sensitivity, compared to 12% in NSS subjects (n=255), reported to have a 
dry facial skin. These percentages were 37% and 24% respectively for a dry skin of the 
body. A dry skin of the body was also more frequently reported in the SS group (n=24) 
compared to the NSS group (n=24) of the clinical studies including immunohisto-
chemistry (p=0.005, Chi square test).
At the same time we found no differences in SC hydration, TEWL, NMF, and water 
concentration neither on the lower back nor on the forearm and face (where water 
and NMF concentration were accessed using Confocal Raman spectroscopy).  This 
rises a fundamental question we have not measured the optimal body region, our 
measurements were not sufficiently accurate, we have not selected the correct 
population or on the contrary, dryness perception of subjects is related to factors 
other than water concentration. One could speculate that the more frequent self- 
reported perception of skin dryness in SS subjects might be primarily mediated by TRP 
channels. TRP channels are sensory receptors activated by a variety of external stimuli 
and known to mediate a range of skin sensations including pain, itch and burning 
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feeling. Increased levels or an upregulated sensitivity of these receptors might account 
for the previously reported increased perception of SS to a variety of stimuli. (43-45) 
Inflammation
Although many biophysical measurements have been performed to characterize the 
skin barrier, the skin is much more than only ‘a mechanical barrier’ and ‘chemical 
substance’, performing functions of hormonal and immune regulation. In our studies, 
we have explored a range of inﬂammatory markers including T-cells, mast cells (MC’s), 
neutrophils, spongiosis and cycling keratinocytes. We observed stronger spongiosis 
formation after tapestripping in the SS group, compared to the NSS group, and a ﬂare 
response solely in the SS group. (44) In addition, we observed a lower number of 
tryptase+ MC’s per mm² dermis in the SS group compared to the NSS groups in all 
three clinical studies. When we analyze the total number of 48 subjects (n=24 SS and 
n=24 NSS subjects), we measure respectively 50.9±2.7 and 61.5±4.1 tryptase+ mast 
cells per mm² dermis, showing significant differences (p=0.034, using Mann-Whitney 
test for non-parametric distributions). 
Following all three skin stimulations (e.g. tapestripping, sodium dodecyl sulphate and 
fractional photothermolysis) we observed a rapid, but transient MC increase. We 
hypothesize that this is caused by MC migration to challenged body sites. (44, 46, 47) 
Whether the number of MC’s returns to baseline following stimulus is not of our 
primary interest, since we are mainly interested in the differences between the SS and 
the NSS groups after the stimulus. However, when we compare the number of MC’s at 
baseline with the number of MC’s at 24 hours following the 24 hour application of 1% 
sodium dodecyl sulphate in water (SDS) we see a significant difference (p=0.006), 
and when we compare the MC’s at baseline with the number of MC’s at 72 hours 
following SDS, we see no difference (p=0.701). The number of MC’s at 24 hours were 
also significantly higher compared to 72h (Paired Samples T-test): (p=0.002). This 
temporary increase has not been reported previously to the best of our knowledge. 
The increase of MC’s could be explained by their migration, rather than being newly 
formed. The MC’s are mainly concentrated near infiltrates. A borderline significant 
strong correlation was observed between CD3+ cells and tryptase+ cells at baseline 
(Pearson’s rho = 0.467, p=0.068). The number of tryptase+ cells at 72 hours did 
correlate with the number of polymorphonuclear neutrophils (Pearson’s rho = 0.477, 
p=0.062), but no correlation with CD3+ cells was found. In literature, one study 
showed also rapid increases in MC counts in the dermis post mortem, reaching 
maximum numbers at 1-3 hours after wounding and death (48). MC’s are able to move 
to stimulated skin sites, in line with fast responses of Langerhans cells, leaving 
stimulated sites to induce immunologic responses. 
Since we use a functional marker for MC’s, tryptase, we could have underestimated 
the number of MC’s in SS subjects, due to undetectable degranulated MC’s by immuno-
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histochemical analysis. We hypothesize MC’s in SS subjects have either been degranulated 
already in response to the stimulus or do not migrate that extensively to the challenged 
skin site. The latter could be caused by a secondary increase of reaction thresholds, to 
prevent unpleasant skin sensations at continuously following very mild skin challenges. 
However, this does not explain the baseline differences in the number of mast cells 
between sensitive and non-sensitive skin. Morphologically, we have not observed 
differences in MC’s between groups or between time points. We did not observe 
differences with respect to distribution of MC’s (superficially or deeper concentration), 
aberrant sizes or shapes of MC’s or aberrant numbers of granules in MC’s between 
biopsies and we did not observe the presence of MC’s present in the epidermis. In 
contrast, increased numbers of MC’s (CD117+)  were found in subjects with ‘reactive 
skin’ and a low CPT in another study. (30) 
Next to changes in MC number, a ﬂaring response could solely be observed in SS 
subjects. The estimated mean thickness of the viable epidermis and spongiosis scores 
are higher 24 hours after stimulus in SS subjects following tapestripping stimulus. 
Epidermal thickening in SS is explained by edema, not by increased proliferation of 
keratinocytes. Flaring responses and edema in the SS subjects imply vascular pathways 
in the pathomechanism of SS. At baseline, in one study significant differences in skin 
redness were found; lower a*-value in self-reported SS compared to NSS. Literature is 
inconclusive on differences in skin redness between sensitive and non-sensitive 
subjects following stimulation of the skin.
With respect to endothelium markers (CD31), no different quantity is found between 
subjects with reactive skin and low electrical current perception thresholds (CPT) and 
subjects with less reactive skin and high CPT. (30) Another hypothesis on the 
underlying mechanisms of SS was recently made by Kim et al, 2015, suggesting that 
adiponectin expression is downregulated in SS subjects, implying relations with 
general skin inﬂammation. (49) 
Do changes in the skin barrier indeed play a role in the SS pathomechanism? Are the 
perceptions of SS subjects solely mediated by TRPV receptors? Are these pathways 
that play a role in one individual or should the term SS be reserved as a container term 
for different skin anomalies resulting in certain skin problems? One could speculate on 
a central role for the innate immune system, in particular MC’s, in these potential 
physiologic anomalies underlying SS. Gschwandtner et al, 2013 (50) proposed a role for 
MC’s and histamine in skin barrier homeostasis. They found that MC’s inhibit epidermal 
keratinocyte differentiation and skin barrier formation in skin models. In our studies 
we found significantly less mast cells in SS subjects, however, one could speculate on 
fast degranulation of MC’s induced by allergens, causing an impaired repair of the skin 
barrier. Therefore, the skin barrier might be affected secondary to MC degranulation. 
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In SS, this might play a role, although we were unable to detect differences in the 
number of proliferating keratinocytes, Keratin 16 expression or SC thickness. On the 
other hand, would downregulation of MC’s improve the repair of the skin barrier? 
Could one consider this mechanism as a compensation for a primary impaired skin 
barrier in SS, addressed as ‘skin adaptation’? 
Final statements
While currently existing solutions to address SS symptoms are mainly aimed at 
restoring an adequate skin barrier (51-53) and seem to improve unpleasant perceptions, 
scientists are still being challenged by this relatively unexplored phenomenon.
We are of the opinion that SS is a condition, in which dermatology should be leading 
in following research, in collaboration with psychologists, biologists and engineers. 
While the SS is more often reported by subjects having an atopic predisposition and/
or having a skin disease, these are not the only conditions underlying skin sensitivity, 
as subjects with no skin diseases or atopic conditions still complain about increase 
skin sensitivity. Sensitive skin can be elicited by multiple triggers and holds sensory 
symptoms as well as erythema. Next to an easily destructible stratum corneum, skin 
inﬂammation plays an important role as well. SS seems to be rather generalized with 
predilection sites, than being localized. Winter has a negative inﬂuence on the skin 
complaints, however, SS is not limited to a cold climate. Whether SS is a constitution 
or a transient condition is not clear yet. 
An integral approach is recommended to unravel the SS phenomenon, taking into the 
picture clinical, biophysical and histological hallmarks of this condition. A new step in 
diagnosis and treatment of the condition could only be taken by conducting cross-dis-
ciplinary, collaborative research, including experts’ contribution in dermatology, 
cosmetic sciences, psychologists and biophysicists. Development of accurate 
non-invasive techniques may facilitate skin research, not only by minimally impacting 
the skin and thus enabling the investigation of larger populations, but also by giving 
multiple complementary read-outs, which could be used to form a more complete 
assessment skin structure and molecular composition. In our opinion, the follow-up 
investigations unravelling SS need to focus on stratum corneum cells adhesion, mast 
cells, vascularisation and TRPV receptors. Zooming in on immunohistochemical 
analysis of MC’s in detail, investigating degranulation, and nerve endings could give 
even deeper insights about pathomechanisms of SS. Such investigations using 
traditional immunohistochemichal technique should ideally go in parallel with 
measurements using in vivo non-invasive highly sensitive and specific devices, 
assessing skin molecular composition. 
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“Around here, however, we don’t look backwards for very long. We keep moving forward, 
opening up new doors and doing new things, because we’re curious...and curiosity keeps 
leading us down new paths.”‐ Walt Disney Company
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Veel mensen in de Westerse wereld noemen hun huid een gevoelige huid. In de literatuur 
worden verschillende definities en indelingen van gevoelige huid genoemd, (1), verwijzend 
naar verschillende theorieën met betrekking tot pathofysiologie. De definitie en 
patho fysiologie van gevoelige huid is tot op heden niet duidelijk. De diversiteit in 
eigenschappen van de huid en verschillende percepties en symptomen van mensen 
met een gevoelige huid, maken het een uitdaging voor onderzoekers en dermatologen 
in de zoektocht naar de rationale achter gevoelige huid, met uiteindelijk het doel om 
hierop een passende therapie te ontwikkelen. 
In hoofdstuk 2 hebben we middels een systematisch literatuur review gepoogd de studies 
naar de morfologische, fysiologische en biofysische karakteristieken van gevoelige huid 
kritisch te beoordelen en de betrouwbaarheid van diagnostische testen voor gevoelige 
huid op gestimuleerde en ongestimuleerde huid te beoordelen. Hierin werden alleen 
studies geincludeerd die proefpersonen hebben geselecteerd op de perceptie van hun 
huid middels een vragenlijst of na stimulatie van de huid. Wij concludeerden een 
heterogeniteit van studies in design en selectiemethoden, waaronder in het bijzonder 
co-existente huidaandoeningen en atopie, uitlees-methoden en parameters, wat de 
vergelijking van de studies onderling bemoeilijkt. Tevens worden de voorschriften van 
de testcondities niet altijd adequaat opgevolgd, waardoor mogelijke subtiele verschillen 
in eigenschappen van de huid niet kunnen worden gevonden. De vertaling van huid -
perceptie naar objectieve meetmethoden werd gemaakt en toonde dat het sterkste 
bewijs bestaat voor de rol van een verminderde barrièrefunctie van de huid in gevoelige 
huid, hoewel er verschillende beperkingen van de studies werden beschreven. De 
verminderde barrièrefunctie zou secundair kunnen zorgen voor een verhoogde sensitiviteit 
en vasculaire reactiviteit. Maar sterk bewijs voor deze mechanismen ontbreekt. 
Hierop beoogden wij in hoofdstuk 3 de patiëntkarakteristieken, het symptoomprofiel 
en discriminerende factoren voor gevoelige huid in kaart te brengen. We stelden een 
vragenlijst op, met hierin sensaties en huidreacties van proefpersonen die rapporteren 
een gevoelige huid te hebben. Door proefpersonen die reageren op multipele 
provocaties te includeren voor klinische studies naar de pathofysiologie van gevoelige 
huid, worden mogelijk personen met een contacteczeem of een warmte intolerantie 
geëxcludeerd. Door personen met een subjectief ernstig gevoelige huid en personen 
zonder gevoelige huid te includeren voor klinische studies, zou mogelijk het verschil in 
eigenschappen van de huid kunnen worden gehighlight. Middels deze vragenlijst onder- 
zochten wij de meest gerapporteerde sensaties, en de ernst hiervan, en objectieve 
kenmerken van de huid bij personen met een gevoelige huid. Tevens bekeken wij welke 
patiëntfactoren significant anders waren dan bij de groep zonder een gevoelige huid 
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en op welke uitlokkende factoren de sterkste reactie optrad en het grootste verschil 
tussen de groepen toonde. Onze resultaten tonen aan dat patiënten met gevoelige 
huid in het algemeen reageren op meerdere stimuli en huidreacties polymorf zijn. 
Deze studie bevestigt tevens de hoge prevalentie van huidziekten in gevoelige huid in 
vergelijking met niet gevoelige huid. Dit is niet verrassend, gezien het symptoompro-
fiel aspecifiek is en tevens kan passen bij een scala aan huidziekten zoals (constitutio-
neel) eczeem. De vraag rest of huidziekten predisponerende factoren zijn voor 
gevoelige huid of de primaire onderliggende factor. 
Hiernaast wilden we middels deze vragenlijst meer begrip hebben van de rol van 
huidziekten bij gevoelige huid. Atopisch eczeem en contact eczeem, allergisch dan wel 
irritatief, komen significant vaker voor in de groep met gevoelige huid ten opzichte van 
de groep zonder gevoelige huid. Astma en allergische rhinoconjunctivitis daarnaast 
kwamen ook significant vaker voor bij gevoelige huid. Wij hebben niet gekeken naar 
de onafhankelijke bijdrage van deze factoren om het risico op gevoelige huid te 
voorspellen. Mogelijk valt dit samen met atopie in het algemeen. 41% van de mensen 
met gevoelige huid had atopie en 48% had een huidziekte naast atopisch eczeem. 
Toch liggen er mogelijk andere factoren ten grondslag aan gevoelige huid, omdat een 
op de twee personen geen huidziekte dan wel atopische constitutie heeft. Voor 
toekomstig onderzoek zouden mensen met atopie en een co-existente huidziekte 
apart moeten worden geanalyseerd in studies naar de pathofysiologie van gevoelige 
huid. Urticaria zouden ook uitgesloten moeten worden, omdat deze symptomen zeer 
sterk lijken op die van gevoelige huid. De vraag of contact eczeem ten grondslag ligt 
aan gevoelige huid is een uitdaging. Gevoelige huid kan echter worden opgewekt door 
verschillende factoren, terwijl bij contact eczeem vaak enkele stof of groep van stoffen 
verantwoordelijk is voor de symptomen.
Huid sensaties
Gevoelige huid lijkt een overwegend subjectief karakter te hebben, zoals een stekend 
gevoel, branderig gevoel, jeuk en gewaarwording van een strakke huid, dat impliceert 
dat de neuronen disfunctioneren en gemakkelijk reageren op bepaalde stimuli. In ons 
onderzoek in hoofdstuk 3 worden kwantificeerden we de percepties van de huid door 
mensen met gevoelige huid beschreven. De ernst van ongemak in het algemeen en 
een stekend gevoel zijn het meest discriminerend voor gevoelige huid. Een perceptie 
van droge huid kan worden gerelateerd aan gevoelens van strakke huid, prikkelend of 
brandend gevoel. 
Gelokaliseerde of diffuse gevoelige huid? 
Of gevoelige huid meer lokaal dan wel diffuus is, is een veel gestelde vraag. Veel 
studies naar gevoelige huid werden uitgevoerd op de onderarm (Richters, Falcone et 
al. 2015), terwijl gevoelige huid hoofdzakelijk wordt gerapporteerd in het gezicht. 
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Farage et al, 2009, (Farage 2009) rapporteerde dat mensen die beweren gevoelige 
huid te hebben dit ook ervaren op een aantal specifieke plaatsen op het lichaam. 
Klinische studies uitgevoerd op verschillende regio’s op het lichaam zijn niet goed 
vergelijkbaar, aangezien huidbarrière functie en huidpermeabiliteit variabel zijn. In 
onze klinische studies in hoofdstuk 4 beschreven, namen we de bovenzijde van de 
billen als testregio. We kozen voor deze plaats op het lichaam om de cosmetische 
hinder van littekenvorming na huidbiopten te verminderen. In het onderzoek 
beschreven in hoofdstuk 3, zagen we 35% van mensen met gevoelige huid ten opzichte 
van 15% bij mensen zonder gevoelige huid de benen in de top 5 van meest gevoelige 
huidgebieden beoordeelden. Mensen met gevoelige huid rapporteerden ook een 
gevoelige huid van de onderrug of bil te hebben. Dit rechtvaardigt onze keuze van de 
bil als testplaats.
Welke mechanismen liggen ten grondslag aan gevoelige huid?
Het doel van het onderzoek in hoofdstuk 4 en 5 was om inzicht te krijgen in de 
onderliggende pathomechanismen van gevoelige huid. Door een nieuwe benadering 
van selectie van proefpersonen en dynamische gecombineerde analyse middels 
klinische, biofysische en immunohistochemische methoden beoogden wij dit te 
bereiken. De vertaling van perceptie van huidreacties van proefpersonen naar 
objectieve metingen en eigenschappen van de huid was volgens ons een juiste 
benadering hierin. Door hierin reproduceerbare in vivo huid modellen te gebruiken en 
uitlezingen over de tijd te doen, zouden verschillen tussen de groepen gehighlight 
kunnen worden. 
De huidbarriere
We hebben kenmerken onderzocht van de epidermis en het stratum corneum 
onderzocht, zoals de dikte van het stratum corneum, de hydratie van het stratum 
corneum en het transepidermaal waterverlies (TEWL). Wanneer we alle eigenschappen 
van de huid van de 48 geincludeerde patiënten in de klinische studies samen namen 
en de groep met gevoelige huid vergeleken met de groep zonder gevoelige huid (n = 
24), vonden we geen significante verschillen in de dikte van het stratum corneum (p = 
0,336, Mann-Whitney test voor niet-parametrische verdelingen). De mediane stratum 
corneum dikte (in µm) ± SEM van de groep met gevoelige huid en de groep zonder 
gevoelige huid was respectievelijk 14,9 ± 0,9 en 13,5 ± 0,8. Metingen met behulp van 
confocale Raman Microspectroscopie beschreven in hoofdstuk 5 bevestigen deze 
bevinding: er is geen significant verschil in de dikte van het stratum corneum tussen 
de groep met en de groep zonder gevoelige huid op de onderarm (p = 0,231) en voor de 
wang (p = 0.850). De mediane dikte van het stratum corneum (in µm) ± SEM op de 
onderarm van de groep met en zonder gevoelige huid waren 16,4 ± 0,4 en 16,8 ± 0,5 
respectievelijk, en op de wang 14,1 ± 0,4 en 14,1 ± 0,2 respectievelijk. 
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Wanneer we dezelfde analyses uitvoeren voor TEWL en stratum corneum hydratie 
tussen de totale groep in de klinische studies in hoofdstuk 4 en 5, vinden we geen 
verschillen. Wanneer we deze eigenschappen van de huid van proefpersonen met 
gevoelige huid  (n = 24) met die van proefpersonen zonder gevoelige huid (n = 24) 
vergelijken, vinden we geen significante verschillen in TEWL of stratum cornuem 
hydratie (p = 0,284 en p = 0,228, respectievelijk, Mann-Whitney test voor niet-parame-
trische verdelingen). 
Ook werden er geen verschillen in natural moisturizing factor (NMF) van de wangen 
en onderarm, een gemiddeld totaal tussen 4 en 12 µm diepte in de huid, tussen de 
beide groepen gemeten. Ook worden er geen verschillen in dikte van de granulaire 
laag gevonden waarin fillagrine tot expressie komt. Hieruit concluderen wij dat er 
geen verschil is in huidbarriere met betrekking tot stratum corneum dikte, stratum 
corneum hydratie en NMF. Verbetering van de gevoelige huid door suppletie en herstel 
van de huidbarriere kunnen wij niet verklaren vanuit onze resultaten. 
Toch wordt het stratum corneum wel gemakkelijker beschadigd bij de gevoelige huid, 
vergeleken met de minder gevoelige huid. Er zijn minder tapes nodig om het hele 
stratum corneum af te nemen en na applicatie van een surfactant wordt het stratum 
corneum dunner bij de gevoelige huid ten opzichte van de niet gevoelige huid. Een 
verminderde adhesie tussen de corneocyten zou een oorzaak kunnen zijn. Ota et al. 
(2002) beschreef onlangs dat het oppervlak van corneocyten verkregen door 
tapestrippen groter is bij gevoelige huid dan bij de niet gevoelige huid. (2) Muizzuddin 
et al, (1998) observeerde ook dat minder tapes nodig waren om de TEWL te verdubbelen 
bij gevoelige huid. (3) Wij onderzochten hierop de corneodesmosomen bij gevoelige 
huid, door corneocyten middels dubbelzijdige tape te vergaren in hoofdstuk 5. We 
vonden echter geen significante verschillen in desmogleine 1 expressie, maar wel een 
trend in een groter oppervlak van afgenomen corneocyten en daarmee hoeveelheid 
desmogleine 1. Raj et al, 2016, vonden ook kleinere en immature corneocyten in een 
groep proefpersonen reagerend op capsaicine applicatie. (4) Ook ‘stingers’, proef -
personen met sensaties van prikkelend gevoel op applicatie van melkzuur, hadden een 
ruwer oppervlak van corneocyten op tapes, een verminderde corneocyten adhesie 
suggererend. (5) Ook werd significant vaker een droge huid gerapporteerd door de 
groep met gevoelige huid in de vragenlijst in hoofdstuk 3. Is deze perceptie van een 
droge huid, die niet objectiveerbaar is, dan gevolg van veranderde sensaties? (6-8) 
Huidontsteking
Hoewel veel biofysische metingen zijn uitgevoerd om de huidbarrière karakteriseren, 
de huid is veel meer dan slechts ‘een mechanische barrière’ of een ‘chemische stof “, 
die functies van verschillende regelsystemen vervult. In onze studies hebben we een 
reeks inﬂammatoire markers waaronder T-cellen, mestcellen (MC’s), neutrofielen, 
spongiose en delende keratinocyten onderzocht. We namen meer spongiose waar na 
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mechanische stimulatie van gevoelige huid middels tapestrippen, vergeleken met de 
niet gevoelige huid. Tevens werd een ﬂare respons alleen in de groep met gevoelige 
huid waargenomen. (7) Tevens werd een lager aantal tryptase positieve MC’s per mm‐ 
dermis in de gevoelige groep vergeleken met de niet gevoelige groep in alle drie de 
klinische studies beschreven in hoofdstuk 4. In de totale groep van 48 proefpersonen 
(n = 24 in elke groep) meten we respectievelijk 50,9 ± 2,7 en 61,5 ± 4,1 tryptase positieve 
mestcellen per mm‐ dermis, significant verschillend tussen de groepen (p = 0,034, 
Mann- Whitney test voor niet-parametrische verdelingen).
Naar aanleiding van alle drie gebruikte stimuli (tapestripping, natriumdodecylsulfaat 
en fractionele photothermolyse) zagen we een snelle, transiente stijging in het aantal 
mestcellen. Onze hypothese is dat dit wordt veroorzaakt door mestcel migratie naar 
getriggerde huid. (7, 9, 10) Het aantal mestcellen na  24 uur applicatie van 1% natrium-
dodecylsulfaat in water (SDS) neemt significant toe (p = 0,006) en bereikt later weer 
het baseline niveau op 72 uur na stimulus.  Deze tijdelijke stijging is niet eerder 
gerapporteerd. Echter het aantal mestcellen zou onderschat kunnen zijn, omdat we 
een functionele marker voor mestcellen gebruikten. Mestcellen zouden al 
gedegranuleerd kunnen zijn in de gevoelige huid als respons op de gegeven stimulus 
of mestcellen migreren minder extensief naar gestimuleerde huidgebieden. Dit zou 
een beschermingsmechanisme kunnen zijn, om onprettige huidreacties op milde 
triggers te voorkomen. Dit verklaart echter niet de baseline verschillen. 
Final statements
De huidige oplossingen voor een gevoelige huid focussen met name op het herstellen 
van de huidbarriere en lijken onprettige sensaties van de huid te verminderen. (15-17) 
Toch blijven wetenschappers uitgedaagd door dit relatief ongeexploreerd fenomeen. 
Wij zijn van mening dat dermatologen de leiding zouden moeten nemen in het 
onderzoek naar gevoelige huid, in samenwerking met psychologen, biologen en 
ingenieurs. Hoewel gevoelige huid vaker wordt gerapporteerd door mensen met 
atopie of een huidaandoening, zijn dit niet de enige predisponerende condities. 
Gevoelige huid lijkt eerder gegeneraliseerd te zijn met voorkeursplaatsen, dan alleen 
gelokaliseerd. Winter heeft een negatieve invloed op de klachten, maar gevoelige huid 
is niet gelimiteerd aan een koud klimaat. Of gevoelige huid een voorbijgaande of een 
blijvende conditie is, is nog niet duidelijk. 
Een integrale aanpak is zou het ontrafelen van het fenomeen van gevoelige huid 
mogelijk faciliteren, waarbij klinische, biofysische en histologische kenmerken van 
deze aandoening worden meegenomen. Ontwikkeling van nauwkeurige niet-invasieve 
technieken is hierbij belangrijk, die kunnen worden gebruikt om een  volledige evaluatie 
van de huidstructuur en moleculaire samenstelling mogelijk te maken. In de toekomst 
zou de focus moeten worden gelegd op adhesie van corneocyten, vascularisatie, TRPV 
receptoren en mestcellen. 
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“Around here, however, we don’t look backwards for very long. We keep moving forward, 
opening up new doors and doing new things, because we’re curious...and curiosity keeps 
leading us down new paths.”‐ Walt Disney Company
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dromedarissen, kabouters, Ami’s en onze vreselijke Buddha hebben me een mooie tijd 
bezorgd! 
Anke, Anne, Romy, Karlijn, Annet, Kim, Inge, Margit en Esther. Wat hebben we een 
leuke tijd gehad in de bieb. Mede dankzij jullie heb ik hier een baan gekregen. Het was 
een super tijd! 
240
CHAPTER 8
Prof. Dr. Schalkwijk, Malou, Ellen, Hanna, Merel, Patrick Z, Patrick J, Jos, Gijs, Daniek, 
Diana, Yvonne, Esther, Elkie en Roy: Bedankt voor de hulp in het lab, journalclubs en 
gezelligheid. 
Lisanne: Het was heel fijn om met je samen te werken. Je moest vallen en opstaan met 
alle kleuringen bij het ontwerpen van de protocollen, maar je bleef altijd zorgvuldig en 
zette altijd door. Veel succes bij de hematologie!
Dear Babu, thanks for the nice time in Copenhagen and all your out-of-the-box thinking 
and ideas. Your sarcasm is great! I am sure you will make large career steps!
Tom Nuijs: Je gaf vaak een eenvoudige oplossing voor problemen waar wij al lang mee 
worstelden!
Jan Hendriks en Jan-Willem Bikker: Na veel geploeter is de statistiek afgerond! Bedankt 
voor jullie hulp! 
Wim Verkruijsse: Je bent herhaaldelijk kritisch door het ontwerp van de pilot studies 
gegaan. Door jouw input hebben we vele beren van de weg gehaald!  
Loes en Marius: Bedankt voor de gezellige theemomentjes tussen alle Philips-meetings 
door! En wat er toch allemaal uit die bureau-lade bij jou komt, Marius! Vooral heel veel 
exclusieve chocolade. En dan vinden ze in de bieb dat ik mijn laatje altijd vol heb liggen! 
Bedankt voor de interessante discussies! 
Bianca, Cecile, Łucia, Harry, Linda, Martin, Marijke, Marjolein, Mieke, Rieko, Rufus, Steffie, 
Wilco, Lucia en andere collega’s van Philips research in Eindhoven. Wat een kennis 
hebben jullie in huis. Jullie input heeft me geholpen in de opzet van studies en het 
interpreteren van de resultaten. Ik vond het erg leuk om kennis te maken met jullie 
groep en samen te werken! Wat een mooi team hebben jullie daar in Eindhoven! 
Paul Keizer, Serge Vrijaldenhoven en Ruud Nagelkerke: Zonder jullie waren deze studies 
nooit van de grond gekomen!
Gabriela: A Brazilian student. I did not know what to expect. Without your help, we 
would not have included that many subjects in our Raman study! Good luck with your 
career in dermatology in Brazil, I am sure you will become a great dermatologist! 
Marion, Giulia, David en andere collega’s van Philips Drachten. Wat een inzichten 
hebben jullie! Bedankt voor de fijne samenwerking! 
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Wilbert: Het was erg gezellig in Mystic met de club uit Nijmegen. Ik heb erg van je 
nuchterheid, chaos en humor kunnen genieten.
Prof. dr. H.I Maibach, dr. Elsner, dr. Fluhr, dr. Piérard, dr Wilhelm and dr. Grove: thank you 
for the Albert Kligman Young Investigator Award and for accepting our work for the 
meetings of the ISBS. It has been great to be surrounded by the experts in the field of 
non-invasive methods in dermatology.
Alle proefpersonen: Wat goed dat u tijd vrijmaakte voor deelname aan de exploratieve 
studies. We hebben hierdoor mooie stappen kunnen maken. 
Staf, AIOS, kamergenootjes, verpleegkundigen, administratief medewerkers en andere 
collega’s van de dermatologie: Ik voel me intussen helemaal thuis, leer erg veel van 
jullie en heb veel zin in de rest van de opleiding!  
Monique: Ik ben heel blij met het mooie kaftje!
Lieve papa, mama, Lot (paranimf), Bram, opa, oma, Marjo, Floor, Eddie, familie, vrienden, 
vriendinnen en Schimmels. We zijn er altijd voor elkaar, bij pieken en bij dalen. Bedankt 
voor alles wat jullie voor mij doen en hebben gedaan. Dat is me alles waard!
Lieve Nici: Jouw oneindige steun, en toch ook wel ons PhD-lied, heeft ervoor gezorgd 
dat ik hier nu sta. Ik ben zo blij dat ik jouw vriendinnetje ben! Ik wil met jou blijven 
genieten van alles wat we samen doen!

